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Summary  
 
 
 
There is an increasing need to develop anti-cancer vaccines that elicit strong and durable 
immune responses and are able to break immune tolerance to cancer antigens. 
Cytomegaloviruses (CMV) induce one of the strongest immune responses of any viral 
vector – as much as 20% of all CD8+ T cells can be specific for a single epitope, thus 
making them an exciting candidate for vaccine development. The majority of work, 
however, has been based on replication-competent viruses. In humans, the use of 
replication-competent human CMV (HCMV) vectors would not be permitted due to safety 
concerns, however replication-deficient vectors may not induce immune responses of 
the same magnitude as wildtype HCMV. In an attempt to make CMV vectors safer, I 
utilised a tetracycline repressor (tetR)-based system and generated a total of 55 mouse 
and human CMV vectors in which viral replication was dependent on inducible 
expression of multiple different viral genes. Having analysed the ability of the vectors to 
replicate in vitro and in vivo, I generated three vectors which replicated well in the 
presence of doxycycline, but in its absence replicated poorly in vitro, and did not appear 
to replicate in vivo. Importantly, in a direct comparison, the level of control was more 
stringent than viruses previously characterized in the literature.  
 
Adenoviruses are one of most widely used vectors in cancer immunotherapy, induce 
strong T-cell responses, and could be used in a prime-boost regiment with CMV vectors. 
However, we found that in a prophylactic regimen, a recombinant human adenovirus 
(Ad) encoding human 5T4 tumour-associated antigen alone did not protect against 5T4-
expressing tumour challenge. We tested the immunogenicity of 5T4 in two mouse strains 
and established three 5T4-expressing cancer models in which vectors can be tested. In 
future work, we hope to use our inducible CMV/Ad vaccine regimen in these models. 
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Chapter 1 Introduction 
  
Cancer Immunology came to prominence as breakthrough of the year in 2013 (Bartlett et al. 
2013). Since then, at least 54 agents for treating cancer have been Food Drug Agency 
(FDA)-approved (CenterWatch 2017). Development of anti-cancer vaccines, however, has 
been a challenging task with slow progress. For the generation of effective vaccines, it is 
necessary to optimise the induction of therapeutic immune responses. Viruses have many 
properties that make them attractive vaccine vectors. Adenoviruses (Ad) have provided one 
of the most efficient means to generate a therapeutic T cell response and are widely used 
in vaccine initiatives, making up 25% of total vector usage in cancer gene therapy trials 
(Fooks et al. 1995; Jacobs et al. 1994). However, other viruses have properties that may 
make them even more effective. Pioneering work using cytomegaloviruses (CMV) has 
demonstrated the potential of these viruses in the vaccine development field, due to their 
unique capacity to generate strong Effector Memory T cell (TEM) responses (Hansen, Sacha, 
et al. 2013; Hansen et al. 2009; Hansen et al. 2011). However, to date, most human CMV 
(HCMV) vaccines have been based on replication competent virus. We sought to improve 
HCMV vaccine vector safety while retaining immunogenicity, with a view to exploiting the 
ability of both HCMV and Adenovirus vectors to induce T-cell responses in cancer 
immunotherapy. 
 
1.1. T cell subsets 
The induction of a T-cell response is a key aim of many cancer vaccine strategies. T 
lymphocytes are part of the adaptive immune system and can be classified into T helper 
(Th) cells (CD4+ T cells), cytotoxic T cells (CD8+ T cells), natural killer T (NKT) cells, 
regulatory T cells (TRegs; CD4+ T cell subset) and γδ T cells. T cells, by definition, express a 
T cell receptor (TCR) that is responsible for binding peptide antigen (Ag) presented on the 
cell surface by major histocompatibility complex (MHC). CD8+ T cells recognize peptides 
presented by MHC class I molecules, whereas CD4+ T cells, including TRegs, recognize 
peptides presented by MHC class II molecules, NKT cells bind lipid-based antigens 
presented by CD1d (a non-classical MHC molecule) and γδ T cells recognize CD1a and 
CD1d molecules (Luoma et al. 2014).  TCRs are comprised of a heterodimer of α and β 
chains joined by a disulphide bond, except on γδ T cells, where the TCR is comprised of a 
distinct range of γ and δ chains that define their specificity.  Activation of T cells results in 
durable antigen-specific immune responses.  
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1.2. CD4+ and CD8+ T cell development 
T lineage cells arise from lymphoid progenitors that are produced in the bone marrow and 
migrate to the thymus to proliferate, differentiate and mature. T cell precursors, thymocytes, 
start off as double-negative cells since they do not express CD4 or CD8 markers (Germain 
2002). Expression of recombination-activating gene results in rearrangement of β TCR 
chains (Variable (V); Diversity (D) and Joining (J) gene segments). Successful 
rearrangement is followed by expression of both CD4 and CD8 co-receptors. These 
immature thymocytes, also termed double positive, rearrange α TCR chains (V and J gene 
segments) to form TCRs. The process of V(D)J rearrangement of TCR chains generates a 
broad repertoire of TCRs with affinity for a wide variety of peptides. αβ T cells then undergo 
positive selection where they interact with cortical epithelial cells expressing either MHC 
class I or class II complexes presenting endogenous peptides (Germain 2002). Only 
CD4/CD8 lineage-committed αβ T cells that receive the survival signal migrate to thymic 
medulla and undergo negative selection that eliminates self-reactive T cells (Germain 2002). 
During thymic development, T cells undergo a process termed ‘central tolerance’ that selects 
out high avidity T cells that would otherwise react to self-proteins.  
 
1.3. αβ T cell receptor-CD3 complex 
TCRs are heterodimeric transmembrane proteins comprised of disulphide-linked α and β 
chains (Kuhns et al. 2006). Each chain is divided into variable (V) and constant domains (C) 
(Kuhns et al. 2006). The variable domains of α and β chains are involved in antigen 
recognition and structurally resemble the Fab fragment of an antibody (Kuhns et al. 2006). 
The TCR does not contain signalling motifs required for T cell activation, differentiation and 
proliferation upon antigen encounter (Birnbaum et al. 2014). The CD3 molecule (comprised 
of invariant chains called γ, δ, ε and ζ), however, contains intracellular signalling motifs and 
binds to the variable antigen recognition region of the TCR, forming the TCR-CD3 complex. 
Only the γ, δ, ε chains are extracellular and form heterodimers CD3γε and CD3δε which 
bind to the variable αβ heterodimer domains whereas ζζ homodimers form an intracellular 
region of the complex (Kuhns et al. 2006).  
 
1.4. Major histocompatibility complexes I and II 
Major histocompatibility complex (MHC) I and II are molecules expressed on the cell surface 
that play a role in antigen presentation to T cells. MHC class I molecules are expressed on 
all nucleated cells as well as platelets whereas MHC class II molecules are expressed on 
antigen-presenting cells (APCs) (e.g. dendritic cells (DCs), macrophages, B cells) and in 
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response to interferon gamma (IFN-γ) can also be expressed on fibroblasts, endothelial cells 
and epithelial cells (Mulder et al. 2011; Geppert & Lipsky 1985).  
 
The MHC locus in humans is called human leukocyte antigen (HLA) whereas in mice it is 
known as the H-2 locus. In humans, MHC class I molecules are called HLA-A, HLA-B, HLA-
C, HLA-E, HLA-F, HLA-G and HLA-H whereas in mice they are H-2D, H-2K and H-2L. Class 
II molecules in humans are called HLA-DP, HLA-DQ and HLA-DR. In mice, MHC class II 
molecules are called H-2A(I-A) and H-2E(I-E). 
 
MHC class I molecules consist of heterodimers of alpha (or heavy) chain and β2-
microglobulin (Hewitt 2003). The alpha chain is comprised of three extracellular domains: α1 
and α2 that form the antigen binding domain and α3 which interacts with β2-microglobulin, as 
well as transmembrane and cytoplasmic domains (Hewitt 2003). MHC class II molecules 
are made up of an α and a β chain. Each chain has two extracellular domains called α1, α2 
and β1, β2 (Jones et al. 2006). The α1 β1 domains form the antigen-binding region (Dasgupta 
et al. 2014). 
 
1.5. Antigen processing and presentation 
T cell receptors can only recognize peptides bound to the MHC molecules. The peptides 
presented are derived from whole proteins and first need to be processed into shorter 
epitopes. MHC class I molecules usually bind peptides 8-10 amino acids in length (Hewitt 
2003) whereas for MHC class II molecules the peptides recognized are longer (13-25 aa) 
(ten Broeke et al. 2013). MHC class I-restricted epitopes tend to be acquired from 
endogenous proteins (viral or self) in the cytosol that get broken down in the proteasome or 
by giant tripeptidyl aminopeptidase II complex and are then transported into the lumen of 
the ER by the transporter associated with antigen processing (TAP) protein (Raghavan et 
al. 2008). In the endoplasmic reticulum (ER), the peptides are assembled onto MHC class I 
molecules. The MHC class I α chains in the ER are bound to an ER chaperone protein 
calnexin that stabilizes them. Binding to β2-microglobulin leads to release of the complex 
from calnexin and binding to a peptide loading complex consisting of tapasin, MHC class I, 
ERp57, calreticulin and TAP transporters (Raghavan et al. 2008). The peptide may be 
further modified/cleaved by ER-associated aminopeptidases and is then loaded onto the 
MHC class I molecule (Raghavan et al. 2008). Peptide containing MHC class I complex is 
then released and transported to the plasma membrane.  
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MHC class II molecules tend to recognize exogenous peptides acquired from the endocytic 
pathway. The α and β chains of the MHC class II molecule associate with an invariant chain 
in the ER that stabilizes the molecule and transports the complex via the trans-Golgi network 
to the late endosomal MHC class II compartment (MIIC) (Rocha & Neefjes 2008). There, the 
invariant chain is cleaved by cathepsin S and L to produce a small peptide fragment called 
class II-associated invariant chain peptide (CLIP) (Rocha & Neefjes 2008). An accessory 
protein called DM (DO in B cells) replaces CLIP residing in the peptide binding groove with 
the antigenic peptide (Rocha & Neefjes 2008). The MHC class II-peptide complexes are 
then transported to the cell membrane. 
 
1.6. T cell activation 
T cells interact transiently and non-specifically with many different APCs by binding to 
adhesion molecules such as ICAM-1. When T cells recognise their respective peptides 
bound to the MHC class I or II complex, a conformational change in adhesion molecule LFA-
1 on T cells is induced via TCR signalling which also aids tighter binding to ICAM-1 or ICAM-
3 expressed on APCs, thus resulting in the formation of an immunological synapse (Brownlie 
& Zamoyska 2013). A three signal T cell activation model has been proposed for the process 
of antigen presentation, resulting in differentiation of naïve T cells into either antigen-specific 
T helper cells or cytotoxic T lymphocytes (CTL). The first signal, also known as Ag-specific 
activation, is the interaction of TCR and antigen bound to the MHC molecule. The second 
signal (co-stimulation) leads to interaction of co-stimulatory molecules CD80/86 expressed 
on the APC and receptors (CD28) on the surface of T cells (Goral 2011). Co-stimulation is 
required to maintain T cell activation. The absence of co-stimulatory signal may lead to 
limited T cell proliferation, T cell anergy or apoptosis (Harding et al. 1992). Lastly, signal 3 
leads to upregulation of cytokines such as interleukin (IL)-12 and their receptors on the 
surface of T cells (Goral 2011).  Release of cytokines results in clonal expansion of T cells. 
The magnitude of the T cell response may be affected by factors such as the antigen, its 
concentration and the TCR binding affinity (Keck et al. 2014). Repeated T cell exposure to 
antigens maintains large populations of T cells. The majority (~90-95%) of antigen-specific 
T cells, however, are eliminated when antigen exposure is low (Harty & Badovinac 2008).  
The remaining 5-10% of antigen-specific T cells become long-lived central memory or 
effector memory T cells that can respond more rapidly and effectively upon subsequent 
antigen encounter.  
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1.7. T cell roles in controlling tumours 
The recent success of checkpoint inhibitors has highlighted the important role that T cells 
play in controlling malignancies. Several characteristics make T cells an appealing cancer 
therapy: 1) they can differentiate between normal and malignant cells; 2) immune responses 
are broad and robust (10,000-fold clonal expansion once activated); 3) they can migrate to 
the tumour and 4) the generation of a memory T cells can provide long term therapeutic 
benefit (Perica et al. 2015). 
 
CD4+ helper T cells play a critical role in promoting adaptive immune responses by priming 
and activating CD8+ T cells, generating CD8+ memory T cells (Shedlock & Shen 2003) or 
recruiting NK cells and macrophages to tumour sites (Durrant et al. 2000). In addition to this, 
CD4+ T cells also prime and induce maturation of APCs and B cells. Studies have 
demonstrated a role for infiltrating antigen-specific cytotoxic CD4+ T cells in arresting tumour 
progression (Tran et al. 2014; Matsuzaki et al. 2015; Shklovskaya et al. 2016; Greenberg et 
al. 1985). Tumours expressing MHC class II peptides can be killed by direct cytotoxic action 
of CD4+ T cells mediated in part by perforin and granzyme release (Quezada et al. 2010; 
Haabeth et al. 2014). Although haematopoietic tumours and melanomas can express MHC 
class II (Mendez et al. 2009), the vast majority of somatic cells and solid tumours do not 
(although expression can be induced by IFN-γ) (Ting et al. 2002; Chamuleau et al. 2006). 
Consequently, the majority of direct anti-tumour immune responses are thought to be 
executed by CD8+ T cells. CD8+ T cells directly lyse cells expressing target peptides. The 
ratio of CD8 T cells/TRegs have been associated with benefit on overall survival of cancer 
patients (Gooden et al. 2011). Tumour infiltrating memory CD8+ T cells have shown clinical 
effect in Merkel cell carcinoma (Paulson et al. 2011) and colorectal cancer patients (Galon 
et al. 2006). 
 
Although TRegs play an important role in suppressing autoimmunity (they are important in 
maintaining self-tolerance in autoimmune diseases as well as allergy), in cancer, these cells 
augment tumour growth progression. TRegs release cytokines that suppress other immune 
cells (T cells, B cells, NK cells, DCs and macrophages) (Sakaguchi et al. 2009). Poor 
prognosis has been associated with large frequencies of TReg tumour infiltrating lymphocytes 
(TIL) in tumour tissues. Depletion of TRegs in a mouse cancer model, has been shown to 
result in increased infiltration of CD8+ T cells into the tumour site and establishment of anti-
tumour immunity upon second tumour challenge (Shimizu et al. 1999; Li et al. 2010). 
Analysis of tumour-antigen (5T4) specific CD4+ T cell responses in colorectal cancer patients 
showed correlation between more advanced stages of cancer and weak T cell responses 
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induced. The loss of T cell responses was caused by induction of antigen-specific TRegs. 
Depletion of TRegs using cyclophosphamide, however, enhanced 5T4-specific CD4+ T cell 
responses in patients (Scurr et al. 2013). 
 
1.8. Adoptive T cell therapy 
The majority of tumour antigens are self-antigens and consequently poor immunogens due 
to the central tolerance mechanism established in the thymus (section 1.2). T cells capable 
of targeting tumour antigens therefore tend to be low frequency, low avidity and may even 
be anergic (Crespo et al. 2013; Staveley-O’Carroll et al. 1998). In addition to this, cancer 
patients undergo multiple rounds of chemotherapy treatment that suppresses their anti-
tumour immune responses. Adoptive T cell therapy is one form of cancer immunotherapy 
that has gained interest in the community. Adoptive T cell therapy is an alternative to cancer 
vaccines and has been successful in treating cancer, when harnessed correctly. Using this 
approach, cytotoxic T cells specific for the cancer are isolated from a patient, modified to 
recognize and destroy cancer cells, expanded ex vivo and re-infused back into the patient 
to increase T cell frequency, specificity, avidity and enhance effector function (Perica et al. 
2015). Tumour-specific T cells can be generated by stimulating them with a tumour-specific 
antigen presented by autologous APCs (i.e. DCs). For effective treatment it is important to 
obtain large numbers of cells; it has been suggested that at least 1-10% of CD8+ T cells 
need to be antigen-specific (2-20× 109 T cells/inoculum in humans) (Yee 2005). Additional 
things to consider are longevity of T cells, their capacity to migrate to tumour sites and the 
strength of anti-tumour response.  
 
In order to generate effective T cell cancer therapy, it is important to break tolerance which 
may, however, result in autoimmunity and put the individual at risk. The most success in 
clinical trials has been achieved by stimulating T cells with tumour antigens that tend to be 
neonatal, expressed in compartments (e.g. testes) or exogenous (viral antigens). Adoptive 
T cell therapy has shown promise in leukaemia and Epstein–Barr virus (EBV)-associated 
post-transplant lymphoproliferative disease (Heslop et al. 1996). The use of T cells 
expressing α and β chains specific for melanoma-associated antigen recognized by T cells 
1 (MART-1) have resulted in tumour regression in melanoma (Morgan et al. 2006). Anti-
CD19 chimeric antigen receptor (CAR) T cell therapy in acute lymphoblastic leukaemia 
(ALL) patients led to complete remission in 90% patients (Maude et al. 2014). The use of 
CD8+ T cells from a matched donor, stimulated against Wilms tumour antigen 1 showed 
transient anti-leukemic responses in some patients (Chapuis et al. 2013). Other types of 
cancer in which adoptive therapy has been applied include ovarian cancer, renal cell 
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carcinoma, B cell ALL and neuroblastoma (Davila et al. 2014; Childs et al. 2000; Lamers et 
al. 2006; Park et al. 2007). Adoptive cell therapy has been adapted to DCs to generate a 
drug (sipuleucel-T (Provenge)) approved by the United States Federal Drug Administration 
to treat prostate cancer. 
 
Although adoptive T cell therapy can clearly be beneficial, its routine use in cancer treatment 
is constrained by the fact it is both expensive, cell production costs >£25,000 per patient 
(Sharpe & Mount 2015), technically complex and labour intensive. Cells may need to be 
cultured for 4-16 weeks (Yee 2005) whilst the patient remains hospitalized. Another 
disadvantage to using adoptive T cell therapy includes thermal instability - cells require 
cryopreservation, storage and transport (Yee 2005). Finally, on-target off-tumour 
toxicity  poses a possible threat to patients (Tey 2014; Johnson et al. 2009) whereby 
engineered TCR chains and the endogenous TCR chains may re-arrange to create a TCR 
with distinct specificities.  
 
1.9. Development of cancer vaccines 
 
1.9.1. Criteria to consider when designing vaccines 
While adoptive T-cell therapy is designed to deliver a transient therapeutic immune 
response, vaccination with a cancer antigen has the potential to stimulate a sustained T-cell 
response in vivo either prophylactically or therapeutically. Ideally, a vaccine vector should 
first and foremost be effective - a single dose of the vaccine should confer life-long immunity 
to the cancer preferably within 2 weeks after administration (Beverley 2002). The vaccine 
should activate B cells, APCs, Th cells and CTLs that would produce pro-inflammatory 
cytokines as well as generate memory T and B cells.  Secondly, the vaccine should be safe 
in the entire population including immunocompromised individuals, and transmission of the 
pathogen should be inhibited (Beverley 2002). For virus vectors, this means that there 
should be limited replication and expression of viral proteins. Mortality rates of >1 in 106 
would not be considered safe in most countries. In addition to this, there should be no 
pleiotropic effects induced by these vaccines. Ideally, the vaccine should also be affordable. 
In addition to this, the route of administration is important. The preferential route of vaccine 
administration is oral, nasal or transcutaneous. Less favoured route of administration are 
injections since delivery requires trained personnel. High thermal stability (does not require 
cold chain) is another requirement that would greatly reduce the cost. Other requirements 
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include allogeneity of the vaccine so that individuals with polymorphic MHC alleles could 
receive the same vaccine. 
 
1.9.2. Virus-based cancer vaccines 
Currently available vaccines used to treat cancer include tumour cell vaccines, antigen 
vaccines (proteins or peptides), DC vaccines (the most successful thus far, e.g. Sipuleucel-
T, Provenge, licensed for use in prostate cancer patients) and vector-based vaccines 
(viruses, bacteria, yeast). The innate immunogenicity of viral and bacterial vectors is likely 
to stimulate pathogen-associated molecular pattern (PAMP) recognition and thus, robust 
immune responses. Viral vectors provide an effective mechanism for high level, sustained 
in vivo expression of cancer antigens in an autologous setting, permit delivery of multiple 
antigens and co-delivery of immunostimulatory molecules that promote appropriate 
responses (e.g. IL-2) and allow for direct delivery to the site of the tumour. Consequently, 
this helps to promote targeting of the immune response to the active tumour. Virus-based 
vectors infect cells that present peptides bound to MHC class I and II complexes on the cell 
surface. The peptide is presented more efficiently to the immune system and can induce a 
more robust immune response.  
 
According to the Wiley gene therapy clinical trial database (Figure 1), only 29% of vaccines 
targeting cancer currently being tested in clinical trials are non-viral. The most widely used 
vector is adenovirus, followed by retroviruses (18%) and members of the Poxviridae family 
of viruses (vaccinia viruses, fowlpox viruses, canarypox viruses and Modified Vaccinia 
Ankara virus (MVA)) that comprise 14% of total vectors being developed. The remaining 
32% of vectors include herpes simplex viruses (HSV), lentiviruses, measles viruses, 
Newcastle disease viruses, polioviruses, Semliki forest viruses, Simian viruses and 
Vesicular stomatitis viruses. 
 
One of the most successful cancer vaccines is a replication-deficient adenovirus encoding 
WT p53 protein under the control of Rous Sarcoma Virus (RSV) promoter called Gendicine. 
This vaccine has been approved by the Chinese State Food and Drug Administration in 
2003 for treating head and neck squamous cell carcinoma (HNSCC) patients. Phase II/III 
clinical trials in neck squamous cell carcinoma patients showed that when Gendicine was 
used with radiotherapy, 64% of the patients exhibited complete regression whilst 29% had 
partial regression (Peng 2005). Gendicine has also enhanced hepatocellular carcinoma 
patient survival and 33% of lung cancer patients had partial regression and the use of the 
vaccine alleviated disease symptoms (Peng 2005).  
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A canarypox virus-based vaccine (ALVAC-CEA-B7.1)(see Table 1) encoding 
carcinoembryonic antigen (CEA) and B7.1 co-stimulatory molecule found on APC that has 
a T cell activating receptor has shown induction of CEA-specific T cells and stabilisation of 
disease in three patients (Hörig et al. 2000).  PSA-TRICOM under the name of PROSTVAC 
is a vaccine regimen that consists of sequential vaccinia virus priming and fowlpox virus 
boost vaccinations. This vector expresses prostate-specific antigen (PSA) and proteins 
expressed on APCs (LFA-3, ICAM-1, and B7.1) and infects a broad range of cells including 
professional APCs such as DCs. Evaluation of six clinical trials showed that PROSTVAC 
induced a ≥ 2-fold increase in PSA-specific T cell counts in 57% of patients (Gulley et al. 
2014). In addition to this, lower frequency of TRegs and higher CD4+ T cell counts were linked 
to longer overall survival (Gulley et al. 2014). An MVA virus encoding a tumour-associated 
5T4 antigen (TroVax) developed by Oxford BioMedica (Kim et al. 2010) has been tested in 
colorectal, renal cell carcinoma and prostate cancer patients. TroVax induced low 
frequencies of 5T4-specific T cells as well as 5T4-specific antibodies that were associated 
with progression-free survival (Harrop et al. 2010; Harrop et al. 2013). In a phase III clinical 
trial conducted in renal patients, TroVax did not meet its primary endpoint of prolonging the 
overall survival, however, a group of patients were identified that showed signs of 
improvement (Amato et al. 2010). 
 
1.9.2.1. Oncolytic vaccines 
A different approach to replication-defective anti-cancer vaccines (described in section 
1.9.2) is the use of oncolytic vectors which have been designed to selectively replicate in 
tumour cells. As part of their replication cycle, oncolytic vectors lyse tumour cells, thus 
promoting the anti-tumour effect. In 2005, H101 was the first oncolytic vaccine approved by 
the Chinese State Food and Drug Administration for treating nasopharyngeal cancer. When 
tested in a Phase III clinical trial, H101 induced responses in 78.8% of head and neck or 
oesophagus squamous cell cancer patients receiving chemotherapy treatment as well as 
the vaccine compared to 39.6% in patients treated with chemotherapy alone (Xia et al. 
2004). A herpesvirus-based oncolytic vector that has been FDA approved for treating 
advanced melanoma called T-VEC, expresses granulocyte macrophage colony-stimulating 
factor (GM-CSF). Advanced melanoma patients receiving T-VEC in a phase III trial showed 
better responses and an improvement in overall survival (23.3 months compared to 18.9 
months) (Andtbacka et al. 2015).  
 
A major challenge in developing an effective cancer immunotherapy is to induce a 
sufficiently strong and durable immune response, capable of overcoming tolerance, poor 
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immunogenicity and an immunosuppressive tumour microenvironment. Although the 
aforementioned vectors have shown efficacy in clinical trials, especially oncolytic vectors, 
their use would not be suitable in immunocompromised patients due to safety concerns. 
There is a clear need to develop and enhance more effective vaccine delivery system 
capable of generating more potent and effective tumour-specific immune responses.    
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Adeno-associated 
virus
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Adenovirus
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Herpes simplex 
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Non-viral
29%
Figure 1: Vector usage in current cancer gene therapy trials. (Generated using data 
from (Wiley 2017))  
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Table 1:  Recent clinical trials using viral vectors as vaccine carriers (adapted 
from: (Cawood et al. 2012)) 
Vaccine 
name 
Virus 
Tumour-
associate
d 
antigen/M
odificatio
ns 
Immuno
stimulat
ory gene 
Outcome References 
ALVAC
-CEA-
B7.1 
Canary 
pox 
CEA B7.1 
16% patients with CEA-
specific T cell responses 
showed disease stabilisation 
(Hörig et al. 
2000) 
TRICO
M-PSA 
(PROS
TVAC) 
Vaccini
a/Fowlp
ox 
PSA 
TRICOM: 
(LFA-3, 
ICAM-1, 
and 
B7.1) 
Compiled data showed that 
57% of patients tested had a 
2-fold increase in the 
frequency of PSA-specific T 
cells following vaccination 
(Gulley et al. 
2014) 
OXB-
301 
(TroVa
x) 
MVA 5T4  
Well tolerated vaccine. 
Higher 5T4-specific antibody 
levels linked to improved 
patient survival. No 
difference in the overall 
survival was seen in phase III 
clinical trial conducted in 
renal cell carcinoma patients. 
(Amato et al. 
2010; Harrop 
et al. 2010; 
Harrop et al. 
2007) 
Gendic
ine 
Ad 
E1 
replaced 
with 
Rous 
Sarcoma 
Virus 
(RSV) 
promoter 
and WT 
p53 
 
Approved by State Food and 
Drug Administration of China 
in 2003 for treating head and 
neck squamous cell 
carcinoma. In clinical trials: 
64% of late-stage head and 
neck squamous cell 
carcinoma (HNSCC) tumours 
experienced complete 
regression and 32% 
experienced partial 
regression. 
(Pearson et 
al. 2004) 
Oncolytic 
vectors 
    
JX-594 
Vaccini
a 
ΔThymidi
ne 
kinase 
GM-CSF 
Tested in phase I and I/II 
trials in liver cancer, 
melanoma and colorectal 
cancer patients: partial 
responses, stable disease 
and lymphocyte infiltration 
(Park et al. 
2008; Hwang 
et al. 2011; 
Breitbach et 
al. 2011) 
OncoV
ex-
GMCS
F/ 
Talimo
gene 
laherpa
repvec 
(T-
VEC) 
HSV 
ΔICP34.
5 and 
ΔICP47 
GM-CSF 
Approved by the FDA in 2015 
for treatment of melanoma. In 
phase I, I/II and III melanoma, 
breast, head and neck, 
gastrointestinal cancer: 
induction of local and 
systemic tumour specific T 
cell responses, decreased 
regulatory T cells; prolonged 
progression-free survival, 
tumour-specific responses 
and complete remission 
(Hu et al. 
2006; 
Harrington et 
al. 2010; 
Senzer et al. 
2009; 
Kaufman et 
al. 2010; 
Bilsland et al. 
2016) 
Oncori
ne 
(H101) 
Ad Δ E1B-
55kDa 
 
 
 
In 2005, the State FDA of 
China approved the use of 
Oncorine for treating 
nasopharyngeal cancer 
(Ma et al. 
2009) 
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Ad – adenovirus; CEA - carcinoembryonic antigen; FDA-  Food and Drug Administration; 
GM-CSF - granulocyte-macrophage colony-stimulating factor; HSV – Herpes Simplex 
virus; ICAM - intercellular adhesion molecule; LFA - Lymphocyte function-associated 
antigen; MVA- Modified Vaccinia Ankara virus; PSA – prostate specific antigen; WT – 
wild type. 
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1.9.3. Cancer antigens 
A key requirement for a cancer vaccine, is that it must raise an immune response against 
a protein present on the tumour. Cancer antigens were first discovered in 1960s and 
since then have been widely used in attempts to eradicate cancer (Black et al. 1963). 
Currently, tumour antigens (see Table 2) are classified into: 1) differentiation antigens 
(e.g. tyrosinase; Tyrosinase-Related Protein, TRP1/gp75; TRP2; glycoprotein 100, 
gp100 and Melanoma antigen, Melan-A) (Vigneron 2015) expressed on tumours as well 
as normal differentiated cells; 2) overexpressed proteins  (e.g. HER2; Wilms’ Tumour 1, 
WT1; Epidermal Growth Factor Receptor, EGFR; telomerase and survivin)(Vigneron 
2015; Bright et al. 2014) that provide a growth advantage to the cell; 3) mutant proteins 
(e.g. ras, β-raf, CDK4, p53, BCR-ABL) (Vigneron 2015) that promote cell cycle 
deregulation, a replicative advantage or tissue invasiveness; 4) antigens altered post-
translationally (e.g. mucin 1, MUC1) (Ghosh et al. 2013); 5) oncoviral antigens (E6 and 
E7 from HPV; T antigen of Simian virus 40 (SV40) and antigens from EBV) (Tashiro & 
Brenner 2017); 6) idiotypic antigens (Ig, TCR) (Zarour et al. 2003); 7) proteins normally 
restricted to testes (e.g. New York oesophageal Squamous cell carcinoma 1, NY-ESO-
1; melanoma antigen, MAGE; B melanoma antigen, BAGE; G antigen, GAGE and 
Synovial Sarcoma X-chromosome breakpoint 1, SSX-1) (Zendman et al. 2003) and 8) 
oncofoetal proteins (e.g. CEA and 5T4) whose expression is normally restricted to testes, 
ovaries or trophoblasts yet absent on somatic cells (Woods et al. 2002; Shuster et al. 
1977).  
 
The vast majority of proteins expressed on cancerous cells are also expressed on normal 
tissues. Tumour-specific antigens are expressed only on neoplastic cells whereas 
tumour-associated antigens are antigens also found on normal tissues that display more 
abundant expression on tumours. Tumour-associated antigens do not bind T cells as 
well as tumour-specific antigens since these are foreign and more immunogenic (Stone 
et al. 2015).   
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Table 2: Tumour antigens and their distribution (adapted from (Wurz et al. 2016)) 
Antigen Cancer types 
B melanoma antigen 
(BAGE) 
Glioblastoma; ovarian 
Carcinoembryonic antigen 
(CEA) 
Colorectal cancer 
Epidermal growth factor 
(EGF) 
Non-small cell lung cancer 
Epidermal growth factor 
receptor (EGFR) 
Non-small cell lung cancer 
G antigen (GAGE) Cervical 
Glycoprotein 100 (gp100) Melanoma 
Human papillomavirus 16 
(HPV-16) 
Cervical; squamous cell 
carcinoma of the head and 
neck 
Melanoma antigen 3 
(MAGE-A3) 
Melanoma; non-small cell 
lung cancer 
Melanoma antigen C2 
(MAGE-C2) 
Gastric; melanoma; multiple 
myeloma 
Melanoma antigen D4 
(MAGE-D4) 
Colorectal cancer 
Melanoma antigen (Melan-
A) 
Melanoma 
Mucin 1 (MUC1) 
Non-small cell lung cancer; 
breast; prostate 
New York oesophageal 
squamous cell carcinoma 
1 (NY-ESO-1) 
Ovarian; melanoma 
Synovial sarcoma X-
chromosome breakpoint 1 
(SSX1) 
Prostate; multiple myeloma 
Survivin 
Melanoma; glioma; solid 
tumours 
Telomerase Pancreatic 
Wilms’ Tumor-1 (WT1) 
Ovarian; uterine; acute 
myelogenous leukaemia 
5T4 
Renal cell carcinoma; 
colorectal cancer; prostate 
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1.9.3.1. 5T4 
5T4 protein is a heavily N-glycosylated, transmembrane protein that is 72 kD in size 
(Hole & Stern 1990). It is made up of an extracellular domain comprising of leucine-rich 
repeats that play a role in protein-protein interactions, a transmembrane domain and a 
short cytoplasmic tail (Shaw et al. 2002). Human 5T4 protein shares 81% sequence 
identity with mouse 5T4. The two proteins differ primarily around the regions containing 
glycosylation sites (Shaw et al. 2002).  
 
5T4 is classed as an oncofoetal tumour-associated antigen since it is highly expressed 
(see Table 3) on primary and metastatic solid tumours (cervical, colorectal, gastric, 
ovarian, prostate, lung and renal cancers) as well as human trophoblasts (Southall et 
al. 1990; Stern et al. 2014). It has been shown that 5T4 downregulates E-cadherin 
(Carsberg et al. 1996), enhances matrix metalloproteinase activity (F. V Castro et al. 
2012), inhibits Wnt/β-catenin signalling, activates non-canonical Wnt pathways 
(Kagermeier-Schenk et al. 2011), disrupts actin microtubules (Carsberg et al. 1996) and 
is involved in facilitating CXCL12/CXCR4 chemotaxis (Southgate et al. 2010). The 
aforementioned roles are linked to epithelial mesenchymal transition (EMT), which is 
important for metastatic spread/invasion of cancer cells.  Overexpression of 5T4 in 
mouse fibroblasts, epithelial cells and canine epithelial cells leads to altered cell 
morphology with reduced adherence and increased cellular motility (Carsberg et al. 
1995; Carsberg et al. 1996). In addition to this, higher 5T4 expression has been 
associated with worse clinical outcomes in colorectal, gastric, ovarian and head and 
neck squamous cell carcinoma patients (Wrigley et al. 1995; Starzynska et al. 1992; 
Starzynska et al. 1998; Kerk et al. 2016). 
 
The limited tissue distribution of 5T4 in healthy adults, its association with metastasis 
and expression on cancer stem cells all make this molecule an exceptionally attractive 
therapeutic target. Stern and Harrop used the criteria devised by the National Cancer 
Institute to calculate the rank of 5T4 antigen among other priority cancer vaccine target 
antigens. Interestingly, 5T4  ranked  9th out of 75 tumour-associated antigens, higher 
than NY-ESO-1, CEA, gp100, PSA and p53 (Stern & Harrop 2017). To date, four 
different approaches have been adopted to target 5T4: 1) an antibody–superantigen 
fusion protein, 2) an antibody-drug conjugate (ADC) 3) CAR T cell therapy and 4) TroVax 
cancer vaccine (Stern & Harrop 2017). An antibody-superantigen fusion protein 
developed under the name of ANYARA (naptumomab estafenatox) has been evaluated 
in numerous clinical trials (Eisen et al. 2014). The use of naptumomab estafenatox 
together with interferon α has improved survival rates of advanced renal cell carcinoma 
(RCC) patients (Elkord et al. 2015; Hawkins et al. 2016). An ADC targeting 5T4 is 
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currently undergoing preclinical trials but thus far has shown improvement in survival of 
mouse models of ALL, an effect further enhanced when ADC was used in conjunction 
with dexamethasone (McGinn et al. 2017). The use of anti-5T4 antibody-drug conjugate 
(MEDI0641) in a HNSCC model resulted in durable tumour-regression and depletion of 
cancer stem cells (Kerk et al. 2016). CAR T cell therapy program developed by Oxford 
BioMedica (OXB-302) is currently undergoing analyses of the most recent clinical trial. 
Previous work tends to suggest, however, that 5T4 epitope-specific CTL cells are 
efficient at killing 5T4 expressing cancer cells as well as impede tumour growth 
completely when prophylactically inoculated into cancer models  (Tykodi et al. 2012; Al-
Taei et al. 2012). Lastly, TroVax has undergone ten phase I and II clinical trials in different 
cancer settings and although the primary endpoints of the clinical trials were not met, 
this vaccine was well tolerated and induced humoral and cellular responses that delayed 
tumour progression (Hawkins et al. 2009; Amato et al. 2009). 
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Table 3: 5T4 expression in cancer evaluated using immunohistochemistry of 
cryostat sections (adapted from (Stern & Harrop 2017)) 
 
Cancer % Positive 5T4 expression 
Bladder 100  
Breast 96  
Cervical 
100  
97  
Colorectal 
100  
54 
Gastric 
56  
40  
52  
Non-small cell lung 
cancer 
100 
>95  
Mesothelioma 100 
Ovarian 
71  
100 
79 
Pancreatic 
100 
>95   
Prostate 
100  
84  
Renal 95  
The table shows a summary of multiple studies (references not shown) identifying 5T4 
expression in different types of cancer. Immunohistochemistry was used to confirm 5T4 
positive tumours using the monoclonal antibody 5T4 was originally identified with.    
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1.10. Adenoviruses 
 
1.10.1. Classification  
Adenoviruses are safe, effective and widely used vaccine vectors, capable of inducing 
specific T-cell responses. The Adenoviridae family of viruses consists of three genera 
that infect mammals, birds and fish and are called Mastadenoviruses, Aviadenoviruses 
and Ichtadenoviruses, respectively. In addition to this, two genera  Atadenoviruses and 
Siadenoviruses  are found in vertebrate species (International Committee on Taxonomy 
of Viruses (ICTV) 2016). Each genus is further subdivided into a total of 62 species of 
viruses. Human adenoviruses are part of Mastadenovirus genus. Currently, there are 
seven human mastadenoviruses that are called A-G that were classified based on 
serology, hemagglutination and oncogenic properties. Genome analysis of the hexon 
capsid protein led to diversification of human mastadenoviruses into 57 serotypes with 
the most common ones being human serotypes 2 and 5 (subgroup C).  
 
1.10.2. Disease and tropism 
Adenoviruses were first isolated from adenoid tissue-derived cell culture. Since then, 
work using these viruses has revealed that they infect a wide variety of dividing and non-
dividing cells. Interestingly, virus tropism may be species-dependent (see Table 4). 
Human adenovirus species A-C and E infect primarily the respiratory tract, species B- E 
are associated with eye infections, species A, C, D, F and G infect intestinal tract 
whereas species B and C affect urinary tract and tonsils/adenoids, respectively (Arnberg 
2012). Other species-specific tissues include pharynx, pancreas, spleen, liver, 
myocardium and central nervous system (CNS) (Wold & Ison 2013). 
 
Approximately 2-5% of respiratory infections in humans are caused by adenoviruses. In 
accordance with serotype-specific tropism, adenovirus serotypes 3, 5 and 7 have been 
associated with lower respiratory tract infections; serotypes 4 and 7 are responsible for 
acute respiratory diseases; serotypes 8, 19 and 37 are known for causing epidemic 
keratoconjunctivitis whereas serotypes 40 and 41 are associated with gastroenteritis. In 
immunosuppressed and immuno-naïve individuals, adenoviruses have also been linked 
to incidents of fatal pneumonia, hepatitis and encephalitis (Ison 2006).  
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Table 4:  Human Adenovirus Receptor usage and Tropism adapted from (Arnberg 
2012) 
 
Species Serotypes Receptors Tropism 
A 12, 18, 31 hCAR 
Cryptic (enteric, 
respiratory) 
B1 3, 7, 16, 21, 50 
CD46, DSG-2, 
CD80, CD86 
Respiratory, ocular 
B2 11, 14, 34, 35 
CD46, DSG-2, 
CD80, CD86 
Renal, ocular, 
respiratory 
C 1, 2, 5, 6 
hCAR, HSPG, 
VCAM-1, SR, MHC-
I-α2 
Respiratory, ocular, 
lymphoid, hepatic 
D 
8-10, 13, 15, 17, 19, 20, 22-
30, 32, 33, 36-39, 42-49, 
51, 53, 54 
SA, CD46, hCAR Ocular, enteric 
E 4 hCAR Ocular, respiratory 
F 40, 41 hCAR Enteric 
G 52 nd Enteric 
hCAR, human Coxsackievirus and adenovirus receptor; DSG-2, desmoglein-2; HSPG, 
heparan sulfate proteoglycan; VCAM-1, vascular cell adhesion molecule 1; SR, 
scavenger receptor; MHC-I, major histocompatibility complex class I; SA, sialic acid; nd, 
not determined.  
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1.10.3. Immunogenicity 
Adenoviruses are highly immunogenic viruses. The first trigger of innate immunity is 
adenovirus fiber protein binding to Coxsackievirus and adenovirus receptor (CAR) which 
activates ERK1/2, JNK, MAPK and Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and upregulates chemokines (IL-8, GRO-alpha, GRO-gamma 
and RANTES and interferon-inducible protein 10) (Tamanini et al. 2006). The presence 
of extracellular virions activates the complement system which leads to blocking of viral 
attachment and entry. Pre-existing neutralizing antibodies are found in the majority of 
the population and prevent virus uptake (Nwanegbo et al. 2004; Zhang et al. 2013; 
Piedra et al. 1998). During natural adenovirus infection, neutralizing antibodies to the 
fiber and penton are induced whilst vaccination using adenovirus vectors/multiple 
infections result in accumulation of neutralizing antibodies to the hexon (Bradley et al. 
2012; Yu et al. 2013). The binding of neutralizing antibodies block Ad receptor binding 
and entry and lead to macrophage uptake (Schagen et al. 2004). Interestingly, virion 
binding to factor X (an enzyme of the coagulation pathway) serves as a protection 
mechanism against inactivation by complement and neutralization by IgM antibodies 
(Doronin et al. 2012; Z. Xu et al. 2013). Adenovirus PAMPs trigger toll-like receptors, 
TLRs (e.g. TLR2 and TLR9) in a cell type-specific manner which activate type I IFN 
(Appledorn et al. 2008). Secretion of IFN acts a chemoattractant for lymphocytes, 
monocytes and DCs. Adenoviruses infect APCs (i.e. DCs) and stimulate their maturation 
which results in improved activation of the adaptive immune response (Morelli et al. 
2000). T-cell responses are induced by the structural proteins (i.e. capsid). Adenovirus-
specific CD4+ and CD8+ T cells recognize hexon and have been found in PBMCs of 
seropositive patients. CD8+ T cells exist in larger frequencies than CD4+ T lymphocytes 
(Wold & Ison 2013). The CD8+ T cells exhibit an effector memory phenotype (Bassett et 
al. 2011). 
 
A lot of work in the adenovirus field has been carried out in mice and involves the use of 
recombinant vectors. It has been shown that within minutes of systemic adenovirus 
administration, innate immune responses to the vector are induced and increase until 
about 24 h post infection (pi). NK cell activation is dependent on accessory cells (i.e. 
macrophages and DCs) and occurs hours after the administration of Ad vectors (Peng 
et al. 2001; Ruzek et al. 2002; Zhu et al. 2010). Transcription of genes is not required for 
induction of innate immune responses (Schnell et al. 2001; Muruve et al. 1999). The 
dose of the virus used, on the other hand, plays an important role in the induction of 
innate immune responses but not to adaptive immune responses  (Liu & Muruve 2003). 
The route of vector administration together with the level of pre-existing neutralizing 
antibody levels plays a more important role in the induction of humoral immune 
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responses (neutralizing antibodies) than dosage (Harvey et al. 1999). Recombinant 
adenovirus vectors are cleared within 2-3 weeks due to CD4+ and CD8+ T cell responses 
to the vector and the expression cassette (Yang et al. 1994; Yang et al. 1996; Zhu et al. 
2007).   
   
1.10.4. Genomic organization 
Adenoviruses are double stranded DNA viruses that are approximately 26-46 kb in 
length. Conserved genes are encoded in the centre of the genome whilst genes specific 
to the particular species are located at the termini. The ends of the genome (Figure 2) 
contain identical inverted terminal repeats (36-200 base pairs, bp) necessary for viral 
DNA replication. Adenoviruses contain genes encoding over 40 proteins. Early proteins 
(E1A, E1B, E2A, E2B, E3 and E4) are expressed before the onset of viral DNA replication 
whereas late proteins (L1-L5 and UXP) are expressed afterwards (Tollefson et al. 2007). 
The E1A gene products activate gene transcription and alter the cell cycle so that it 
enters the S phase. The E1B proteins prolong cell survival by inhibiting apoptosis. The 
E2 region encodes proteins that play a role in DNA synthesis whereas E3 and E4 
proteins are essential for immunomodulation of the host cell environment, transcription, 
splicing and translation. Some late gene products (L1-L5 and UXP) are viral capsid 
proteins whereas others may play a role in DNA replication, virion assembly and DNA 
packaging (Tollefson et al. 2007). In addition to early and late proteins, adenoviruses 
encode four intermediate gene products (IX, IVa2, VA RNAs I and II) that are vital for 
DNA packaging, and modulating host cell responses. 
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Figure 2: Genome organization of Ad5. The genome is ~36 kb in size divided into early 
(light blue), intermediate (dark blue) and late transcription units (black). Inverted terminal 
repeats (ITRs) on either end of the genome play a role in DNA synthesis whereas the 
packaging signal (Ψ) is involved in packaging viral DNA into the virion. Major late 
promoter (MLP) is required for late gene transcription. Viral-associated (VA) RNAs 
(green) play a role in virus replication, interferon signalling and RNA interference 
pathway. 
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1.10.5. Generation of adenovirus vectors 
Adenoviruses have been well characterized and thus, modifications to the genome 
making these viruses safe and less immunogenic have also been established. Three 
different types of replication-deficient adenovirus vectors have been constructed. In first-
generation vectors, E1 and (in some vectors) the E3 region are removed and may be 
replaced with an expression cassette (Danthinne & Imperiale 2000). Since proteins 
produced from the E1 region are required for trans-activating expression of other viral 
genes, these vectors are replication-deficient and need to be grown in complementing 
cell lines that express the E1 proteins (e.g. HEK293, 911 and PER.C6) (Danthinne & 
Imperiale 2000). The E3 gene products are non-essential for virus growth in vitro and 
therefore do not need to be trans-complemented (Danthinne & Imperiale 2000). First-
generation vectors can accommodate ~5-8 kb of foreign DNA, due to DNA packaging 
constraints (Danthinne & Imperiale 2000; Vetrini & Ng 2010). Second-generation vectors 
are also E2/E4-deleted to allow insertion of 10-14kb DNA (Danthinne & Imperiale 2000). 
The E4 region is essential for virus replication; these vectors must be grown in cells that 
also trans-complement the E4 region. In addition to this, a third generation of vectors 
have also been developed. These vectors, termed ‘gutted vectors’ have all of the viral 
genes deleted and only encode the cis-acting sequences which increases the coding 
capacity of these vectors to 37 kb (Danthinne & Imperiale 2000). Growing these vectors 
up requires a helper virus encoding adenovirus genes, and a number of techniques must 
be used to reduce contamination of virus stocks with the helper virus (Parks et al. 1996). 
 
1.10.6. Currently available anti-cancer vectors 
To date, there have been over 500 clinical trials using adenoviruses in gene therapy 
settings (Wiley 2017). Several characteristics account for the widespread use of these 
vectors. Adenoviruses induce strong cellular and humoral immune responses.  Due to 
the small genome size, adenoviruses have been well characterized and can be easily 
manipulated. In addition to this, adenoviruses can be stably grown to high titre stocks 
with strong transgene expression. These viruses infect both dividing and non-dividing 
cells of different types without integrating into the host genome. The use of first-third 
generation adenovirus vectors ensures safety of these vectors whilst also allowing 
accommodation of large foreign DNA inserts. First-generation vectors with the E1 
deleted region are one of the most commonly used type of adenovirus vectors. Some of 
these vectors encode costimulatory molecules like CD40 ligand, IL-2, IL-7, IL-12, GM-
CSF, IFN-α, β and γ whereas others express tumour-associated antigens (gp100, pp65, 
a-fetoprotein, MUC-1 and PSA). A number of studies have used adenovirus vectors that 
encode pro-apoptotic genes (p53, tumour necrosis factor (TNF)-α and TNF-related 
apoptosis-inducing ligand, TRAIL) as well as cell cycle inhibitors (pRB, p21 and p16), 
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anti-angiogenic agents (endostatin), epidermal growth factor receptors and sodium 
iodine symporter. 
 
Numerous vectors have been tested in clinical trials but the most widely studied are 
Advexin and Gendicine that encode the pro-apoptotic protein p53 in the E1 region 
(Gabrilovich 2006). P53 is a tumour suppressor mutated in about 50% of cancer patients 
which results in cell cycle disruption and neoplasia. Targeting this protein would thus 
allow selective cell killing.  Advexin has shown promise in non-small cell lung cancer, 
squamous cell carcinoma of the head and neck, hepatocellular carcinoma, glioma, 
breast, ovary, prostate, bladder and colorectal cancers (Nemunaitis & Nemunaitis 2011; 
Senzer & Nemunaitis 2009; Roth 2006; Wold & Ison 2013). The use of Gendicine as 
treatment for head and neck squamous cell carcinoma was approved  in 2003 by the 
State Food and Drug Administration of China (Peng 2005). Since then, it has been 
estimated that over 7000 patients have been treated with Gendicine (Ma et al. 2009). 
Another vector called sitimagene caradenovec, encoding herpes virus thymidine kinase 
(TK) (serves as a suicide gene as it converts prodrugs to active drugs) has been used in 
phase I/II and III clinical trials and has improved survival rates in patients with operable 
high-grade glioma (van Putten et al. 2010). Treatment with a nucleoside analogue 
ganciclovir results in phosphorylation of ganciclovir. Ganciclovir triphosphate is 
incorporated into DNA and kills TK expressing cells. Similar vectors have also been used 
for treating hepatocellular carcinoma and prostate cancer models (Sangro et al. 2010; 
Cheon et al. 2000). Replication-deficient adenovirus vector (CTL-102) encoding bacterial 
enzyme nitroreductase has been studied together with a pro-drug (CB1954) in phase I/II 
clinical trials and showed low cytotoxicity and induction of antibodies in prostate cancer 
patients (Palmer et al. 2004). More recently, preclinical studies looking at adenovirus 
vector encoding guanylate cyclase 2C  (a receptor serving as a biomarker, expressed 
primarily on intestinal epithelium that shows dysregulated signalling in colorectal cancer 
due to loss of hormone ligands, guanylin and uroguanylin), fused to a CD4+ T cell epitope 
have shown the safety of this vector and strong anti-tumour responses (Snook et al. 
2016). In addition to this, adenovirus vector expressing human papillomavirus type 16 
and 18 antigens have shown great promise in cancer models in mice (Khan et al. 2017). 
The large number of trials that use these viruses underlines their safety and 
immunogenicity. 
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1.11. Cytomegaloviruses 
 
1.11.1. Classification and significance 
Cytomegaloviruses (CMV) have recently come to prominence as potentially powerful 
vaccine vectors. CMV are members of the Herpervirales order, the Herpesviridae family, 
Betaherpesvirinae subfamily, the genus Cytomegalovirus. The Cytomegalovirus genus 
consists of 8 species of viruses. Other genera that belong to herpesviridae family (see 
Figure 3) are muromegaloviruses (mouse and rat viruses) and roseoloviruses (human 
herpesvirus types 6A, 6B and 7) whereas three species that have not yet been assigned 
to a genus are Caviid betaherpesvirus (guinea pig) 2, Suid betaherpesvirus (porcine) 2, 
Tupaiid betaherpesvirus 1 (tree shrew) (International Committee on Taxonomy of 
Viruses (ICTV) 2016).  
 
The viruses within the Betaherpesvirinae subfamily exhibit higher level of evolutionary 
and genetic heterogeneity than other viruses within the herpesviridae family. These 
viruses are highly species-specific, infect differentiated hematopoietic and epithelial cells 
from homologous species, display similar cytopathology under the electron microscope 
(EM) and exhibit longer replication cycles during in vitro infection (Görzer et al. 2010; 
Cunningham et al. 2010; Bobek et al. 2010; Renzette et al. 2011). 
 
1.11.2. Prevalence 
Human CMV (HCMV) is a ubiquitous pathogen found in 45-100% of humans worldwide, 
depending on the age and socioeconomic status of the population sampled (Cannon et 
al. 2010). Generally, in developing countries most people will contract the virus in the 
first few years of life whereas in developed countries, where the seroprevalence is lower, 
the virus tends to be gradually acquired through life and thus associated with a higher 
rate of primary infection during pregnancy (Cannon et al. 2010; Gratacap-Cavallier et al. 
1998; Griffiths et al. 1985; Staras et al. 2006). Interestingly, HCMV infection rates tend 
to be higher in females than males as a study in Germany had demonstrated 49% 
seroprevalence compared to 42.5% in males (Hecker et al. 2004; Staras et al. 2006). 
Additional risk factors that associate with higher incidence of HCMV infection include 
premature birth, lower household income, household crowding, ethnicity and age 
(Cannon 2009; Bate et al. 2010; Pembrey et al. 2013). Although the total seroprevalence 
rate in US is 59%, it varies greatly between different states (Cannon 2009). For example, 
there are 40% of HCMV seropositive individuals in Albany, New York compared to 79% 
in Houston (Ho 1990). 
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Figure 3: Evolutionary comparison of viruses in the Betaherpesviridae family 
(adapted from (Wilkie et al. 2015)). The phylogenetic neighbour-joining tree was 
generated using amino acid sequences of essential genes (U38, U39, U40, U41, U57, 
U60, U77, and U81) from viruses of the Betaherpesviridae family. The scale bar 
represents nucleotide differences/nucleotide. HCMV, human cytomegalovirus; CCMV, 
chimpanzee cytomegalovirus; GMCMV, green monkey cytomegalovirus; RhCMV, 
rhesus cytomegalovirus; OMCMV, owl monkey cytomegalovirus; SMCMV, squirrel 
monkey cytomegalovirus; GPCMV, guinea pig cytomegalovirus; MSHV, Miniopterus 
schreibersii herpesvirus; TuHV, tupaiid herpesvirus 1; MCMV, murine cytomegalovirus; 
RCMVE, rat cytomegalovirus England; RCMV, rat cytomegalovirus; HHV6A, human 
herpesvirus 6A; HHV6B, human herpesvirus 6B; HHV7, human herpesvirus 7; and 
PCMV, porcine cytomegalovirus. 
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1.11.3. Tropism 
CMV is a species-specific virus that displays very wide tissue tropism, enabling it to infect 
the majority of organs in the host. Despite species-specificity, the HCMV Towne strain 
can replicate in chimpanzee fibroblasts in vitro (Sinzger & Jahn 1996) whereas, mouse 
CMV (MCMV) is capable of infecting rats (Smith et al. 1986). In many cases when CMV 
crosses species, virus can enter cells, express immediate early genes but fails to 
promote efficient virus DNA synthesis and proceed to late stages of infection.   
 
HCMV can readily be detected in bodily fluids (saliva, semen, urine)  with epithelial cells 
thought to be an important primary site of infection and, ultimately, virus shedding 
(Sinzger & Jahn 1996). Virus dissemination through the host is mediated primarily in the 
bloodstream by cells of the immune system, most notably monocytes, macrophages and 
DCs. Permissive endothelial cells include capillaries and venules lining the brain, in the 
lung, gastrointestinal tract, cardiac endothelial cells, and microvessels in placenta 
(Sinzger & Jahn 1996). CMV has also been shown to infect fibroblasts and specialized 
parenchymal cells such as smooth muscle cells in gastrointestinal tract, neuronal cells 
and hepatocytes (Sinzger & Jahn 1996; Revello & Gerna 2010; van Den Pol et al. 1999). 
Following initial infection, the virus establishes latency for the lifetime of the host. CMV 
is known to persist in bone marrow-derived hematopoietic cells (e.g. CD34+ progenitors 
and CD14+ monocytes) and endothelial cells (arterial walls). Studies have shown that 
infection of monocytes with HCMV is limited to expression of latency transcripts with the 
full transcriptional cascade and progeny virus being produced only when the cells 
differentiate into macrophages or DCs (Ioudinkova et al. 2006; Mendelson et al. 1996).  
 
The immune system plays a critical role in controlling CMV infections through life. In an 
immune-naïve individual, the virus spreads to all organs except for pancreas, kidney, 
spleen, adrenal, small bowel, placenta, liver, brain, bone marrow, and heart (Bissinger 
et al. 2002). In immunocompromised patients, the disseminated virus can be associated 
with severe multi-organ disease. Infection can be detected in mucosal layers of the 
stomach, duodenum, ileum and rectum  (Sinzger & Jahn 1996).  
 
1.11.4. Transmission 
HCMV is transmitted person-to-person via bodily secretions such as urine, saliva, breast 
milk and genital secretions or fomites contaminated with secretions (Cannon 2009; 
Staras et al. 2008). There is no evidence suggesting that the virus could be spread by 
aerosols, therefore, good personal hygiene (e.g. handwashing) is one of the most 
effective ways of reducing viral transmission (Stowell et al. 2012). In seropositive adults, 
the virus is shed in 7-20% population, and those with greater numbers of sexual partners 
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or STDs are more susceptible to HCMV infection  (Sohn et al. 1991; Chandler et al. 1985; 
Coonrod et al. 1998; Hyde et al. 2010; Pereira & Maidji 2008).   
 
Although of great clinical significance, the rate of HCMV transplacental transmission is 
remarkably low with only about 0.5-4% of newborns become infected with HCMV in 
developed countries and 2-4% in developing countries (Kaye et al. 2008; Mussi‐Pinhata 
et al. 2009; Schopfer et al. 1978; Stagno et al. 1982). HCMV-seronegative pregnant 
women that become infected with HCMV pose a greater risk of passing the virus to their 
foetus than seropositive mothers do (Mocarski et al. 2013). In seropositive women, 
congenital infection with HCMV is observed following re-infection or reactivation of latent 
virus (Mocarski et al. 2013). Approximately 33% of mothers experiencing a primary 
infection transmit the virus to their foetus as compared to 1% of HCMV-seropositive 
mothers (Kenneson & Cannon 2007; Cannon et al. 2011). Seropositive mothers secrete 
neutralizing antibodies in their breast milk that impede virus transmission to about 69% 
of nursed infants (Ehlinger et al. 2011). Approximately 95% of HCMV-seropositive 
mothers shed virus in their milk from day 9 to 3 months postpartum  (Vochem et al. 1998; 
Asanuma et al. 1996; Hotsubo et al. 1994; Jim et al. 2004; Ahlfors & Ivarsson 1985). 
Newborns infected with HCMV shed virus for many months to years in their saliva and 
urine and this serves as a route for viral transmission, most notably to siblings  (Cannon 
et al. 2011). About 10% of women shed HCMV in their vaginal excretions around the 
time of delivery  (Stagno et al. 1982). In about 50% of cases where a newborn comes 
into contact with the virus during delivery it becomes infected (Reynolds et al. 1973). 
Infection of newborns at the time of delivery or breastfeeding does not cause clinical 
disease unless the newborn is premature or of low birth weight.  
 
1.11.5. Disease 
HCMV infection in healthy individuals is usually sub-clinical and 90% of primary 
infections in  pregnant women is asymptomatic (Stagno et al. 1986; Griffiths & Baboonian 
1984). Immunocompetent individuals will occasionally develop infectious  
mononucleosis that manifest as prolonged fever, fatigue, headache, skin rash, 
splenomegaly, hepatomegaly,  myalgia or enlarged lymph nodes (Correa et al. 2011). 
HCMV can also be a cause of enteritis, transverse myelitis, thrombosis, haemolytic 
anaemia, encephalitis, myocarditis as well as various eye condition problems in 
otherwise healthy adults (Abgueguen et al. 2010; Markomichelakis et al. 2002; Veldhuis 
et al. 2004; Fux et al. 2003; Sato et al. 2004). HCMV infection in these patients is usually 
controlled by the immune system, although, there have been rare cases in which death 
has been reported (Studahl et al. 1994; Arribas et al. 1996). Whilst adults are twice as 
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likely to be febrile, children are more prone to develop hepatomegaly and splenomegaly 
(Pannuti et al. 1985).  
 
Although the majority of newborns will remain asymptomatic, 12.7% may display signs 
of petechiae, jaundice with associated hyperbilirubinemia, hepatosplenomegaly, 
thrombocytopenia, chorioretinitis, seizures, microcephaly and others (Dollard et al. 
2007).  Premature babies and those of low birth weight are highly susceptible to HCMV 
disease, often manifesting as hepatomegaly or pneumonitis (Stagno et al. 1981; Kumar 
et al. 1984). Preterm neonates that acquire HCMV through vertical transmission develop 
neutropenia, lymphocytosis, thrombocytopenia, hepatosplenomegaly and respiratory 
problems (Yeager et al. 1983). Congenital HCMV infection acquired postpartum from the 
mother can result in sepsis-like syndrome apnea, bradycardia, grey pallor and bowel 
distention (Vochem et al. 1998; Hamprecht et al. 2008; Hamprecht et al. 2001). One of 
the most common symptoms in HCMV-infected newborns is sensorineural damage 
characterized by hearing loss (25%), eyesight problems (11%) and learning difficulties 
affecting 12-25% of neonates (Boppana et al. 1992; Istas et al. 1995; Dollard et al. 2007). 
The level of viremia is linked to the severity of congenital disease (Boppana et al. 2005; 
Bradford et al. 2005; Lanari et al. 2006) and high virus loads detected in placenta have 
been linked to stillbirth (Iwasenko et al. 2011).   
 
In immunosuppressed and immunocompromised individuals such as Acquired 
Immunodeficiency Syndrome (AIDS) patients or solid organ transplant recipients, latent 
virus reactivates. Severe HCMV disease symptoms are usually observed in 
immunocompromised patients and have been associated with HCMV viremia (Drew 
2007). The onset of HCMV disease is usually observed 4-8 weeks after solid organ 
transplant (Fishman 2011). In liver transplant patients, where the donor is HCMV-
seropositive and the recipient is seronegative (D+R-),  the rate of HCMV infection within 
the first year after transplant is 17.6% (Freeman et al. 2004). Pneumonitis, 
gastrointestinal disease, hepatitis, retinitis, pancreatitis, myocarditis, encephalitis and 
peripheral neuropathy are all symptoms that have been linked to end-organ-disease in 
transplant patients. Pneumonitis and gastrointestinal disease are the two most common 
symptoms in hematopoietic cell transplant (HCT) patients. HCT recipients  (D+R-)  usually 
develop complications and have the lowest survival rates (Nichols et al. 2002). Heart 
transplant patients can develop cardiac allograft vasculopathy which greatly affects graft 
survival (Potena & Valantine 2007).  Studies looking at hospital care costs required for 
HCMV-associated symptoms in organ transplant showed that these patients require 
longer hospital stay and have a higher cost of care (Falagas et al. 1997; Legendre et al. 
2000; Mauskopf et al. 2000).  Hospital readmission of renal and heart transplant patients 
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raised hospital costs by $22,598 and $42,111, respectively (Henderson et al. 2001). 
HCMV has been associated with atherosclerosis (Derhovanessian et al. 2011) and 
cancer (Cobbs 2011; Melnick et al. 2012; Soroceanu et al. 2011) but lack of direct 
scientific proof makes this topic controversial. Apart from increased susceptibility to 
bacterial and fungal infections in immunocompromised, HCMV has also been shown to 
weaken immune responses to vaccines (Pawelec et al. 2009).   
 
1.11.6. Treatment 
Currently available CMV antiviral drugs (ganciclovir, valganciclovir, foscarnet and 
cidofovir) target the viral DNA polymerase and HCMV DNA synthesis (Fishman 2007; 
Snydman et al. 2011). Ganciclovir and its prodrug valganciclovir are nucleoside analogue 
drugs that are phosphorylated to ganciclovir triphosphate but when incorporated into 
DNA strand, they terminate DNA synthesis (Littler et al. 1992). Patients are treated with 
ganciclovir/valganciclovir for two weeks or until symptoms subside and virus is no longer 
detected in the blood.  Foscarnet, on the other hand, targets pyrophosphate (PPi)  
binding sites on viral DNA polymerase and prevents cleavage and release of a PPi 
moiety which inhibits DNA synthesis (Zahn et al. 2011). In cases where HCMV mutates 
and becomes resistant to ganciclovir/valganciclovir, foscarnet  or cidofovir are used 
instead (Razonable 2011). Occasionally, acyclovir and valaciclovir (500 
mg/m2 intravenously (i.v.) 3 times daily for 1 month, followed by 800 mg 4 times daily for 
6 months) are prescribed for HCMV treatment, however, their mode of action is non-
specific to HCMV since it does not encode a thymidine kinase necessary to 
phosphorylate acyclovir to make it biologically active against the viral DNA polymerase 
(Meyers et al. 1988; Prentice et al. 1994).  
 
The use of the aforementioned drugs with the exception of acyclovir is strictly regulated 
since all of them are associated with toxicity. Ganciclovir is recommended for patients 
who are Human Immunodeficiency Virus (HIV)-positive or who are HCMV-seropositive 
and whose CD4+ T cell counts are lower than 50 cells/μl (www.cdc.gov). Antiviral therapy 
is recommended to all HCMV-seronegative patients undergoing kidney, liver, pancreas, 
heart and lung transplants as well as individuals receiving immunosuppressive treatment 
to prevent organ rejection (Kidney Disease: Improving Global Outcomes (KDIGO) 
Transplant Work Group 2009; Kotton et al. 2010). In the organ pre-transplant setting, 
prophylaxis with i.v. ganciclovir and oral valganciclovir is the standard procedure 
whereas post-transplant, their use is deferred in case they induce graft failure. To limit 
virus transmission in blood transfusions, HCMV-seronegative blood is preferred but 
when it is unavailable, seropositive blood products are filtered to remove latently infected 
leukocytes. CMV seropositive immunoglobulin is available for the treatment in 
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ganciclovir-resistant infections.  Passive immunization using T cells from HCMV-
seropositive donors have shown good results in HCT recipients but this method is not 
routinely used due to costs and time-effectiveness (Walter et al. 1995; Cobbold et al. 
2005; Einsele & Hamprecht 2003; Peggs et al. 2011; Peggs et al. 2009). Prophylactic 
immunization of renal transplant patients with live-attenuated Towne strain induced  
antibody and cellular immune responses that protected against challenge with low dose 
of Toledo (Plotkin et al. 1989; Jacobson et al. 2006). Interestingly, the use of  highly 
active antiretroviral therapy (HAART) in HIV-infected individuals has an indirect effect in 
reduction of HCMV viremia, severity of the disease and opportunistic infections 
(Snydman et al. 1993; Steininger et al. 2006).  
 
The recommendation for treating congenital HCMV disease symptoms is by i.v. 
ganciclovir administered  (6 mg/kg of body weight) every 12 hours for 6 weeks (Mofenson 
et al. 2009). In an attempt to prevent and treat congenital disease, neutralizing HCMV-
specific IgG are either given to pregnant women with primary CMV or infected newborn 
(Mussi‐Pinhata et al. 2009; Nigro et al. 2012; Nigro et al. 2005). Several promising 
antiviral drugs exist that have not yet been FDA-approved and are not yet available on 
the market. One of these drugs (maribavir) targets UL97, however, more testing to 
determine the dosage and safety of the drug needs to be carried out. A distinct mode of 
mechanism is used by Letermovir (AIC246) which is highly specific for HCMV and targets 
ppUL56 terminase subunit that blocks late stages of viral replication (Goldner et al. 
2011). Antiviral therapy, although effective at controlling lytic CMV replication, cannot 
eliminate latent virus pools.  
 
The National Vaccine Program Office in the United States have placed HCMV as a 
priority in vaccine development (Arvin et al. 2004). Up until now the attempts to generate 
a CMV vaccine include a subunit vaccine made of glycoprotein B (gB) in an oil-in-water 
MF59 adjuvant that has been tested in a phase II clinical trial and decreased HCMV 
infection in pregnant women by 50% in another trial (Pass et al. 2009; Griffiths et al. 
2011). A bivalent DNA vaccine (VCL-CB01/TransVax/ASP0113) comprised of DNA 
plasmids encoding gB and pp65 are undergoing clinical trials at the moment but thus far 
have shown tolerance, induction of T cell responses and reduction of CMV viremia 
(Schleiss 2009; Wloch et al. 2008; Kharfan-Dabaja et al. 2012).  Other attempts to 
generate an effective CMV vaccine include a recombinant canarypox vector encoding 
pp65 (Berencsi et al. 2001); a chimeric virus made up of Towne and Toledo strains 
(Heineman et al. 2006); alphavirus replicon vaccine expressing CMV gB or pp65/IE1 
(Bernstein et al. 2009); defective virus particles (dense bodies) containing immunogenic 
peptide (IE1) (Becke et al. 2010);  a chimeric replication-deficient adenovirus vaccine 
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encoding HCMV epitopes (Zhong et al. 2008)  and vectors expressing activating NK cell 
receptor ligands (Slavuljica et al. 2010). Before a CMV vaccine gets FDA approved, 
however, many factors need to be considered: 1) serostatus; 2) age; and 3) risk group 
of the individuals to be vaccinated. 
 
1.11.7. Viral strains   
For HCMV work to progress, it is important to work with CMV strains that closely 
resemble clinical CMV isolates. Complete genomes sequenced from patient samples 
and passaged strains have shown that CMV exhibits a high level of genome 
heterogeneity; it is more diverse than any other betaherpesvirus (Cunningham et al. 
2010; Görzer et al. 2010; Görzer et al. 2008; Renzette et al. 2011; Sijmons et al. 2015; 
Mocarski Jr. 2007; Davison 2007). Sijmons et al analysed 100 clinical HCMV isolates 
and showed that 77% of clinical HCMV isolates contain open reading frame (ORF)-
disrupting mutations and only a minority of clinical viral isolates (23%) are genetically 
intact (Sijmons et al. 2015). It has been suggested that superinfection with multiple 
HCMV strains may serve to trans-complement deleterious mutations (Cicin-Sain et al. 
2005).  
 
Thus far, a lot of work in the CMV field has been carried out using the AD169, Toledo 
and TB40 HCMV strains.  The limitations to using AD169  (Chee et al. 1990)  and Towne 
(Dunn et al. 2003; E. Murphy et al. 2003) are that these lab-adapted strains have been 
extensively propagated in vitro and contain a lot of mutations, deletions and have 
genome rearrangements  (Ahlqvist & Mocarski 2011; Cunningham et al. 2010; Dargan 
et al. 2010; Cui et al. 2012).  
 
To address the issue of genome stability, low-passage HCMV isolates have been cloned 
into a bacterial artificial chromosome (BAC) (FIX, TB40/E, PH) but the original virus stock 
has not been sequenced prior to BAC cloning, therefore the viruses may have acquired 
mutations that may affect virus biology. In addition to this, most BACs contain prokaryotic 
sequences in place of US2, US3, US6 and US11 genes that are involved in viral tropism 
and NK cell recognition (Murrell et al. 2013; Magri et al. 2011). The Merlin HCMV strain 
has been designated as the first World Health Organization reference sequence for 
HCMV. Stanton and others cloned a low-passage (p5) strain Merlin genome into a BAC 
(Stanton et al. 2010).  Any acquired mutations were repaired by comparing the sequence 
to the sequence of the original clinical sample. This clone contains the WT CMV genome 
complement, and virus derived from the BAC differs from the original clinical virus just 
by the addition of a loxP site in between US28 and US29 (Stanton et al. 2010).   
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1.11.8. Genomic organization 
HCMV is the largest human virus ever characterized. Its genome comprises of linear 
double-stranded DNA, approximately 236 kbp in size containing 3’-single base 
overhangs at each termini (Davison 2007). The DNA can be subdivided into unique long 
UL (193,019 bp) and unique short US (35,481 bp) regions with  inverted and terminal 
repeats on either side containing cis-acting signals (pac1 and pac2) necessary for 
genome cleavage, isomerisation and encapsidation (Wang & McVoy 2011). Closely 
related CMV strains tend to have terminal repeats of a similar size (e.g. HCMV and 
guinea pig CMV terminal repeats are 1000 bp whereas MCMV terminal repeats are only 
50 bp long). HCMV and chimpanzee CMV genomes are the only ones to encode inverted 
a sequence repeats, thus their genomes are also known as class E genomes. As a result 
of sequence inversion, class E genomes form 4 equimolar isomers (Davison 2007). 
Other CMV genomes (RhCMV and MCMV) are class A genomes since their unique 
sequences are flanked by direct sequence repeats (Hansen et al. 2003; Rivailler et al. 
2006; Davison 2007). The structure for HCMV is best depicted using the following 
configuration: 5’ ab-UL-b’a’c’-US-ca 3’. In the Merlin strain of HCMV, the a/a’ repeat is 
578 bp long, the b/b’ (Terminal Repeat Long, TRL and Internal Repeat Long, IRL) is 1324 
bp and c/c’ (Terminal Repeat Short, TRS and Internal Repeat Short, IRS) is 2537 bp in 
length. Several HCMV strains that have been heavily passaged contain a duplicated a’ 
sequence.  
 
A substantial proportion of the HCMV genome is comprised of 15 gene families that tend 
to be located at the extremities of the UL region or in US. The herpesvirus core genes: 
(Figure 4) have homologues in other herpesviruses that are responsible for virus 
replication and encode virion structural proteins. Comparison with the genomes of simian 
cytomegalovirus suggest that genes close to the distal regions of the UL region have 
been acquired relatively recently. The numbering system of genes UL148-UL133 (UL/b’ 
sequence) is inverse because the element was first characterised in strain Toledo; 
unfortunately the UL/b’ sequence is inverted in strain Toledo (Cha et al. 1996). The 
current genome nomenclature is as follows: RL1-13, UL1-150, IRS1, US1-US34, TRS1. 
Genomic analysis of HCMV DNA led to identification of 167 protein-coding genes, 4 
genes coding for large non-coding RNAs (lnRNA), 2 oriLyt RNAs and 23 microRNAs 
(miRNAs) (Grey et al. 2005; Dunn et al. 2005; Pfeffer et al. 2005; Stark et al. 2012; 
Cunningham et al. 2010). Similarly to genes coding for miRNA and long non-coding RNA 
(lncRNA), genes encoding proteins of different kinetic classes (immediate early, early 
and late) do not form distinct clusters and are interspersed throughout the genome. The 
location of origin of DNA synthesis (oriLyt) is conserved in herpesviruses and is found 
between genes UL57 and UL69. 
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Figure 4: Genomic structure of WT HCMV (strain Merlin)(Mocarski et al. 2013). 
Inverted repeats (terminal repeat long/internal repeat long (TRL/IRL) and terminal repeat 
short/internal repeat short (TRS/IRS)) are represented as broader lines. Protein-coding 
regions are colour-coded (see legend) whereas introns are indicated by white bars. 
Essential (core) genes are displayed in red. CXCL - chemokine (C-X-C motif) ligand; 
DURP- deoxyuridine triphosphatase-related protein; GPCR - (G protein-coupled 
receptor; MHC – major histocompatibility complex; RL – repeat long; UL- unique long; 
US – unique short; ORF- open reading frame.    
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1.11.9. Essential and non-essential genes 
The annotation of the HCMV genome has changed over the years. Sequencing of the 
lab-adapted AD169 HCMV genome, followed by bioinformatic analysis, led to the 
identification of  208 ORFs  with 14 gene duplications (Chee et al. 1990; Eain Murphy et 
al. 2003). Analysis of an earlier passage HCMV strain (Toledo) led to the addition of 19 
additional ORFs. More recently, alignment of a clinical HCMV strain and chimpanzee 
CMV (CCMV) (the most evolutionary similar virus to HCMV), along with analysis of a 
clinical strain (Merlin) at passage 3, resulted in refinement of the number of protein-
coding ORFs to 165 ORFs (Davison et al. 2003).  Other groups have used in silico 
pattern-based approaches (ProCeryon and Bio-Dictionary) as well as deep sequencing 
of viral RNA transcripts to predict the number of protein-coding genes (Gatherer et al. 
2011; E. Murphy et al. 2003; Rigoutsos et al. 2003; Novotny et al. 2001), while analysis 
of temporal mRNA expression by ribosome profiling has led to identification of 751 
translated ORFs, some of which have been confirmed by mass spectrometry (Stern-
Ginossar et al. 2012).  
 
Functional analysis of Towne genome deletion mutants revealed that only 45 of the gene 
products are essential (Table 5) for virus replication in fibroblasts (Dunn et al. 2003). The 
core genes U44-UL105; Ul114-115) clustered in the middle of the genome (Figure 4) are 
largely essential, with non-essential genes located at either end of the genome. 78% of 
these core proteins are conserved and found in other herpesviruses (Dunn et al. 2003).  
More than 50% of the conserved genes encode structural capsid proteins, tegument 
gene products and envelope proteins (Mocarski Jr. 2007). Deletion of some ORFs 
impaired viral replication in endothelial and epithelial cells, but not fibroblasts, suggesting 
that these proteins play an important role in cell tropism, while other gene products 
actually appeared to inhibit replication (Dunn et al. 2003).  Overall, 117 proteins were 
non-essential for HCMV growth in fibroblasts. These results were validated by another 
group that used random transposon mutagenesis targeting approximately 150 ORFs and 
found that AD169 HCMV genome encoded 41 essential, 88 non-essential and 27 
augmenting ORFs (Yu et al. 2003). Sequence alignment of HCMV genome to other 
betaherpesviruses has shown that CCMV is the closest evolutionary relative (163/168 
protein homologs), followed by rhesus CMV (111 homologs), guinea pig CMV (84), 
MCMV and rat CMV (75 homologs), however, these numbers may change as more 
protein coding ORFs are discovered in CMV (Mocarski et al. 2013).  
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Table 5: Essential and non-essential HCMV genes (adapted from (Dunn et al. 
2003)). 
ORFs 
Conservati
on 
Function Growth ORFs 
Conserv
ation 
Function Growth 
UL32 β-herpes Tegument Essential UL2 CMV Unknown 10-1–10-2 
UL34 CMV 
Unknown 
(transcriptio
n) 
Essential UL11 CMV 
Glycoprotei
n 
10-2-10-3 
UL37.1 
β-
herpes/CM
V 
Anti-
apoptotic 
Essential UL12 CMV Unknown 10-1-10-2 
UL44 Core 
DNA 
replication 
Essential UL14 CMV Unknown 10-2-10-3 
UL46 Core Capsid Essential UL20 CMV 
TCR 
homolog 
10-2–10-3 
UL48 Core Tegument Essential UL29 β-herpes Unknown 10-2-10-3 
UL48.5 Core 
Capsid 
protein 
Essential UL31 β-herpes 
Transcriptio
n 
10-2-10-3 
UL49 Core Unknown Essential UL35 β-herpes 
Tegument/t
ranscription 
10-2-10-3 
UL50 Core Egress Essential UL38 β-herpes Unknown 10-2-10-3 
UL51 Core 
DNA 
packaging/cl
eavage 
Essential UL47 Core 
Tegument-
DNA 
release 
10-3–10-4 
UL52 Core 
DNA 
packaging/cl
eavage 
Essential UL65 CMV 
Unknown 
(pp67 virion 
protein) 
10-2-10-3 
UL53 Core Egress Essential UL72 Core dUTPase 10-3-10-4 
UL54 Core 
DNA 
polymerase 
Essential UL74 β-herpes 
Glycoprotei
n O 
10-3–10-4 
UL55 Core 
Glycoprotein 
B 
Essential UL88 β-herpes Tegument 10-2-10-3 
UL56 Core 
DNA 
packaging/cl
eavage 
Essential UL97 Core 
Protein 
kinase 
10-2–10-3 
UL57 Core 
ssDNA 
binding 
protein 
Essential UL103 Core Unknown 10-2-10-3 
UL60 CMV 
Unknown 
(oriLyt?) 
Essential UL108 CMV Unknown 10-2-10-3 
UL70 Core 
Helicase/pri
mase 
Essential UL114 Core 
Uracil DNA 
glycosylase 
10-3–10-4 
UL71 Core Unknown Essential UL129 CMV Unknown 10-2-10-3 
UL73 Core 
Glycoprotein 
N 
Essential UL132 CMV Unknown 10-2-10-3 
UL75 Core 
Glycoprotein 
H 
Essential US13 CMV Unknown 10-1–10-2 
UL76 Core Unknown Essential US23 β-herpes Unknown 10-2-10-3 
UL77 Core 
DNA 
packaging/cl
eavage 
Essential TRS1 CMV 
Transcriptio
n/egress 
10-2–10-3 
UL79 Core Unknown Essential Growth like wild type (68 mutants, 78 ORFs) 
UL80 Core 
Capsid 
assembly 
Essential UL3 CMV Unknown 
Dispensa
ble 
UL84 β-herpes 
DNA 
replication 
Essential UL4 CMV 
Glycoprotei
n 
Dispensa
ble 
UL85 Core Capsid Essential UL5 CMV Unknown 
Dispensa
ble 
UL86 Core Capsid Essential UL6 CMV Unknown 
Dispensa
ble 
UL87 Core Unknown Essential UL7 CMV Unknown 
Dispensa
ble 
UL89.1 Core 
DNA 
packaging/cl
eavage 
Essential UL8 CMV Unknown 
Dispensa
ble 
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CMV – cytomegalovirus; IE – immediate early; IL- interleukin; MHC – major 
histocompatibility complex; ORF – open reading frame; ssDNA – single stranded 
DNA; TCR – T cell receptor; UL- unique long; US – unique short.  
UL90 CMV Unknown Essential UL10 CMV Unknown 
Dispensa
ble 
UL91 β-herpes Unknown Essential UL13 CMV Unknown 
Dispensa
ble 
UL92 β-herpes Unknown Essential UL15 CMV Unknown 
Dispensa
ble 
UL93 Core Unknown Essential UL16 CMV 
Immunomo
dulation 
Dispensa
ble 
UL94 Core 
Unknown 
(tegument) 
Essential UL17 CMV Unknown 
Dispensa
ble 
UL95 Core Unknown Essential UL18 CMV 
MHC 
homolog 
Dispensa
ble 
UL96 β-herpes Unknown Essential UL19 CMV Unknown 
Dispensa
ble 
UL98 Core 
Alkaline 
nuclease 
Essential UL24 β-herpes Tegument 
Dispensa
ble 
UL99 Core Tegument Essential UL25 β-herpes Tegument 
Dispensa
ble 
UL100 Core 
Glycoprotein 
M 
Essential UL27 β-herpes Unknown 
Dispensa
ble 
UL102 Core 
Helicase/pri
mase 
Essential UL33 β-herpes 
G protein 
receptor 
Dispensa
ble 
UL104 Core 
DNA 
packaging/cl
eavage 
Essential UL36 β-herpes 
Anti-
apoptotic 
Dispensa
ble 
UL105 Core 
Helicase/pri
mase 
Essential UL37.3 β-herpes Unknown 
Dispensa
ble 
UL115 Core 
Glycoprotein 
L 
Essential UL39 CMV Unknown 
Dispensa
ble 
UL122 β-herpes 
IE2 
(transcriptio
n) 
Essential UL42 CMV Unknown 
Dispensa
ble 
Severe growth defect (12 mutants) UL43 β-herpes Tegument 
Dispensa
ble 
UL21 CMV Unknown <2×10-4 UL45 Core 
Ribonucleot
ide 
reductase 
Dispensa
ble 
UL26 CMV 
Tegument 
(transcription
) 
<2×10-4 UL59 CMV Unknown 
Dispensa
ble 
UL28 β-herpes Unknown <2×10-4 UL62 CMV Unknown 
Dispensa
ble 
UL30 CMV Unknown <2×10-4 UL64 CMV Unknown 
Dispensa
ble 
UL69 Core 
Tegument 
(transcription
) 
<2×10-4 UL67 CMV Unknown 
Dispensa
ble 
UL82 β-herpes 
Tegument 
(transcription
) 
<2×10-4 UL78 CMV 
G protein 
receptor 
Dispensa
ble 
UL112 β-herpes 
Major early 
protein 
<2×10-4 UL83 β-herpes Tegument 
Dispensa
ble 
UL113 β-herpes 
Major early 
protein 
<2×10-4 UL89.2 Core 
DNA 
packaging/c
leavage 
Dispensa
ble 
UL117 β-herpes Unknown <2×10-4 UL109 CMV Unknown 
Dispensa
ble 
UL123 CMV IE1 <2×10-4 UL110 CMV Unknown 
Dispensa
ble 
UL124 CMV 
Latent 
transcript 
(ORF152) 
<2×10-4 
UL111
a 
CMV 
IL-1O 
homolog 
Dispensa
ble 
US26 β-herpes Unknown <2×10-4 UL116 CMV Unknown 
Dispensa
ble 
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1.11.10. Replication cycle 
Infection (Figure 5) begins with attachment of virion glycoproteins to their cellular 
receptors. The glycoprotein-receptor binding results either in a pH-independent entry as 
seen in fibroblasts, where the virus fuses with the plasma membrane at the cell 
membrane or endocytic viral entry (in endothelial and epithelial cells) that may be either 
pH-dependent or pH-independent (Compton et al. 1992; Ryckman et al. 2006; Sinzger 
2008). The virus enters DCs via a pathway that resembles macropinocytosis and is pH-
independent (Haspot et al. 2012). Upon envelope fusion, ppUL47 and ppUL48 mediate 
viral uncoating and tegument proteins are released into the cytoplasm where they 
interact with cellular proteins and modulate the environment to enable virus replication. 
The viral nucleocapsid is transported to the nuclear pores via cytoskeletal filaments by a 
dynein/dynactin motor protein complex. These microtubules may also play a role in virus 
release (Mocarski Jr. 2007). Next, the nucleocapsid interacts with nuclear pores and the 
viral DNA is released from the portal into the nucleus. After entering the nucleus, viral 
DNA localizes with promyelocytic leukaemia (PML)-bodies which are matrix-associated 
structures that act as an intrinsic defence mechanism against the virus. Viral pp71 protein 
acts to relieve transcriptional suppression by degrading a PML-body protein. ppUL84 
binds to IE2 and attracts other viral proteins to PML-bodies and initiates transcription of 
viral  genes (Spector & Tevethia 1994). The viral genome circularies and RNA pol II 
transcribes immediate early genes (α or IE genes). Translation of genes is carried out by 
host cell ribosomes. Once IE1 is expressed, it disrupts the PML-bodies in the nucleus 
thus enhancing viral gene expression and consequently, replication (Wilkinson et al. 
1998; Kelly et al. 1995). Immediate early genes act as transactivators of expression of 
other CMV genes by binding to cellular transcription factors. This in turn, activates the 
transcription of delayed early genes (β or DE) which can be further classified into β1 and 
β2 that play a role in DNA synthesis. IE1-p72, IE2-p86, ppUL84, UL112-UL113 and 
ppUL44 proteins attract other replisome proteins. ppUL84 binds to the origin of 
replication and initiates DNA replication. Although initially lytic DNA replication is likely to 
proceed in the theta form it switches to the rolling circle mechanism of replication, then 
covalent head-to-tail concatemers are cleaved to single genome units (Challberg 1996).  
In fibroblasts, DNA synthesis starts at about 14-16 hours post infection (hpi) and reaches 
a peak at about 24 hpi (10,000 genomes/cell) (Towler et al. 2012; Pari 2008). In other 
cell types, such as epithelial cells and astrocytomas, the virus only replicates to 1,000 
genome copies per cell. Expression of L genes (γ) (48-72 hpi) which are involved in virion 
formation, maturation and release relies on expression of delayed early genes. Late 
genes can be categorized into leaky late (γ1) or true late (γ2) genes. This depends on the 
pattern of expression – the majority of late genes are leaky since their expression is DNA 
replication-independent and commences even if no DE genes have been expressed.  
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True late genes are absolutely dependent on DNA replication for expression. Viral 
maturation and release takes place in this final stage of viral replication at 48-72 hpi. 
 
Viral procapsids assemble in the nucleus adjacently to the DNA replication compartment. 
The scaffold inside the capsids is replaced with viral DNA that is cleaved at pac 
(cleavage/packaging) sites as the DNA is being encapsidated. Terminase, consisting of 
two proteins pUL56 and pUL89 plays a role in encapsidation. pUL56 binds to the pac 
sequences and allows the DNA to be packaged whereas pUL89 mediates the cleavage 
of viral DNA at these sites (Bogner 2002). UL51, UL52, UL56, UL77, UL80, UL89, UL93 
and UL95 gene products may also play a role in encapsidation (Mocarski Jr. 2007). 
Newly formed nucleocapsids are translocated to the cytoplasm by a nuclear egress 
complex (NEC) via a two-step envelopment and de-envelopment process (Tandon & 
Mocarski 2012; Britt 2007).  During the first stage of envelopment and de-envelopment 
process, the virus passes through the inner nuclear membrane and as it leaves the 
nucleus, it loses its envelope by merging with the outer nuclear membrane. As the 
capsids transit through the nuclear envelope, pUL53/NEC remains attached. pUL50 
becomes incorporated into the virion as a tegument protein together with other proteins 
(viral proteins, cellular proteins and RNAs) that bind to the nucleocapsid in the 
cytoplasmic assembly compartment  (Kattenhorn et al. 2004; Varnum et al. 2004; 
Terhune et al. 2004; Greijer et al. 2000; Mocarski Jr. 2007). Virions acquire their final 
envelope by budding through ER-Golgi intermediate compartment 
(ERGIC)/endosomal/exosomal membranes and exit the cells via an exocytic vesicle 
(Tandon & Mocarski 2012; Tooze et al. 1993; Britt 2007; Liu et al. 2011). These last 
stages of viral maturation and release are usually completed within 24 hours. The peak 
of virion release occurs at around day 5 post infection until the cells die. 
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Figure 5: HCMV replication cycle (adapted from (Mocarski et al. 2013)). HCMV gains 
entry into cells either via fusion at the plasma membrane or endocytic pathway. Upon 
entry and uncoating, the nucleocapsid is transported into the nucleus. Immediate early 
genes are expressed and facilitate DNA synthesis. Next, viral DNA is encapsidated and 
as it leaves the nucleus, it is enveloped. Secondary envelopment occurs at the ER-Golgi 
intermediate compartment. Lastly, infectious virions are released via exocytosis. MT – 
microtubules; IE – immediate early; DE- delayed early; L- late; ER – endoplasmic 
reticulum; GB- Golgi body; ERGIC - The ER-Golgi intermediate compartment.  
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1.11.11. Latency and reactivation 
A characteristic feature of all herpesviruses is establishment of latency - a state in which 
the virus persists in the host for a prolonged period of time without producing any progeny 
virions. In response to certain stimuli, it reactivates and goes into a lytic replication cycle 
to produce infectious virions. HCMV establishes latency in bone marrow-derived 
mononuclear myeloid progenitor cells (CD14+ monocytes, and their CD34+ progenitors) 
where DNA is present as a non-integrated episome at very low frequency (<1 in 10,000 
cells) and low genome copy numbers (2-10 genomes/cell) (Slobedman & Mocarski 1999; 
M. B. Reeves et al. 2005; Hahn et al. 1998). There have been studies suggesting that 
HCMV may establish latency in non-hemopoietic cells as well. In vitro work has 
suggested that HCMV establishes latency in DCs and endothelial cells, however 
evidence confirming this has not been obtained in vivo (M B Reeves et al. 2005).  
 
In vitro, the virus is maintained as an episome in close proximity to nuclear structures 
called PML-bodies which are also important for IE gene expression (Tang & Maul 2006). 
It has been suggested that the major immediate early promoter (MIEP) enhancer may 
play a role in inducing latent viral state and maintaining latency in dividing hematopoietic 
progenitor cells (Reeves & Sinclair 2008; Reeves 2011; Reeves & Sinclair 2010; Stinski 
& Isomura 2008). During latency, the MIEP is repressed by epigenetic modifications such 
as methylation and de-acetylation and binding of heterochromatin 1 protein leads to 
transcriptional silencing (Poole, Wills, et al. 2014; Kumar & Herbein 2014). Histone 
deacetylase inhibiting drugs result in de-repression of the inhibited MIEP state leading 
to viral reactivation (Reeves & Sinclair 2008; Reeves 2011; Sinclair 2010). Therefore, 
regulation of MIEP expression may act as a ‘switch’ from latency to reactivation.  
 
Although no new virions are produced during latency, latency is not a transcriptionally 
quiescent state, a number of latency-associated transcripts have been discovered. CMV 
latency-specific transcripts localize to the HCMV major IE region (Kondo et al. 1996). 
Transcriptional profiling studies of CD14+ cells identified the following transcripts: long 
noncoding RNA (RNA2.7, RNA4.9) and mRNA coding for UL144, UL44, UL50, UL84, 
UL87, UL95, UL138 and antisense RNA from the UL81–82 region (LUNA) (Kumar & 
Herbein 2014). Numerous other transcripts were identified in CD34+ progenitors in 
addition to those found in CD14+ cells: mRNA coding for US17, UL28/29, UL37/38, 
UL133/135 and UL114 (Kumar & Herbein 2014). Other groups have also detected 
UL111a (LAvIL-10) and US28 transcripts (Kondo et al. 1994; Bego et al. 2005; Goodrum 
et al. 2007; Avdic et al. 2011; Poole et al. 2013; Beisser et al. 2001; Kumar & Herbein 
2014). UL111a (LAvIL-10), UL144 and US28 play immune evasion roles. LAvIL-10 
affects the cellular IL-10 levels by downregulating hsa-miR-92a which in turn leads to 
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increase in GATA2 levels and expression of cIL-10 (Poole, Avdic, et al. 2014). The anti-
inflammatory and immunosuppressive functions of IL-10 allows HCMV to persist. 
 
A study looking at immune responses to latency-associated transcripts in healthy 
seropositive adults showed that all 4 (LUNA and UL138, US28 and LAvIL-10) latency-
associated proteins that were examined were immunogenic, and that the responses 
were CD4+ T cell mediated with IFN-y effector function that also secreted cIL-10 (Mason 
et al. 2013). A number of miRNAs have been detected in latently infected cells including 
miR-UL112.1, miR-US4.1, UL148D, miR-UL112.1, miR-US4.1 miR-US25–1, miR-
US25–2 and miR-US33 that work to induce and maintain latent viral state (Kumar & 
Herbein 2014). Viral mir112.1 inhibits expression of UL123 mRNA (IE72) necessary for 
major immediate early (MIE) gene expression. 
 
1.11.12. Immunomodulation 
Even though CMV induces one of the strongest, broadest and most durable cellular and 
humoral responses of any virus, the virus establishes latency and persists for the lifetime 
of the host where it may sporadically reactivate (Cannon et al. 2010; Schoenfisch et al. 
2011; Sylwester et al. 2005; Bitmansour et al. 2001; Jackson et al. 2011). In order to 
persist for the lifetime of the host, CMV has evolved mechanisms to counteract cellular 
responses that may inhibit viral replication. The fact that only about 26% of the viral 
genome is essential for replication implies that majority of the genome may play roles in 
modulation (Table 6) of the host cell environment (Dunn et al. 2003). 
 
During its replication cycle, HCMV forms double-stranded RNA intermediates that 
activate proteins of the IFN pathway (protein kinase R (PKR) and 2’-5’ oligoadenylate 
synthetase) via TLR3 (Tabeta et al. 2004). Input pp65 protein can block interferon 
regulatory transcription factor (IRF) 3, IRF1, and/or NF-κB, however, the mechanism is 
not very well characterized (Marshall & Geballe 2009). 
 
Viral input pp71 protein de-represses immediate early gene transcription by binding to a 
PML-body protein Daxx (which would otherwise play a role in mediating apoptosis) and 
degrading it (Saffert & Kalejta 2006). Expression of immediate early genes results in 
accumulation of the p53 protein, however, the IE2 gene product (pp86) and pUL44 bind 
to p53 and block its activity (Kwon et al. 2012). Other HCMV-encoded anti-apoptotic 
proteins are viral mitochondria-localized inhibitor of apoptosis (vMIA, UL37) and viral 
inhibitor of caspase-8 apoptosis (vICA, UL36) (Poncet et al. 2004). vMIA blocks 
apoptosis by sequestering Bax in the mitochondria whereas vICA binds to caspase-8  
Introduction 
44 
 
and blocks activation of Fas/Fas ligand pathway (Poncet et al. 2004; Skaletskaya et al. 
2001).  
 
The DNA-dependent activator detects viral DNA in the cytosol and activates IRF3 and 
NF-κB/IFN-like response and RIP3-dependent cell necrotic death in HCMV and MCMV 
infected cells, respectively (Kaiser et al. 2008; Upton et al. 2010; Upton et al. 2012; Sung 
& Schleiss 2010). pIRS1 or pTRS1 target this IFN response in HCMV infected cells (Child 
et al. 2004; Marshall et al. 2009; Marshall & Geballe 2009) whilst in MCMV infected cells, 
m142 and m143 inhibit PKR activation (Budt et al. 2009; Marshall & Geballe 2009).  
 
HCMV also encodes genes (UL21.5, US27, US28, UL33, UL78 and UL144) that mimic 
cellular cytokine and chemokine receptors to alter host cellular signalling  (McSharry et 
al. 2012). It has been hypothesized that CMV has acquired genes from the host that 
have mutated over time (Alcami & Koszinowski 2000). HCMV encodes and secretes a 
cellular IL10 gene homolog (UL111A) that is likely to play a broad anti-inflammatory role. 
gpUS2, gpUS3,gpUS6 and gpUS11 play a role in retaining MHC I molecules loaded with 
HCMV peptides in the ER and degrading them which consequently allows CMV to 
escape recognition by cytotoxic T cells (Jackson et al. 2011). Although safe from 
cytotoxic T cells, HCMV infected cells become more susceptible to NK cell mediated 
lysis (Jackson et al. 2011). To counteract this, HCMV encodes genes that either 1) 
downregulate NK activating ligands (UL16); 2) mimic HLA class I (UL18); 3) up-regulate 
HLA-E (UL40);  or 4) sequester activating ligands in the Golgi (UL142) (Prod’homme et 
al. 2012; Yang & Bjorkman 2008; Prod’homme et al. 2010; Ashiru et al. 2009). HCMV 
also encodes proteins RL11-13 and UL118-119 that bind IgG and protect against 
antibody-dependent cytotoxicity (Sprague et al. 2008).  
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Table 6: Immunomodulatory genes encoded by HCMV and their targets (adapted 
from (McSharry et al. 2012; Wilkinson et al. 2015)) 
ER – endoplasmic reticulum; gp – glycoprotein; HLA- human leukocyte antigen; IgG- 
immunoglobulin G; IL- interleukin; LIR - leukocyte Ig-like receptor; MHC – major 
histocompatibility complex; MICA - MHC class I chain-related protein A; MICB - MHC 
class I chain-related protein B; mIR-microRNA, NK- natural killer; PVR- poliovirus 
receptor; TAP - transporter associated with antigen processing; TNF – tumour necrosis 
factor; TRAIL-R - ; tumour necrosis factor-related apoptosis-inducing ligand receptor; 
UL- unique long; ULBP- UL16 binding protein; US – unique short. 
  
Gene Target/Role 
miR112 miRNA against MICB 
RL11-13 IgG 
UL16 MICB, ULBP1, ULBP2 
UL18 HLA-1 homologue, binds LIR1 
UL21.5 Mimics a soluble chemokine receptor 
UL33 Mimics a chemokine receptor 
UL36 Inhibits apoptosis 
UL37 Inhibits apoptosis 
UL40 Upregulates HLA-E and gpUL18 
UL78 Mimics a chemokine receptor 
UL83 Binds NKp30 
UL111A IL-10 homologue 
UL118-119 IgG 
UL135 Inhibits synapse formation 
UL141 PVR, Nectin 2 TRAIL-R 
UL142 MICA 
UL144 Mimics TNF receptor 
US2 Promote proteasomal degradation of MHC Class I heavy chains 
US3 Retains MHC class I complexes in ER 
US6 Blocks TAP 
US11 Promote proteasomal degradation of MHC Class I heavy chains 
US18 MICA; NK cell activating ligand B7-H6 (Fielding et al. 2017) 
US20 MICA;  NK cell activating ligand B7-H6 (Fielding et al. 2017) 
US27 Mimics a chemokine receptor 
US28 Mimics a chemokine receptor 
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1.11.13. Immunogenicity of CMV 
 
1.11.13.1. Immune responses to HCMV in humans 
Prior to virus entry, extracellular virions bind to the cell surface and CMV glycoproteins 
gB and gH activate pattern recognition receptors TLR1 and TLR2; resulting in induction 
of NF-κB and inflammatory cytokine release (Boehme et al. 2006). The innate cellular 
immune responses to CMV involves professional APCs, phagocytes and NK cells. NK 
cells play an important role in initial control of virus infection (Villard 2011; Jackson et al. 
2011). T-cell responses to CMV are very variable – in some individuals a dominant 
response to a single peptide can dominate whereas in others, a broad range of  antigens 
are recognized; a particularly detailed screen was able to detect response covering 39 
ORFs (Sylwester et al. 2005). Interestingly, the frequencies of CMV-specific CD8+ T cells 
inflate throughout life, a process termed ‘memory inflation’ (Klenerman & Oxenius 2016). 
CMV-specific CD8+ T cells in the blood may make up 5-10% of total CD8+ T cells but in 
some individuals, can be as high as 30% (Sylwester et al. 2005). Majority of CMV-
specific T cells tend to be effector-memory T cells characterized by lack of lymph node-
homing receptor expression and thus, found in peripheral blood and non-lymphoid 
tissues. Unlike central memory T cells which differentiate, proliferate and provide effector 
functions only following antigen stimulation, effector memory T cells provide immediate 
protection and release high amounts of inflammatory cytokines.  
 
CD4+ T cells do not inflate to the same extent as CD8+ T cells, however they do display 
the characteristic TEM phenotype and release cytokines like IFN-γ and TNF-α  (Sylwester 
et al. 2005; Gamadia et al. 2004). CMV-specific CD4+ T cells make up 0.45% of CD4+ T 
cell pool and may be as high as 24% in some CMV-seropositive patients (Pachnio et al. 
2016). Interestingly, in individuals with asymptomatic CMV infection, the CD4+ T cell 
response is detected before CD8+ T cell response whereas in symptomatic patients, it is 
in reverse order thus demonstrating the important role of CD4+ T cells (Gamadia et al. 
2004). CD4+ T cells have also shown to be highly useful in controlling CMV in transplant 
patients. The frequencies of CD4+ T cells in kidney transplant patients can be used to 
predict the risk of virus replication for 8 weeks (Egli et al. 2008).  
 
Clearance of acute primary CMV infection has been attributed to cell-mediated 
responses, however, antibodies also play an important role (Sester et al. 2005). Studies 
have suggested that CMV-specific antibodies may play a role in controlling virus 
dissemination. Antibodies may arise 2-4 weeks after primary infection and are 
presumably raised to all expressed CMV proteins, but substantial specific response to 
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pp65, pp150, pp52, gB, gH/gL and IE1 have been used to follow infections (Genini et al. 
2011).  
 
1.11.13.2. MCMV-elicited immune responses in mice 
Studies in the mouse model of CMV have demonstrated the importance of CD4+, CD8+ 
T cells and NK cells in primary infection (Jonjić et al. 1990; Bukowski et al. 1984; Walton 
et al. 2008). Although antibodies do not appear to play a role in primary infection, they 
are of great importance in controlling reactivation of the virus (Jonjić et al. 1994). Both 
CD8+ T cells and NK cells control virus replication in majority of the organs whereas CD4+ 
T cells are crucial in controlling CMV in salivary glands (Jonjić et al. 1990). 
 
Infectious dose plays an important role in the magnitude of the immune response 
induced. Mice injected with two different doses of MCMV showed that a higher dose of 
MCMV resulted in stronger inflationary responses where up to 20% of all CD8+ T cells 
were pp89-specific (Karrer et al. 2003). In addition to this, the majority of these cells (75-
85%) were associated with the functional effector memory phenotype. A lower virus dose 
during primary infection resulted in smaller memory inflation (Redeker et al. 2014).  Re-
infection, however, may rescue this partial memory inflation (Trgovcich et al. 2016). 
Trgovcich et al noted that single transcriptional reactivation was not sufficient to restore 
memory inflation in mice injected with low virus  dose (Trgovcich et al. 2016). Conversely, 
other groups have suggested that the expansion of T cells with effector memory 
phenotype may in fact be due to chronic replication/reactivation of the virus and low-level 
expression of virus antigens is essential (Seckert et al. 2012; Beswick et al. 2013). 
 
1.11.14. Murine cytomegalovirus – model system for human 
CMV 
Understanding of human CMV biology requires a model system since these viruses are 
associated with morbidity and they do not grow in cells derived from other species. To 
date, the majority of work helping to elucidate HCMV pathology and immunology has 
been done in mice. 
  
Both HCMV and MCMV are large (230 kb) double-stranded DNA viruses that encode 
approximately 170 ORFs. The overall structure of the viral genomes is relatively similar. 
The HCMV genome is comprised of unique long and unique short regions flanked by 
inverted repeats, MCMV only contains one unique region. This means that the MCMV 
genome does not have an isomeric structure as seen in HCMV. Comparative sequence 
analysis of viral DNA shows that homology of the two viruses is 42.5% (DNA) and 78 
genes are conserved (Streblow et al. 2006).  Over millions of years, these CMVs have 
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co-evolved with their respective hosts which means that these viruses have become 
highly adapted to their host species, encoding proteins tailored to interact with host 
proteins and mechanisms that may not be found in other species. MCMV genes that 
have sequence homologues in HCMV are designated with an ‘M’ followed by the gene 
number whereas those specific to MCMV have an ‘m’. Some proteins have functional 
homologs that are located in different regions of the genome, for example the M144 gene 
product acts as a MHC class I homolog, similar to HCMV pUL18 (Rawlinson et al. 1996). 
MCMV IE1 and IE3 proteins are functional homologs of HCMV IE1 and IE2, respectively 
(Messerle et al. 1992). Even amongst functional homologues, differences exist. For 
example, IE1 in MCMV does not bind chromatin whereas HCMV IE1 protein does (Maul 
& Negorev 2008). In addition to this, HCMV IE2 plays a role in cell cycle arrest whereas 
MCMV IE3 does not (Maul & Negorev 2008).   
 
Analogous receptors are believed to play a role in viral entry and the overall mechanism 
of entry is conserved (Streblow et al. 2006). After viral entry into permissive cells, lytic 
replication cycle is induced. The two viruses express proteins of different temporal 
classes that are expressed at immediate early, early and late stages of the infection. 
Expression of immediate early proteins activates early protein expression, whilst genome 
replication is required for late protein expression. Structural analysis of HCMV and 
MCMV virion composition have shown that similar cellular proteins (actin, annexin I/IV, 
histone 2A, translation factor EF1a, glyceraldehydes 3-phosphate dehydrogenase, 
cadherin and the RhoGDP dissociation factor) as well as 37 homologous virion proteins 
have been incorporated into infectious virions (Baldick & Shenk 1996; Kattenhorn et al. 
2004)(Murrell. I; unpublished work). The viruses establish latency in similar cell types 
and are able to reactivate upon stimulus such as immunosuppressive drugs (Sweet 
1999).  
 
Like HCMV, susceptible animals are usually asymptomatic when infected with MCMV 
(Krmpotic et al. 1999). Both MCMV and HCMV acquire adaptive mutations when cultured 
in vitro. Acquisition of mutations can also be studied to understand viral resistance to 
antiviral drugs since both HCMV and MCMV are inhibited by nucleoside analogues that 
target the viral DNA polymerase protein. Immune responses induced upon infection with 
MCMV and HCMV are broad and diverse. CMV-specific CD8+ T cells are inflationary and 
increase over time in mice and humans infected with MCMV and HCMV, respectively 
(Karrer et al. 2003; Khan et al. 2002). Interestingly, however, the frequency of CD4+ T 
cells in latently infected patients increase over time whereas in mice the levels remain 
the same (Walton et al. 2008; Pourgheysari et al. 2007). 
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When it comes to understanding HCMV pathogenesis, MCMV is a useful tool that 
enables a CMV virus to be studied in vivo, in its natural host. Numerous disease models 
have been established in mice and include: interstitial pneumonitis, hepatitis, 
myocarditis, adrenalitis, atherosclerosis, hearing loss and hemopoietic failure retinitis  
(Shellam et al. 2006; Bradford et al. 2015). Since MCMV is not transmitted vertically, 
understanding congenital disease is less straightforward and requires direct injection of 
the virus into the vulva (Shellam et al. 2006). In addition to this, MCMV is not 
recommended for studies of congenital CNS impairment (Shellam et al. 2006).  
 
Overall, MCMV is one of the most convenient models used in understanding HCMV 
biology due to relatively high virus homology, low costs and well-established animal 
procedures. Although the two viruses clearly differ in some respects, understanding the 
similarities as well as the differences between the two viruses can enable rational 
interpretation of experiments.  
 
1.11.15. Cytomegaloviruses in vector design 
Conventional vaccine vectors induce strong CD8+ T cell responses that expand upon 
vaccination and then contract over time. Once the infection is cleared by the immune 
system, low levels of specific memory T cells are maintained in the host. 
Cytomegaloviruses on the other hand, induce inflationary CD4+ and CD8+ T cell 
responses of an effector-memory phenotype. These increase over time and remain fully 
functional (can produce IFN-γ and TNF-α when stimulated) and show no signs of 
exhaustion (Klenerman & Oxenius 2016). The half-life of terminally differentiated 
inflationary CD8+ T cells is approximately 40-60 days (Snyder et al. 2008; Kim et al. 
2015). High frequencies of CMV-specific T cells circulate in the blood and reside in 
tissues such as the liver and lung (Karrer et al. 2003; Akulian et al. 2013; Ward et al. 
2004). Memory T cells make up approximately 10% of CD4+ and CD8+ T cell memory 
cells in the peripheral blood (Sylwester et al. 2005).  
 
The growing interest in CMV as vaccine vectors is based on a series of studies 
undertaken over recent years in the mouse and rhesus macaque models that have 
sought to redirect the strong immune response generated to CMV onto a series of 
antigens from a variety of infectious agents and cancer cells. T cell expansions 
characteristic of MCMV responses have been observed to inserted transgenes in mice 
vaccinated with a single dose of MCMV encoding either influenza A virus or lymphocytic 
choriomeningitis virus epitopes (Karrer et al. 2004). The T cell responses generated were 
observed to elicit protective immunity. Moreover, an MCMV recombinant encoding a 
CD8+ T cell-specific epitope for an Ebola nucleoprotein induced lasting (>8 months) 
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protection in prophylactically vaccinated mice who received a single vaccine dose. High 
levels of CD8+ T cells induced protection in vaccinated animals (Tsuda et al. 2011).  A 
follow-up study showed that this protection was durable even after 119 days (Tsuda et 
al. 2015). Work by Redwood et al, showed that MCMV encoding murine zona pellucida 
3 (mouse ovary Ag) induced sterility of vaccinated mice (Redwood et al. 2005). Another 
group inserted Mycobacterium tuberculosis Ag 85A into an MCMV vector and compared 
the immune responses to an empty control vector. Surprisingly, both viruses induced 
protective NK cell responses showing that Ag specificity is not required to protect against 
M. Tuberculosis (Beverley et al. 2014).  Targeting Listeria monocytogenes with MCMV 
encoding a Listeria monocytogenes epitope together with NKG2D receptor activating 
ligand (RAE-1γ) induced strong and durable CD8+ T cell response protective of 
subsequent challenge with the pathogenic bacteria (Trsan et al. 2013). Antibody-
conferred protection was described in a study where a single dose of tetanus toxin 
encoding MCMV induced long-term protection in mice (>13 months) (Tierney et al. 
2012).  
 
The most ground-breaking work in CMV vaccine vector development, however, was 
carried out by Louis J Picker’s group in Oregon. Live-attenuated RhCMV vectors 
encoding simian immunodeficiency (SIV) antigens were used to vaccinate rhesus 
macaques that were later repeatedly challenged (intra-rectally) with a highly virulent 
SIVmac239 strain (Hansen et al. 2009). Surprisingly, half of the animals became elite 
controllers and were able to resist SIV infection (Hansen et al. 2011). Protected rhesus 
macaques displayed transient SIV viremia in sites other than the site of virus challenge 
(e.g. draining lymph nodes, bone marrow, spleen and liver) with occasional viral blips 
that waned by week 70 (Hansen et al. 2013). In addition to this, the levels of tissue-
associated SIV DNA and RNA of 89% (8/9 animals) of protected rhesus macaques were 
at the limit of detection and in one animal the levels were 454 copies per 108 cells 
(Hansen et al. 2013). The immune responses associated with this remarkable control of 
SIV infection were  very broad, consisting of unusual and diverse supertopes (MHC class 
II and HLA-E restricted) (Hansen et al. 2013). When the protective immune responses 
were analysed, it became apparent that the CD8+ T cells were of effector memory 
phenotype, residing in close proximity to viral entry sites (Hansen et al. 2011). In 
comparison, immune responses mediated by an adenovirus vector displayed the 
canonical central memory phenotype, and were not protective (Hansen et al. 2011). The 
authors showed that a recombinant RhCMV vector can be used to superinfect a 
seropositive rhesus macaque; possibly due to the presence of immune evasion genes 
(Hansen et al. 2010). Whereas majority of virus-based vectors (e.g. adenoviruses) can 
only be used once due to pre-existing immunity; this characteristic feature of 
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cytomegaloviruses makes them highly attractive for use in CMV-based vaccine 
development. 
 
Not only are CMV vectors effective against infectious agents but they can also be utilized 
as anti-cancer therapy. Two groups have tested recombinant MCMV vaccines in the B16 
melanoma cancer model. An MCMV mouse tyrosinase-related protein (TRP2) 
recombinant induced long-term protection against tumour formation that was mediated 
solely by a TRP2-specific antibody response (G. Xu et al. 2013). The second group 
modified gp100 tumour-associated antigen to make it more immunogenic. Vaccination 
with the MCMV-gp100KGP recombinant resulted in protection against aggressive lung 
B16-F10 melanoma cells driven by a CD8+ T cell response (Qiu et al. 2015). CD8+ T-cell 
response has also been suggested to play a role in tumour growth delay observed in a 
murine prostate cancer model (PSA-expressing Transgenic Adenocarcinoma of the 
Mouse Prostate; TRAMP-PSA) immunized with MCMV vector encoding a PSA epitope 
(Klyushnenkova et al. 2012).  
 
As the studies move toward clinical trials, vaccine vector safety becomes a priority. 
Health concerns in immune-naïve and immunosuppressed individuals require the use of 
non-replicating virus vectors. However, attenuated CMV is unable to induce immune 
responses comparable to WT virus (Snyder et al. 2011). It has been hypothesized that 
chronic low-level replication of the virus is responsible for the characteristic immune 
responses seen to date in vaccine vectors (O’Hara et al. 2012). Alternative strategies 
allowing limited virus replication are therefore needed (O’Hara et al. 2012).  
 
1.11.16. T-REx system 
Gene regulation systems are essential in the gene therapy setting. The ideal expression 
system should 1) be highly specific; 2) not exhibit pleiotropic effects; 3) induce high levels 
of the gene of interest; 4) be cost-effective and 5) be strictly regulated and inhibit leaky 
gene transcription. Prokaryotic conditional expression systems meet most of the 
requirements. Tetracycline-regulated systems, in particular, have been widely used. 
These systems rely on expression of tetracycline repressor (tetR) that responds to an 
antibiotic called tetracycline or its derivative – doxycycline (DOX). TetR homodimers bind 
with high specificity to tetracycline operator and induce or block gene transcription. 
Multiple variants of this regulation system exist: 1) Tet-On; 2) Tet-Off and 3) TREx (see 
Figure 6).  
 
In the Tet-Off system, the Escherichia coli (E. coli) tetR is fused to HSV VP16 activation 
domain to generate a chimeric protein called tetracycline transactivator (tTA). This 
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protein recognizes the tetracycline response element (TRE) which comprises of a 
minimal promoter and seven tetracycline operator (tetO) sequence repeats. If the tTA 
binds to the tetO, it activates gene expression from the TRE. In the presence of 
tetracycline, tetracycline binds to the tTA and causes a conformational change. This, in 
turn prevents tTA from binding to the tetO sequences, and gene expression is turned off. 
The Tet-On system, on the other hand, relies on reverse tTA (rtTA) which was obtained 
through mutating tTA so that it would bind to tetO only in the absence of tetracycline. 
Thus, addition of DOX activates gene expression. The T-REx system responds to 
tetracycline in a similar way to the Tet-On system, however, the major difference is the 
absence of a transactivation domain in the tetR protein which makes it less toxic than 
Tet-On or Tet-Off systems since transactivation domains are known to interact to cellular 
proteins genes and affect their expression (Yao et al. 1998; Hillen & Berens 1994; Hall 
& Struhl 2002). In the T-Rex system, gene expression is driven from an intact promoter 
(as compared to the minimal promoter used in Tet-On/Tet-Off) and two tetO sequences 
are placed downstream of the promoter. TetR homodimers bind to the two tetO (TetO2) 
sequences with high specificity (binding constant =2 x 1011 M-I) and inhibit transcription 
(Hillen & Berens 1994). Addition of DOX prevents tetR from binding to the tetO and 
relieves this repression, allowing the gene downstream of TetO2 to be expressed (Yao 
et al. 1998). 
 
Several groups have used tetracycline-regulated systems to generate cell lines with 
transient protein expression (Nagarajan & Sinha 2008; Krishnapuram et al. 2013; Tian 
et al. 2009; Bai et al. 2013). One such attempt resulted in development of a cell line 
secreting pig growth hormone where mRNA expression could be regulated by 10-fold in 
response to DOX (Jiang et al. 2012). Others have used the tetR-based system to 
generate vectors with tetR-regulated promoters to target expression of specific genes 
within the vector (Debowski et al. 2015; Heinz et al. 2011). Analysis of tet-responsive 
green fluorescent protein (GFP) expression in vivo showed that the highest regulation 
by tet-responsive promoters could be achieved 16h after addition of anhydrotetracycline 
(tetracycline analogue)(Debowski et al. 2013). Multiple groups have looked at gene 
expression in vivo using tet-based regulation systems that have shown promising results 
and no reported toxicity (Sato et al. 2013; Debowski et al. 2013; Huang et al. 2015). In 
addition to this, several transgenic animal models have been generated using these 
systems (Tillack et al. 2015; Heindorf & Hasan 2015). Concerns over leakiness of 
tetracycline-regulated system led to advanced improvements such as Tet-On 3G that is 
10-100 fold more sensitive to DOX (Fan et al. 2012). In addition to this, rtTA variants 
have been generated that are 7-fold more active and 100-fold more sensitive to DOX  
than the original Tet-On system (Zhou et al. 2006). Modifications with improved 
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background expression and 25-fold higher inducible expression have also been 
observed (Peacock et al. 2012).  
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A 
B 
C 
Figure 6: Tet-Off (A), Tet-On (B) and TREx (C) systems. A: in the Tet-Off system, 
tetracycline transactivator protein (tTA) through binding to tetracycline response 
element (TRE) in the absence of doxycycline (DOX) allows downstream gene 
transcription. Addition of DOX blocks the binding to TRE and thus, transcription. B: 
reverse tetracycline transactivator protein requires DOX to bind to TRE and enable 
gene transcription. C: tetR binds to tetracycline operators (tetO) in the absence of DOX 
and prevent gene transcription. DOX, however, binds to tetR and blocks the binding to 
tetO and transcription can commence. 
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1.12. Hypothesis 
A HCMV virus in which replication is controlled by doxycycline would be a safe vector, 
that is capable of inducing an immune response comparable to wild type virus. 
 
1.13. Aims of the current study 
 
The aims of this project were: 
 
Adenovirus-specific 
i. To generate replication-deficient Adenovirus serotype 5 vectors encoding a 
human tumour-associated antigen (human 5T4). 
ii. To test immunogenicity of 5T4 in two mouse strains (BALB/c and C57bl/6). 
iii. To compare immunogenicity of first-generation (E1 and E3 genes deleted) and 
second-generation (E1, E3 and E4 genes deleted, except for E4-ORF6) 
adenovirus vectors in vivo. 
iv. To establish murine cancer models expressing the 5T4 antigen. 
v. To test the efficacy of Ad-h5T4 prophylaxis in cancer models.  
 
 
CMV-specific 
i. To construct conditionally replicating human and mouse CMV vectors by using 
tetR-based (TREx) system.  
ii. To analyse virus replicative capacity in vitro. 
iii. To determine whether propagation of virus vectors results in mutations that 
impair conditional control of virus replication. 
iv. To test safety of conditional MCMV vectors in vivo. 
v. To test immunogenicity of conditional MCMV vectors in vivo, as compared to 
adenovirus. 
 
  
Methods 
56 
 
Chapter 2 Methods 
 
2.1. Buffers, media and gels 
 
1 x TD buffer pH 7.4 
750 mM NaCl (Fisher Scientific), 50 mM KCl (Sigma), 10 
mM Na2HPO4· 12H2O (AnalaR), 250 mM Tris-base; pH 
adjusted with HCl to 7.4. The solution was autoclaved and 
stored at 4°C. 
1x TAE buffer 
50x TAE buffer (National Diagnostics) diluted 1:50 with 
ddH2O 
2x media 
50% (v/v) ddH2O; 20% (v/v) 10x Minimum Essential 
Medium (MEM) (Life technologies); 20% (v/v) Foetal 
Bovine Serum (FBS) (Life Technologies), 0.45% (v/v) 
sodium bicarbonate (Life Technologies); 100,000 Units 
penicillin (Life technologies); 100mg/ml streptomycin (Life 
technologies); 4 mM L-glutamine (Life Technologies) 
4% paraformaldehyde 
(PFA) solution 
4% (w/v) paraformaldehyde (Acros Organics) in 
phosphate buffered saline (PBS) (Life Technologies) 
6x loading buffer 
30% glycerol (Fisher) in ddH2O; 0.025 % (w/v) 
bromophenol blue (Sigma); 0.025 % xylene cyanole 
(Sigma) 
Ampicillin (Amp) 
stock 
100 mg/ml ampicillin (Melford) in ddH2O 
Blocking buffer 5% (w/v) fat-free milk (Marvel)  
Chloramphenicol 
stock 
12.5 mg/ml chloramphenicol (Melford) in 70% ethanol 
Collagenase 
5% FBS (v/v); 1 mg collagenase D (Roche); 5 mM CaCl2; 
50 µg DNAse 1 (Sigma) in RPMI 
Dialysis buffer 
10 mM Tris-HCl pH 7.8, 135 mM NaCl (Fisher Scientific), 
1mM MgCl2(H2O)6, (Acros Organics) 10% glycerol (v/v) 
(Fisher) 
Fluorescence-
activated cell sorting 
(FACS) buffer 
2% FBS; 0.05% sodium azide (Sigma) in PBS  
Freezing media 
90% FBS; 10% Dimethyl Sulfoxide (DMSO) Hybri-Max 
(Sigma) 
Growth media 1 (GM1) 
Dulbecco's Modified Eagle's medium (DMEM) (Sigma) 
with 10% v/v FBS; 250 Units penicillin; 250 µg/ml of 
streptomycin  
Growth media 2 (GM2) 
DMEM supplemented with 10% v/v FBS (Invitrogen), 250 
Units of penicillin, 250 µg/ml of streptomycin, 0.26 mg/ml 
of L-glutamine and 97 mg/ml of sodium pyruvate. 
Growth media 3 (GM3) 
RPMI-1640 (Life Technologies) with 10% v/v FBS (Life 
Technologies), 250 Units of penicillin, 250 µg/ml of 
streptomycin and 0.26 mg/ml of L-glutamine  
Heavy CsCl solution 
3.69 M Caesium chloride (Melford) in 100 ml of TD buffer; 
sterilized using 22 μm filter (Merck Millipore) 
Isopropyl β-D-1-
thiogalactopyranoside 
(IPTG) stock 
0.1M isopropyl β-D-1-thiogalactopyranoside (Melford), in 
ddH2O 
Kanamycin stock 25 mg/ml Kanamycin (Melford) in ddH2O 
LB Agar LB broth and 15% (w/v) agar (Oxoid) 
LB Agar (sucrose) 
LB broth, 5% (w/v) D-sucrose (Fisher scientific), 15% 
(w/v) agar, 1% (w/v) tryptone (Fisher) and 0.5% (w/v) 
yeast extract (Oxoid) 
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Light CsCl solution 
2.14 M Caesium chloride (Melford) in 100 ml of TD buffer; 
sterilized using 22 μm filter (Merck Millipore) 
Luria Bertani (LB) 
broth 
LB broth low salt powder (Melford) in ddH2O 
Lysis buffer 
1× NuPAGE LDS sample buffer (Life Technologies); 10% 
(v/v) Dithiothreitol (DTT) (Sigma) in ddH2O 
MOPS buffer 
1× NuPAGE MOPS Sodium dodecyl sulphate (SDS) 
Running Buffer (ThermoFisher Scientific) 
Overlay medium A 2× media mixed 1:1 ratio with Avicel (IMCD UK Limited) 
Overlay medium B 0.8% carboxymethyl cellulose (Sigma) in GM2 
Red blood cell (RBC) 
lysis buffer 
155 mM NH4Cl (Sigma), 10 mM KHCO3, 1 mM 
Ethylenediaminetetraacetic Acid (EDTA) (Alfa Aesar), pH 
8  
Saponin buffer 
2% FBS; 0.5% (w/v) saponin (Acros Organics) and 0.05% 
(v/v) sodium azide in PBS;  
Sorbitol cushion 20% (w/v) D-sorbitol (Sigma) in ddH2O 
Streptomycin solution 200 mg/ml of streptomycin sulphate (Melford) in ddH2O 
Transfer buffer 
2× NuPAGE transfer buffer (Life Technologies); 10% (v/v) 
methanol in ddH2O 
Wash buffer for 
western blot 
Phosphate buffered saline (Oxoid); 0.1% (v/v) Tween20 
(Sigma) in ddH2O 
X-gal stock 
40 mg/mL 5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside (X-gal) (Melford) in DMSO (Fisher) 
 
 
  
APC - Allophycocyanin; Cy7 – cyanine 7; FITC - Fluorescein isothiocyanate; HRP - Horseradish peroxidase; ICS- intracellular cytokine staining; IHC –   
immunohistochemistry; KLRG1- Killer cell lectin-like receptor subfamily G member 1; PB- Pacific Blue; PE – Phycoerythrin; PerCP- Peridinin Chlorophyll.  
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Table 7: Antibodies used in this study 
Immunogen Company 
Catalogue 
number 
Species Conjugate Dilution Application Size 
β-actin Sigma A-2066 Rabbit - 1/2000 Western Blot 40 kDa 
E. coli TetR (residues 1-50) Novus biologicals NBP1-78424 Rabbit - 1/1000 Western Blot 23 kDa 
Mouse 5T4 R&D Systems AF5049 Sheep - 1/2000 Western Blot 72 kDa 
Mouse IgG (H+L) Bio-Rad 170-6516 Goat HRP 1/2000 Western Blot - 
Rabbit IgG (H+L) Bio-Rad 170-6515 Goat HRP 1/2000 Western Blot - 
Sheep IgG Sigma A3415 Donkey HRP 1/2000 Western Blot - 
Mouse M123/IE1 CapRi 
HR-MCMV-12 
 
Mouse - 1/1000 
Western Blot 
IHC/Titration 
95 kDa 
Mouse IgG (H+L) Life Technologies A-11020 Goat Alexa Fluor 594 1/2000 IHC/Titration - 
MHC Class I H2 Kb + Db Abcam ab112492 Mouse PE 1/50 Stability assay - 
Mouse IgG2a Beckman coulter A09141 Mouse PE 1/50 Stability assay - 
Hexon (Adenovirus serotype 2) Merck Millipore AB1056 Goat - 1/5000 IHC/Titration - 
Goat IgG Santa Cruz Biotechnology Sc-2056 Donkey HRP 1/1000 IHC/Titration - 
Mouse CD3 Clone: 17A2 BioLegend 100205 Rat PE 1/100 ICS/Tetramer staining  
Mouse CD4 Clone: RM4-5 BioLegend 100547 Rat Brilliant Violet 605 1/100 ICS/Tetramer staining - 
Mouse CD8a Clone: 53-6.7 BioLegend 100725 Rat PB 1/100 Tetramer staining - 
Mouse CD8a Clone: 53-6.7 BioLegend 100732 Rat PerCP 1/100 ICS - 
Mouse/human CD27 Clone: LG.7F9 ThermoFisher Scientific 12-0271-82 
Armenian 
hamster 
PE 1/100 Tetramer staining - 
Mouse/human CD44 Clone: IM7 BioLegend 103012 Rat APC 1/100 Tetramer staining - 
Mouse/human CD44 Clone: IM7 BioLegend 103028 Rat APC/Cy7 1/100 ICS - 
Mouse CD69 Clone: H1.2F3 BioLegend 104537 
Armenian 
Hamster 
Brilliant Violet 711 1/100 Tetramer staining - 
Mouse CD103 Clone: 2EF BioLegend 121416 
Armenian 
Hamster 
PerCP/Cy5.5 1/100 Tetramer staining - 
Mouse/human KLRG1 (MAFA) Clone: 
2F1/KLRG1 
BioLegend 138410 Syrian hamster FITC 1/100 ICS/Tetramer staining - 
Mouse TNF-α Clone: MP6-XT22 BioLegend 506306 Rat PE 1/100 ICS - 
Mouse IFN-γ Clone: XMG1.2 BioLegend 505810 Rat APC 1/100 ICS - 
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2.2. Cell lines 
Growth media used for culturing all the cell lines listed above are described in Tables 8 
and 9. Human foetal foreskin fibroblasts (HFFFs), a kind gift from Dr Graham Farrar 
(CAMR, Salisbury, UK), were immortalized with human telomerase reverse transcriptase 
(HF-hTERTs) as previously described by (McSharry et al. 2001). HFFFs expressing 
tetracycline repressor (HFFF-tets) (Stanton et al. 2010) served as a positive control in 
experiments looking at repression of virus replication. NIH 3T3-tet cell line was generated 
by transfection of an immortalized mouse embryo fibroblast cell line, NIH 3T3 (American 
Tissue Culture Collection, ATCC CRL-1658) with retrovirus expressing the tet-repressor 
and selected in puromycin (1 μg/ml) at 48 hours pi. A complementing cell line, expressing 
E1 protein called T-REx-293 (human embryonic kidney cells)(Graham & Smiley 1977) 
and HF-TERTs transfected with the Coxsackie-adenovirus receptor (HF-CAR) 
(McSharry et al. 2008) were used for adenovirus work.  
 
To establish tumour models, three different cell lines were used: 1) 4T1 mouse mammary 
carcinoma cells (ATCC CRL-2539); 2) CT26 mouse colon carcinoma (ATCC CRL-2638) 
provided by Professor Awen Gallimore and 3) L/L2 (LLC1) were purchased from ATCC 
(CRL-1642). For peptide stability assays, TAP-deficient human lymphoblast T2 cell line 
transfected with Db and Kb and thereof referred to as T2 Db and T2 Kb, respectively, were 
a generous gift from Professor Awen Gallimore. Apcfl/fl small intestine and large intestine 
samples were provided by Dr Lee Parry (Cardiff University).  
 
2.2.1. Maintenance of cell lines 
In vitro cell culture was carried out under sterile conditions in a Class II biological safety 
cabinet (Microflow). The cells were cultured at 37˚C in Sanyo CO2 incubators 
supplemented with 5% CO2 until 80-90% confluent. Adherent cells were washed with 
PBS and incubated with 3 ml of 0.05% trypsin-EDTA (Life Technologies) at 37˚C until all 
the monolayer had detached. Trypsin-EDTA was then neutralized with media containing 
FBS and the cells were split and re-seeded into tissue culture flasks and passaged until 
necessary. Cells growing in suspension were split by pelleting at 1,500 revolutions per 
minute (rpm) for 3 min, then washing the cells with 10 ml of PBS and re-suspending the 
cell pellet in growth media and then dividing into the required volume (Table 9) and 
seeding back into tissue culture flasks.  
 
2.2.2. Counting cells 
Cell counts were determined by pipetting 20 µl of cells into a disposable BVS100 
counting chamber (Immune Systems) and counting the number of cells in a 4×4 square 
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using an inverted light microscope (Nikon TMS). To calculate the total cell number in 1 
ml of media, the number obtained was multiplied by 104. 
 
2.2.3. Cryopreservation of cells 
Cells were trypsinized and counted as described in section 2.2.1 and 2.2.2, respectively. 
The cells were collected by spinning at 1,500 rpm for 3 min. The cell pellet was then re-
suspended in freezing media to the required volume and aliquoted out into cryovials 
(ThermoFisher Scientific) that were then incubated in an isopropanol-based freezing 
vessel (Nalgene) at -80˚C. Following a 24-hour incubation, the cryovials were transferred 
to a vapour phase liquid nitrogen tank 
 
2.2.4. Resuscitation of frozen cells 
Cryovials containing frozen cells were placed in a 37˚C water bath until all the cells in 
suspension had thawed. Next, cells were pipetted into 10 ml of pre-warmed growth 
medium and centrifuged at 1,500 rpm for 3 min at room temperature (RT) to remove any 
cryoprotectant. The cell pellet was then resuspended in 15 ml PBS and after spinning 
the tubes at 1,500 rpm for 3 min (RT), the cell pellet was reconstituted in compatible 
growth medium, seeded into a tissue culture flask and incubated at 37˚C 5% CO2.  
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Table 8: Cell lines and subculturing conditions 
Cell line Growth media Application 
Subcultivation ratio/ 
cell density 
HFFF 
GM1 (see 2.1) 
Growing HCMV 
stocks/testing virus growth 
1:3-1:5 
HF-
hTERTs 
HFFF-
tets 
Testing HCMV vector 
replication/growth 
T-REx-
293 
Growing Ad stocks 1:8-1:10 
HF-CAR 
Expression of protein from 
recombinant Ad vectors 
1:3-1:5 
L/L2 
(LLC1) 
Establishment of cancer 
model in mice 
1:4-1:6 
NIH 3T3 
GM2 (see 2.1) 
Growing MCMV stocks and 
testing virus growth 
1:3-1:5 
NIH 3T3-
tet 
Testing MCMV vector 
replication/growth 
4T1 
GM3 (see 2.1) 
Establishment of cancer 
models in mice 
1:6 to 1:8 
CT26 1:4 to 1:10 
T2 Db 
Stability assay 3 x 105 and 1 x 106/ml 
T2 Kb 
 
 
 
 
Table 9: Volumes of medium used for culturing and infecting cells 
 
  
Culture 
vessels 
Cell number for 
seeding 
Media volume (ml) 
for seeding cells 
Media volume (µl) for 
infecting cells 
T150 4×106 15-20 - 
T75 3×106 10-15 - 
T25 6×105 5 - 
Plates    
6-well 2.5×105 2 500 
12-well 1.25×105 1 300 
24- well 6.25×104 0.5 200 
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2.3. BAC-cloned viruses  
 
2.3.1. HCMV 
BAC-cloned Merlin HCMV strain (GenBank accession number GU179001.1) referred to 
as ‘pAL1111’ was provided by Dr Richard Stanton (Cardiff University) (Stanton et al. 
2010).  pAL1111 contains the complete HCMV genome.  
 
2.3.2. MCMV 
K181Perth (GenBank accession number: AM886412) plasmid designated as pARK25 was 
a kind gift from Dr Ian Humphreys and encodes a MCMV strain K181 genome (Cardiff 
University) (Redwood et al. 2005). The BAC plasmid was transfected into empty SW102 
E. coli cells as detailed in section 2.4.9. M50 and SCP viruses cloned into BACmids were 
kindly provided by Dr Zsolt Ruzsics (Rupp et al. 2005).  M50 and SCP viruses are a 
Smith strain of MCMV.  
 
2.3.3. Adenovirus 
Replication-deficient human adenovirus serotype 5 lacking E1 and E3 regions (first 
generation) as well as a virus missing the E4 gene (second-generation), were supplied 
by Dr Richard Stanton (Stanton et al. 2008). The E1 region of the virus was replaced 
with an expression cassette containing the HCMV MIE promoter and its polyadenylation 
sequence.  
 
2.4. Molecular biology techniques 
 
2.4.1. Oligonucleotide design and storage 
Oligonucleotide primers (listed in Appendix A) were designed using CLC Main 
Workbench 7 software and Oligo Explorer 1.2. The forward and reverse primers were 
designed to have a similar melting temperature of 60-65°C and exhibit minimal or no 
primer-dimer formation, self-annealing and secondary structure. The primers were 
purchased from Eurofins MWG at de-salted purity. The lyophilized primers were 
reconstituted with ddH2O to 100 μM concentration and were stored at -20°C. 
 
2.4.2. Polymerase Chain Reaction (PCR) 
PCR was either used 1) to amplify regions of DNA required for recombineering or 2) for 
screening positive BAC clones. 50 μl PCR reactions were set up on ice in thin-walled 
DNAse and RNAse-free tubes (ELKay) containing ddH2O, 5 μl of HIFI buffer (Expand 
High fidelity; HIFI, 11732641001, Roche), 3% (v/v) DMSO (Fisher), 1 μl of template DNA, 
1 μl of deoxynucleotides (dNTPs) (NEB), 1 μM forward and reverse primers (see 
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Appendix A) and 0.5 μl of HIFI polymerase (HIFI, 11732641001, Roche). All PCR 
reactions were performed using T3000 Thermocycler (Biometra). The extension time in 
PCR programs (Table 10 and Table 11) was modified accordingly to the length of the 
region to be amplified whereas annealing temperature was changed depending on the 
melting temperature of the primers.     
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Table 10: PCR protocol LONG for amp/sacB/lacZ cassette 
Stages Temperature (˚C) Time Cycle 
Pre-heating 99 2 min - 
Initial denaturation 95 2 min 1 
Denaturation 
Annealing 
Extension 
95 
55 
68 
30 s 
30 s 
4 min 30 s 
33 
Final extension 68 15 min 1 
Hold 4 ∞ - 
 
 
 
 
 
 
 
 
 
Table 11: PCR protocol HIFI for kan/rpsL/lacZ cassette and other inserts 
Stages Temperature (˚C) Time Cycle 
Pre-heating 99 2 min - 
Initial denaturation 94 2 min 1 
Denaturation 
Annealing 
Extension 
94 
55 
72 
15 s 
30 s 
3 min 
34 
Final extension 72 7 min 1 
Hold 4 ∞ - 
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2.4.3. DNA gel electrophoresis 
0.7% (w/v) agarose gels were prepared by dissolving 0.35g of Hi-Res Standard Agarose 
(AGTC Bioproducts) in 50 ml of TAE buffer (see section 2.1). The solution was 
supplemented with 0.5 µg/ml of ethidium bromide (Sigma), poured into pre-assembled 
gel casts and left at RT for 30 min to solidify. DNA samples to be analysed were diluted 
with 1× agarose loading buffer (see section 2.1) and loaded onto the gel alongside 10 µl 
of HighRanger Plus 100 bp DNA Ladder (Norgen biotek) which served as a standard 
weight measure. The electrophoresis was carried out in TAE buffer at 100 Volts for 1-2 
hours. The DNA bands were visualized using the GeneSys gel doc system. 
 
2.4.4. DNA isolation and extraction from agarose 
DNA fragments to be excised were visualized under a UV transilluminator (Spectroline 
TVC-312A) with minimal UV exposure time to prevent DNA damage. The isolated bands 
were placed in a clean 1.5 ml Eppendorf tube (Fisher Scientific) and weighed. The DNA 
purification was carried out using Geneflow Q-Spin gel extraction/PCR purification kit 
according to the instructions provided by the manufacturer. In brief, the agarose was 
mixed with capture buffer and melted at 60˚C and the solution was transferred to the 
columns supplied by the manufacturer. The columns were centrifuged at 13,000 rpm for 
30 s. The flow-through was discarded and the columns were washed with 500 µl of wash 
buffer. Following centrifugation at 13,000 rpm for 1 min, the collection tube was replaced 
and the DNA was eluted with 30 µl of ddH2O.  
 
2.4.5. Miniprep 
BAC DNA was isolated from SW102 E. coli cells containing the BAC of interest using the 
QIAGEN Spin Miniprep Kit (27016) buffers. Single colonies were inoculated in 5 ml LB 
cultures (section 2.1) containing 12.5 µg/ml chloramphenicol and incubated overnight in 
a shaking incubator at 32˚C at 250 rpm. The following day, the cells were pelleted at 
4,000 rpm (4˚C) for 5 min. The supernatant was discarded and the cells were re-
suspended in 250 µl of P1 buffer supplemented with RNase A.  The cells were lysed by 
adding 250 µl of P2 buffer and incubating at RT for 5 min. To terminate the lysis step, 
250 µl of N3 buffer were added and the tubes were centrifuged at 13,000 rpm for 10 min. 
To precipitate the DNA, supernatants were transferred to a new 1.5ml Eppendorf tube 
(Fisher Scientific), mixed with 750 µl of isopropanol (Fisher) and spun at 13,000 rpm at 
4˚C for 10 min. Cell pellets were then washed with 500 µl of 70% ethanol for 10 min at 
RT. The pellets were then dried at 37˚C to remove residual ethanol and the pellet was 
re-suspended in 30 µl of ddH2O. 
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2.4.6. Maxi prep 
To isolate transfection grade BAC DNA, SW102 E. coli containing the BAC of interest 
were grown in large scale cultures and purified using NucleoBond BAC100 kit 
(Macherey-Nagel) in accordance with the manufacturer’s instructions for low-copy 
number plasmids. First, 500 ml of overnight culture was pelleted by spinning at 6,000 
rpm at 4˚C for 15 min.  The cell pellet was then mixed with 24 ml of S1 buffer and upon 
addition of 24 ml of S2 buffer, incubated for 5 min at RT. 24 ml of N3 was then added 
and the cell lysates were incubated on ice for 5 min then centrifuged at 6,000 rpm (4˚C) 
for 15 min. The cellular debris was discarded and supernatant was filtered and applied 
to a pre-equilibrated column. The column was washed twice with 18 ml of wash buffer 
and then eluted with 15 ml of N5 buffer (pre-heated to 50˚C). The BAC DNA was then 
precipitated by adding 11 ml of isopropanol (Fisher) to the eluted DNA and spinning at 
15,000 rpm and 4°C for 30 minutes. The supernatant was discarded and the cell pellet 
was washed with 5ml of 70% (v/v) ethanol and centrifuged at 15,000 rpm for 15 minutes. 
The ethanol was removed, the pellet was allowed to air-dry and DNA was then 
reconstituted in 100 µl of 10 mM TAE buffer pH8.  
 
2.4.7. Determination of DNA concentration 
To quantify DNA and evaluate its’ purity, ND1000 spectrophotometer (NanoDrop) was 
cleaned then equilibrated with 2 µl of ddH2O. Next 2 µl of solvent was pipetted onto the 
lower measurement pedestal to generate a reference for the 2 µl of DNA sample that 
was loaded afterwards.  
 
2.4.8. Restriction digestion 
Ten µl restriction digestion reactions containing 8 µl of DNA, 20 Units of restriction 
nuclease (NEB) and 1 µl of compatible NEB buffer were incubated at 37˚C for 1 hour. 
The generated DNA fragment sizes were resolved by gel electrophoresis (see section 
2.4.3).  
 
2.4.9. Transfection of BAC DNA into SW102 E. coli 
Empty SW102 E. coli cells were inoculated into 5 ml of low salt LB media and incubated 
overnight at 32 °C in a shaking incubator (200 rpm). Next, 500 μl of overnight culture 
were mixed with 25 ml of LB media (section 2.1) and were placed back in the shaking 
incubator until the A600 reached 0.6. Then, the cells were chilled on ice for 15 min on a 
rocking platform (200 rpm). For one transfection reaction, 1.5 ml of SW102 E. coli cells 
were pelleted by spinning at 13,000 rpm for 1 min at 0°C. The supernatant was discarded 
and the cells were subjected to two successive rounds of washing with 1 ml of ice cold 
water and spinning at 13,000 rpm for 1 min (0°C). The cells were resuspended in 30 μl 
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of water, mixed with 10 ng of high purity DNA and transferred to a 0.2 cm cuvette (Bio-
Rad, Hertfordshire, UK) and pulsed at 2.5 kV. The transfected cells were recovered with 
1 ml of LB for 1 hour at 32°C in a shaking incubator. Stable transfectants were selected 
on LB agar plates (section 2.1) supplemented with 12.5 μg/ml chloramphenicol and 
screened by minipreparing DNA, performing restriction digestion and sequencing. 
 
2.4.10. Recombineering 
E. coli strain SW102 containing the BAC of interest was grown overnight at 32°C in LB 
medium supplemented with 12.5 µg/ml of chloramphenicol. Next, 500 µl of overnight 
culture was diluted in 25 ml of LB and incubated at 32°C until A600=0.6. Lambda red gene 
expression was induced by incubating SW102 E. coli cells at 42°C for 15 min.  Following 
a 15min incubation on ice, the cells were centrifuged three times at 4,500 rpm for 5 min 
(0°C) with 2 washes with 25 ml of ice-cold ddH2O in between. After the final spin, cell 
pellet was resuspended in 500 µl of ddH2O. Either purified PCR product or 
oligonucleotide primers (Appendix A) purchased from MWG Operon (Germany) at de-
salted purity were mixed with 25 µl of SW102 E. coli cells, transferred to a 0.2 cm cuvette 
and electroporated at 2.5 kV. In the first round of recombineering, lacZ/kanr/RpsL 
cassette was amplified with oligonucleotide primers containing 70 bp homology arms 
flanking the genes of interest. The cells were recovered with 1 ml of LB for 1 h at 32°C 
and selected onto LB agar plates containing 12.5 µg/ml chloramphenicol, 80 µg/ml 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 200 μM IPTG and 25 μg/ml 
kanamycin. In the second round, lacZ/kanr/RpsL cassette was seamlessly removed 
using oligonucleotide primers containing the modification of choice. The cells were 
recovered in 5 ml of LB (section 2.1) for 3h at 32°C and plated onto LB plates with 12.5 
µg/ml chloramphenicol, 80 µg/ml X-gal, 200 μM IPTG and 200 μg/ml streptomycin.  
 
2.4.11. Sequencing BACs 
Following recombineering, to verify that the BAC contained the correct modification, the 
modified region in the miniprepared BAC DNA was amplified with sequencing primers 
(Appendix A) and purified as described in section 2.4.4. Sequencing reactions were set 
up using Mix2Seq kit (Eurofins Genomics) according to manufacturer’s guidelines. 
Fifteen µl of BAC DNA were mixed with 2µl of either the forward or reverse sequencing 
primers at 10 µM concentration and aliquoted into Mix2Seq tubes (Eurofins Genomics) 
that were sent away to be sequenced. 
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2.4.12. Generating glycerol stocks 
Overnight bacterial cultures grown in appropriate antibiotic and containing the BAC of 
interest were mixed with 15% glycerol (v/v) (Fisher), aliquoted into a freezing cryovial 
and stored at -80°C. 
 
2.4.13. Virus DNA deep-sequencing 
Purified virus DNA was sequenced on the MiSeq (Illumina) as previously described 
(Murrell et al. 2016).  
 
2.4.14. Western blot 
Cells were lysed with 200 µl of 1x NUPAGE LDS buffer (Life Technologies) containing 
10% DTT (Sigma) and boiled at 100°C for 10 min. For analysing protein expression 
within tissues, the tissue of interest was washed with PBS and sonicated in 100 µl of 
lysis buffer for 30 s at 20% maximum amplitude using Vibra-Cell VCX130 sonicator 
(Sonics).  The proteins were then loaded onto a NUPAGE 10% Bis-Tris gel (Life 
Technologies) and separated by running the gel at 200 Volts for 1 hour in manufacturers 
running buffer. To determine the size of the protein of interest, 7 µl of Novex Sharp Pre-
stained Protein Standard (ThermoFisher Scientific) was loaded alongside the samples. 
Once electrophoresed, the proteins within the gel were transferred onto Amersham 
nitrocellulose membrane (GE Healthcare) at 20 Volts in transfer buffer (section 2.1) for 
1 h in a Trans-Blot SD semidry transfer cell (Bio-Rad). The membrane was blocked 
overnight at 4°C in blocking buffer (0.1% Tween in PBS, 5% milk) and then washed three 
times with wash buffer (0.1% Tween in PBS). Next, the membrane was probed with a 
primary antibody (Table 7) at 4°C overnight. Following three washes with wash buffer, a 
horse radish peroxidase conjugated secondary antibody was added and the membrane 
was incubated at RT for 1 h, then exposed using AutoChemi imaging system and 
SuperSignal reagent (ThermoFisher Scientific) following the manufacturer’s instructions. 
 
2.4.15. Quantitative PCR (qPCR) 
To quantify virus copy numbers in mouse organs, DNA extracted from tissue 
homogenates as described in section 2.5.2.8 and cell-free supernatants as described in 
section 2.5.2.7 were added to a qPCR reaction consisting of 500 nM primers and 1× iQ™ 
SYBR® Green Supermix. The samples were prepared in triplicates and analysed using 
QuantStudio 12K Flex Real-Time PCR system under the following thermal-cycling 
conditions: 50˚C for 2 min; 95˚C for 10 min; 40 cycles at 95˚C for 15s and 60˚C for 1 min 
followed by 95˚C incubation for 15s; 60˚C for 1 min and 95˚C for 15 min. Virus backbone 
was amplified using primers IE1F (AGCCACCAACATTGACCACGCAC) and IE1R 
(GCCCCAACCAGGACACACAACTC) whilst amplification of murine β-actin with β-actin 
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F (GGGCTATGCTCTCCCTCAC) and β-actin R (GATGTCACGCACGATTTCC) served 
as an additional control. Serial dilutions of K181 BAC and DNA extracted from NIH 3T3 
cells were used to generate a standard curve.  
  
2.5. In vitro techniques 
 
2.5.1. HCMV 
 
2.5.1.1. Transfection into mammalian cells 
HCMV BACs were transfected into HFFF-hTERTs and HFFF-tets (106 cells) using 
Amaxa Basic Nucleofector kit (Lonza) as per manufacturer’s guidelines. The cells were 
trypsinized (see section 2.2.1) and centrifuged at 90 × g for 10 minutes at RT. The cell 
pellet was then mixed with 100 µl of nucleofector solution and 4 µg of BAC DNA and 
transferred to a cuvette (supplied by the manufacturer) which was placed into a 
nucleofector device and electroporated using program T-16. Growth medium was added 
to the cuvette and the cells were transferred to a 60 mm2 tissue culture flask (Corning).  
 
2.5.1.2. HCMV virus stock preparation 
HCMV virus stocks were generated by co-culturing HFFF-hTERTs with cell-associated 
virus from transfected cells or by infecting sub-confluent cells (80%) with cell-free virus 
as described in section 2.5.4 using multiplicity of infection (MOI) of 0.1. To disperse viral 
infection throughout the monolayer, the cells were trypsinized weekly as detailed in 
section 2.2.1 and re-seeded back into the same flask. Once 100% of cells were infected, 
the supernatant was harvested every other day until all of the cells were lysed and stored 
at -80°C.  
 
2.5.1.3. Virus preparation and storage 
Supernatants from HCMV infected cells were thawed in a water bath at 37°C and 
pelleted at 1,500 rpm for 3 min at RT. Cellular debris was discarded and the supernatants 
were pooled and centrifuged at 14,000 rpm for 2h at 21°C. Concentrated HCMV virions 
in the form of a visible pellet were reconstituted in growth media, aliquoted, and stored 
at -80°C. 
 
2.5.1.4. Titration by plaque assay 
To determine virus stock concentration for downstream experiments, 2.5×105 HFFFs or 
HFFF-hTERTs were seeded in a 6-well plate (Corning) and incubated at 37˚C overnight. 
The next day, the media was aspirated and replaced with 500 µl of fresh growth media 
and 100 µl of serially diluted virus was added to the cells in duplicates and incubated for 
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2 h at 37˚C. Following this, the virus was removed and semi-solid overlay medium A 
(section 2.1) was added to the plates to prevent cell-free spread of virus. After incubating 
the plates for 2-3 weeks, the semi-solid overlay medium was removed, the wells were 
washed twice with PBS and plaques were counted using a light microscope. To 
determine the titre of HCMV stock, the following formula was applied; 
 
Eqn 1: 
  𝑇𝑖𝑡𝑟𝑒 (𝑃𝐹𝑈 𝑚𝑙⁄ ) = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 × 10 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
2.5.2. MCMV 
2.5.2.1. Transfection of NIH 3T3 cells 
Prior to the day of transfection, 8x105 NIH 3T3 cells were seeded in a 60 mm2 Corning 
CellBIND flasks and incubated overnight. All the transfection steps were carried out using 
Effectene transfection reagent (QIAGEN) following the manufacturer’s instructions. In 
brief, 1 µg of BAC DNA was mixed with DNA condensation buffer to a final volume of 
150 µl. Next, 8 µl of enhancer were added to the mixture and incubated at RT for 5 min. 
Effectene-DNA complex formation was then induced upon incubating the condensed 
DNA with 25 µl of Effectene transfection reagent for 5-10 minutes at RT. Finally, 1ml of 
growth medium B was mixed with the complexes and was then added to the cells. 
 
2.5.2.2. Virus stock preparation from transfected cells 
Transfected NIH 3T3s were propagated for 14 days in 25 cm2 Corning CellBIND flasks 
(Corning) until 80% of the cells displayed cytopathic effect (CPE). The supernatant, 
containing cell-released virions was then collected every other day and stored at -80˚C 
until all the cells were 100% infected. The infected cell monolayer was scraped and 
frozen down at -80˚C. To expand virus infections, the cell-free supernatant was used to 
infect one 75 cm2 then one 150 cm2 flask and so on until twelve 150 cm2 flasks. 
Alternatively, the cells were infected with virus stock at an MOI of 0.005-0.01 as 
described in section 2.5.2.3. 
 
2.5.2.3. Infection with cell-free virus 
A day before the infection, cells were seeded in a plate or a cell culture flask and allowed 
to adhere. Next, the supernatant was removed and 200 µl of virus was incubated with 
the cells at 37˚C for 1 hour. Afterwards, the virus was aspirated and replaced with growth 
media, then incubated at 37˚C. 
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2.5.2.4. Virus purification on sucrose gradient 
Supernatants, as well as the cells were defrosted at 37˚C in a water bath and all of the 
subsequent steps were carried out at 4°C to minimize the loss of virus titre. Cells in the 
cell culture supernatants were pelleted at 2,000 rpm for 5 min. The cell-free virus was 
then transferred to 250 ml virus pots and centrifuged at 12,000 rpm for 100 min whilst 
the cell pellet containing cell-associated virus was re-suspended in 5 ml of cold DMEM 
(Sigma), sonicated in a sonicating water bath (Fisher Scientific, FB15053) for 7 min and 
centrifuged at 3,000 rpm for 5 min to remove cellular debris. The supernatant from the 
cell-associated virus was transferred to a fresh tube and incubated on ice. The cell-free 
virus pellet was re-suspended in 5 ml of DMEM (Sigma), sonicated in a sonicating water 
bath (Fisher Scientific, FB15053) for 7 min and centrifuged at 3,000 rpm for 5 min. The 
supernatants were pooled and the virus was centrifuged at 18,100 rpm for 100 min over 
a 20% sorbitol cushion (see section 2.1). The supernatant was removed and the pellet 
was re-suspended in growth media 2, sonicated in sonicating water bath (Fisher 
Scientific, FB15053) for 5 min and centrifuged at 3,000 rpm for 5 min. Cellular debris was 
discarded and the virus was stored at -80°C.  
 
2.5.2.5. Titration by plaque assay 
MCMV virus titres were determined by incubating 200 µl of serially diluted virus stock in 
duplicates onto 1×105 of NIH 3T3s in a 12-well plate for 1 h at 37˚C. The virus was 
removed and overlay medium B was added to the cells and incubated for 6 days at 37˚C. 
Following this, the medium was discarded and the cells were fixed for 4h with 10% 
formaldehyde (Fisher) (in PBS) and then stained with 0.1% crystal violet (Sigma Aldrich). 
The plaques were counted using an inverted light microscope. Plaque forming units in 1 
ml were calculated using the following equation: 
 
Eqn 2: 
   𝑇𝑖𝑡𝑟𝑒 (𝑃𝐹𝑈 𝑚𝑙⁄ ) = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 × 5 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
2.5.2.6. Quantification of viral particles in mouse tissues 
Liver, lung, spleen and salivary glands isolated from mice were homogenized in 1ml of 
DMEM (Sigma) containing Falcon round-bottom polypropylene tubes using IKA T10 
basic homogenizer (model number: T10 B S2) To sterilize the probe of the homogenizer 
between samples within the same group, the probe was submerged in 70% ethanol and 
rinsed three times with PBS. An additional step where the probe was washed in bleach 
was added to ensure no cross-contamination between different sample groups. NIH-3t3 
were then inoculated with serial dilutions of organ homogenates in duplicates and plates 
spun at 1,000 × g for 30 min. The supernatant was aspirated, 1 ml of CMV media was 
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added and the plates were incubated for 6 days at 37°C. Then, the overlay media was 
flicked off and the cell monolayer was fixed and stained with 10% formaldehyde (Fisher) 
(in PBS) and 0.1% crystal violet (Sigma Aldrich). To determine the plaque forming 
unit/gram of tissue, the following formula was used:  
 
Eqn 3:    𝑃𝐹𝑈 𝑔⁄ =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 ×𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑇𝑖𝑠𝑠𝑢𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 
 
 
2.5.2.7. Cell-free viral DNA extraction 
DNA was extracted from virus stocks and cell-free supernatants using QIAamp MinElute 
Virus Spin Kit (QIAGEN) following the manufacturer’s protocol. In brief, 200 µl of virus 
was mixed with 25 µl of protease and 200 µl of buffer AL supplemented with 28 µg/ml of 
carrier RNA and incubated at 56˚C for 15 min. Addition of 250 µl of 100% ethanol to the 
lysate at RT for 5 min facilitated the binding of viral RNA and DNA to the membrane of 
the MinElute column. The tubes were centrifuged at 8,000 rpm for 1 min and the 
collection tube was replaced. Next, the tubes were washed with 500 µl of AW1 buffer, 
followed by 500 µl of AW2 buffer and precipitated with 500 µl of 96-100% ethanol. The 
flow-through was discarded and the column was dried by spinning at 20,000 x g for 3 
min and the DNA was eluted using 20-150 µl of buffer AVE, incubating at RT for 1 min 
and centrifuging at 20,000 x g for an additional minute. The extracted DNA was then 
stored at -20°C. 
 
2.5.2.8. Cell-associated viral DNA extraction from mouse tissues 
Viral DNA was extracted from either the lung, liver, spleen or salivary glands using 
DNeasy Blood & Tissue (QIAGEN) buffers and columns. First, snippets of mouse tissues 
were lysed by incubating the sample in 360 µl of ATL buffer and 0.8 mg of proteinase K 
and incubating overnight at 200 rpm at 56˚C. Next, the samples were passed through a 
23 and 27-gauge needles until the solution was homogenous. Then, buffer AL and 96-
100% ethanol was mixed in a 1:1 ratio and 800 µl were added to the samples which were 
then vortexed and transferred into a DNeasy mini spin column and centrifuged at 6,000 
x g for 1 min or until all of the sample had gone through the filter of the column. The 
supernatant was discarded and the columns were washed once by adding 500 µl of AW1 
and then 500 µl of AW2 buffer and spinning at 6,000 x g for 1 min. The flow through was 
removed and the DNA was eluted by aliquoting 200 µl of elution buffer, incubating for 1 
min at RT and spinning at 6000 x g for 1 min. The DNA was then stored at -20°C.  
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2.5.2.9. Growth assay 
Supernatants from 1×105 NIH 3T3 or NIH 3T3-tet cells infected at MOI of 0.1 in 
tetracycline-free growth medium containing 1 µg of DOX were collected daily until all the 
cells had been killed/lysed, and stored in two aliquots at -80˚C. The supernatants were 
then serially diluted to 100, 10-1, 10-2 and 10-3 and titrated as described in section 2.5.2.5.  
 
2.5.2.10. Peripheral lymphocyte extraction 
Blood (see section 2.6.4.3) was transferred into a 1.5 ml (1 ml) Eppendorf containing 
Red Blood Cell lysis (RBC) buffer (section 2.1) and incubated at RT for 5 min. The 
samples were then centrifuged at 1,500 rpm for 5 min. The pellet was washed in 1 ml of 
PBS and spun 1,500 rpm for 5 min. The cells were then reconstituted in GM3 media.   
 
2.5.2.11. Splenocyte isolation 
To isolate splenocytes, spleens were mashed through a 70 µm strainer (Fisher Scientific, 
cat no 22363548) using a plunger top of a 5ml syringe. The filter was washed twice with 
10 ml of PBS and once a single cell suspension was obtained, the cells were centrifuged 
at 1,500 rpm for 5 min at RT. The supernatant was discarded and the cells were 
resuspended with 3 ml of RBC lysis buffer and incubated for 5 min. The lysis was 
terminated by adding 3 ml of PBS after which the cells were spun for 5 min at 1,500 rpm. 
Cell pellet was reconstituted in 5 ml of GM3 media and the cells were counted and frozen 
as described in sections 2.2.2 and 2.2.3, respectively.  
 
2.5.2.12. Intestine processing 
Peyer’s patches were removed from small intestine and colon isolated from mice. Faeces 
were removed and the intestines were flushed with PBS. The intestines were cut 
longitudinally. Intestinal tissue was placed in 20 ml of PBS and vortexed to remove any 
debris. Then, the tissue was transferred into 20 ml of Hank's Balanced Salt Solution 
(HBSS) (ThermoFisher Scientific) supplemented with 5 mM EDTA, 10% FBS and 25 mM 
HEPES (Life Technologies) and incubated in a water bath (37˚C) at 200 rpm for 20 min.  
 
2.5.2.13. Isolation of lamina propria lymphocytes 
Intestinal tissue described in section 2.5.2.12 was washed in ml GM3 medium. The tissue 
was placed in a 1.5 ml Eppendorf containing 600 µl of GM3 medium and cut with 
scissors. For collagenase treatment, the tissue was transferred into 5 ml of RPMI 
(supplemented with 5% FBS, 250 Units of penicillin, 250 µg/ml of streptomycin and 2.4 
mg/ml of collagenase A) and incubated at 37˚C at 100 rpm for 30 min. The suspension 
was filtered using a 40 µM cell strainer. Cells were centrifuged and reconstituted in GM3 
medium.  
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2.5.3. Adenovirus 
 
2.5.3.1. Transfection of 293-TREx  
One day before transfecting adenovirus BACs, 2x106 293-TREx cells were seeded in a 
60 mm2 Corning CellBIND flask and incubated at 37˚C overnight. The same transfection 
protocol was carried out as the one described in section 2.5.2.1. 
 
2.5.3.2. Expanding virus stocks 
To bulk up existing virus stocks, 293TREx cells of 80–90% confluency were infected with 
purified virus with an MOI of 0.1/flask. When virus stocks had not been previously 
generated, virus extracted from transfected cells was used to infect the required number 
of flasks. 
 
2.5.3.3. Extraction of virus from infected cells 
Infected cells starting to detach from the flask and showing CPE were harvested and 
centrifuged at 1,500 rpm for 3 min. The cell pellet was resuspended in 5 ml of PBS and 
an equal volume of tetrachloroethylene (Fisher) was added. Following a 30s shake of 
the tube containing cells and tetrachloroethylene (Fisher), the tube was centrifuged at 
2200 rpm 20 min. The top layer containing the virus was either purified on a caesium 
chloride gradient as described in section 2.5.3.4 or stored at -80°C. 
 
2.5.3.4. Purification by caesium chloride (CsCl) gradient  
Adenoviruses were purified on a caesium chloride gradient as previously described (Alba 
et al. 2012). First, the extracted virus prep was layered on top of 1.6 ml of heavy and 3 
ml of light caesium chloride solution in an ultracentrifuge tube (Beckman Coulter). The 
tubes were then filled to the top with PBS and centrifuged at 90,000 × g for 2h at RT.  
The virus layer was then extracted using a 21-gauge needle attached to a 2ml syringe 
and then transferred to sterilized dialysis tubing (Medicell International, London) and 
dialyzed as described in section 2.5.3.5. 
 
2.5.3.5. Dialysis 
Virus in dialysis tubing (described in section 2.5.3.4) was placed in 2 l of dialysis buffer 
and incubated on a rocker for 2 hours at 4°C. Then dialysis buffer was replaced and the 
virus was dialyzed overnight at 4°C with constant rocking. The following day, the virus 
was removed from the dialysis tubing, aliquoted and stored at -80°C. 
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2.5.3.6. Titration by immunofluorescence 
A 12-well plate (Corning) was seeded with 5x105 293TREx cells in 1 ml of growth media. 
The following day, 100 µl of serially diluted virus was added to the wells in duplicates 
and the plate was incubated at 37 ˚C for 48 hours. Next, the media was removed and 
the wells were incubated at RT for 5-10 min to air dry. Following this, 1 ml of acetone-
methanol mix (50:50) was added to the wells and the plate was chilled at -20˚C for 10 
min. Following the removal of acetone-methanol mix, the cells were washed three times 
with 1 ml of PBS and 500 µl of PBS containing anti-hexon primary antibody (1/5000) was 
added, then the plate was incubated on a rocking platform at 37˚C or 1 hour. Next, the 
antibody was removed and the cells were washed three times with PBS then 500 µl of 
diluted HRP-conjugated anti-goat antibody (1/1000) was added and the plate was 
incubated at 37˚C for 1 hour with constant rocking.  Upon washing the cells 3 times with 
PBS, the infected cells were stained using a peroxidase substrate kit DAB SK-4100 
(Vector laboratories) following the manufacturer’s instruction. Once brown precipitate 
had formed, the plates were viewed under a microscope and infected cells were counted 
in five different fields of the well. To determine the titre, the following formula was applied: 
 
Eqn 4: 
  𝑉𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑟𝑒 (𝑃𝐹𝑈 𝑚𝑙⁄ )
=  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑓𝑖𝑒𝑙𝑑 × 150 (𝑓𝑖𝑒𝑙𝑑𝑠 𝑤𝑒𝑙𝑙⁄  ) 
0. 1 𝑚𝑙 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
 
 
2.5.4. Infections with HCMV and adenoviruses 
Fibroblasts were seeded either in a 6-well plate (Corning) or a cell culture flask a day 
prior to infection. Once the volume of virus required was calculated using Eqn5 (see 
below), the virus was diluted in growth media. The media was aspirated from the cells 
and the virus was applied onto the cells for 2 h at 37 °C on a rocking platform (5-10 rpm). 
Subsequently, the virus was removed and replaced with 2 ml of growth media and the 
cells were incubated at 37 °C.  
 
 
Eqn 5: 
   𝑉𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙) =
𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑖𝑡𝑦 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 × 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
𝑉𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟 (𝑃𝐹𝑈 𝑚𝑙⁄ )
 
 
2.5.5. Viral spread assay 
NIH 3T3s (for MCMV) and HFFF-hTERTs (for HCMV) were transfected with BAC DNA 
as described in sections 2.5.2.1 and 2.5.1.1, respectively, and cultured until formation of 
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a single plaque. Then, the cells in the flask were trypsinized as detailed in section 2.2.1 
and split into two flasks. Every 2-3 days the growth media in flask 1 was replaced with 
regular growth media whereas the media in flask 2 was supplemented with 1 µg/ml of 
DOX. The rate of virus infection was compared between the two flasks by eye using an 
inverted microscope.   
 
2.5.6. Plaque size measurements 
To quantify cell-associated viral spread, fibroblasts were infected with CMV (see sections 
2.5.2.3 and 2.5.4), covered with overlay medium and incubated for 6 and 14 days, 
respectively. After the indicated time of infection, the overlay medium was removed and 
the cells were washed twice with PBS. For HCMV plaques, the cells were covered in 
PBS and images of plaques were taken using Zeiss Observer Z1 microscope and Zen 
software at 4× magnification. For MCMV, the cells were fixed and stained with IE1 
antibody as described in section 2.5.7. Images of plaques were taken using Zeiss 
Observer Z1 microscope and Zenworks program at 10x magnification. To determine 
plaque sizes, the images were loaded onto Fiji and free-hand drawing tool was used to 
outline the shape of the plaque and measure its area. 
 
2.5.7. Intracellular IE1 staining 
After a 14-day infection with HCMV and 6-day incubation with MCMV, the overlay 
medium was removed and the cells were washed twice with PBS. Upon fixing the cells 
with acetone-methanol mix (50:50) for 5 min at RT, the acetone-methanol mix was 
aspirated and the cells were washed with PBS, then incubated with primary anti-IE1 
antibody (see Table 7) at 37˚C for 30 min on a rocking platform. Excess unbound 
antibody was removed by washing twice with PBS and the cell monolayer was incubated 
at 37 ˚C for 30 min on a rocking platform with AlexaFluor 594 conjugated anti-mouse 
antibody (1:500). Cells were then washed twice with PBS and visualized using a Leica 
fluorescent microscope (Leica, Germany) at 4× and 10× magnification. Pictures of IE1 
stained cells were taken using Openlab 3 software and further analysed using Fiji. 
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2.6. Preclinical animal models 
 
2.6.1. Animals and ethics  
All experiments were conducted under UK Home Office project licenses (30/2891, 
30/3428 and 30/2969). Female C57BL/6 and BALB/c mice were purchased from (Envigo 
or Charles River, UK) and housed in Cardiff University Animal Research Lab. The mice 
were quarantined for one week in the animal facility before experiments were conducted. 
Mice were 6-8 weeks old at the time of vaccination. Mice immunizations, tumour 
challenge, tumour measurements, saliva collection, tail vein blood collection and organ 
harvest was performed by colleagues in the lab holding a UK Home Office project license 
in accordance with Home Office regulations.  
 
2.6.2. Mice immunization 
Mice were injected subcutaneously (s.c.) into the chest region with 50 μl of 8 × 
105 plaque forming units (PFU) of recombinant adenoviruses (RAds) on day 0 and again 
on day 42. Mice were weighed on the day of injection and thereafter until the weight of 
the mice had recovered to the starting weight. For MCMV experiments, BALB/c were 
intraperitoneally injected with 400 μl containing 2× 105 PFU of virus into the left flank. 
Viruses were diluted in sterile PBS (Life Technologies) and incubated on ice until the 
time of injection. 
 
2.6.3. Adenovirus-specific techniques 
 
2.6.3.1. Induction of tumour growth 
One week after the RAd boost injection (see section 2.6.2), tumour cells, resuspended 
in PBS (Life Technologies) (105/100 µl 4T1 and CT26 and 2×105/50 µl LLC1) were 
subcutaneously injected into the left flank of either BALB/c or C57BL/6 mice. 4T1 and 
CT26 were used in the BALB/c mouse strain and took 7 and 10 days for the tumours to 
form, respectively. LLC1 cells were implanted into C57BL/6 strain and took 
approximately 11 days to grow to a palpable size. 
 
2.6.3.2. Analysis of tumour bearing mice 
Tumour development was evaluated 3 times a week. Once palpable tumour nodules had 
formed, the greatest longitudinal diameter (length) and the greatest transverse diameter 
(width) of the tumour were measured with an external caliper. To determine tumour 
volume, Eqn6 (see below) was used. To comply with Home Office regulations, tumour 
growth was measured until the tumours reached 14 mm in diameter, after which time the 
mice were sacrificed. In instances when the tumour had become necrotic, mice were 
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monitored daily and any signs of discharge, redness, crater-like appearance or mouse 
discomfort indicated that the mice needed to be culled. 
 
Eqn 6: 
𝑇𝑢𝑚𝑜𝑢𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑚2)
= 𝑤𝑖𝑑𝑡ℎ (𝑚𝑚) × 𝑙𝑒𝑛𝑔𝑡ℎ (𝑚𝑚) ×  𝑠𝑚𝑎𝑙𝑙𝑒𝑟 𝑣𝑎𝑙𝑢𝑒 (𝑤𝑖𝑑𝑡ℎ 𝑜𝑟 𝑙𝑒𝑛𝑔𝑡ℎ) × (3.14 6⁄ ) 
 
2.6.4. MCMV-specific techniques 
 
2.6.4.1. Doxycycline delivery in vivo 
To enable replication of conditionally-replicating MCMV in vivo, mice injected with MCMV 
were given irradiated DOX feed (TD.01306, Envigo) at a concentration of 625 mg/kg for 
1 week and 2 weeks. The feed was stored at 4°C and replenished in mice cages every 
other day. 
 
2.6.4.2. Collection of murine saliva samples 
Mice were anesthetized with isoflurane (Piramal Healthcare). Sublingual cavity was then 
rinsed with 20 µl of sterile PBS. Saliva samples were stored at -20˚C until further 
analysis.  
 
2.6.4.3. Tail vein blood collection 
Mice were placed in a heating chamber at 37˚C for 20 minutes. The mice were then 
placed in a mouse restrainer. The tail of the mouse was sprayed with anaesthetic ethyl 
chloride B.P fine spray. A small cut in the tail was then made with a sterile scalpel blade 
(Swann-Morton) and the blood was collected in a heparin-coated microvette (Sarstedt). 
 
2.7. 5T4 epitope mapping 
 
2.7.1. Peptide pools and matrix systems 
Human 5T4 peptide pools were kindly provided by Prof Awen Gallimore.  These peptide 
pools were generated by using forty-one 20mers (Table 12), overlapping by 10 aa that 
covered the entire length of h5T4 protein (Appendix B). The peptide pools were designed 
by Dr Martin Scurr by adapting a matrix system (shown in Table 13) whereby 5-7 
peptides at a concentration of 5 μg/ml per peptide would make up a single peptide pool. 
The peptides were ordered from GLBiocem (Shanghai, China) at a 95% purity. 
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2.7.2. Ex vivo Enzyme-Linked ImmunoSpot (ELISpot) assay 
Polymer-backed 96-well filtration plates (MerckMillipore) were washed once with 70% 
ethanol followed by four washes with PBS. The plates were pre-coated with anti-mIFN-
γ antibody (15 μg/ml) overnight at 4°C. The following day, the antibody was discarded 
and the wells were blocked with 100 μl of RPMI 5% at 37°C for 1 h. Next, splenocytes 
isolated as described in section 2.5.2.11 were plated out in duplicate wells/condition and 
stimulated with either whole 5T4 protein (10 μg/ml, Oxford BioMedica) (provided by Prof 
Awen Gallimore), 5T4 peptide pools (5 μg/ml per peptide, GL Biochem, China) or 
individual 5T4 peptides (5 μg/ml/peptide, Severn Biotech) for 18-24 h (37°C, 5% CO2). 
As a positive control, Phytohemagglutinin (PHA) was used at a concentration of 10 μg/ml. 
The cells were discarded and the plates were handled as per the instructions supplied 
by the manufacturer. In brief, the wells were washed 5 times with 150 μl of PBS. 50 
μl/well of biotinylated rat anti-mouse interferon-gamma antibody diluted to 1 μg/ml in PBS 
was added to the wells and the plate was incubated for 2 hours at room temperature. 
Next, unbound antibody was removed with 5 washes with PBS and the plate was 
incubated with 50 μl of Streptavidin Alkaline Phosphatase Polymer diluted to 1μg/ml per 
well for 1 hour at RT.  Finally, the antibody was discarded, the plates were washed with 
PBS and 50μl/well of colour development buffer (BCIP/NBT-plus substrate, Mabtech) 
was added to each well and incubated at RT in the dark for 10-15 min. To terminate the 
reaction, the plate was rinsed with ddH2O and was left to air-dry. The numbers of spot 
forming units were quantified using an automated ELISpot plate reader (CTL 
Immunospot, USA). 
 
2.7.3. Peptide stability assay 
Peptide stability assay was performed as previously described by (Gallimore et al. 1998). 
In brief, T2 Kb and T2 Db cells were counted and 4x105 cells/peptide/time point were 
centrifuged at 1,600 rpm for 4 min at RT. The cells were washed twice with PBS followed 
by a spinning step at 1,600 rpm for 4 min at RT. The cell pellet was resuspended in 100 
μl of 0% RPMI containing 20 μM peptide (Table 14) for 1h at 37°C (5% CO2). Next, the 
cells were washed 3 times with cold 0% RPMI, the cell pellet was resuspended in 1 ml 
of 0% RPMI and the plate was incubated for a further 0, 2 or 4 hours at 37°C (5% CO2). 
At each time point, 250 μl of cells were transferred to a v-bottom 96-well plate 
(ThermoFisher Scientific) and centrifuged at 1,600 rpm for 4 min. The cells were 
resuspended in 50 μl of PBS containing either anti-MHC Class I H2 Kb + Db-PE (Table 
7) or anti-Mouse IgG2a-PE antibody (isotype control) and incubated at 4°C for 30 min. 
After that, the plate was spun at 1,600 rpm for 4 min and washed once with PBS. The 
cell pellet was fixed with 2% (v/v) PFA (section 2.1) and the samples were analysed on 
Accuri C6 flow cytometer as described in section 2.11. 
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Table 12: h5T4 20mers 
No. Sequence No. Sequence No. Sequence   
1 MPGGCSRGPAAGDGRLRLAR 15 LPSLRQLDLSHNPLADLSPF 29 LQGLPHIRVFLDNNPWVCDC 
2 AGDGRLRLARLALVLLGWVS 16 HNPLADLSPFAFSGSNASVS 30 LDNNPWVCDCHMADMVTWLK 
3 LALVLLGWVSSSSPTSSASS 17 AFSGSNASVSAPSPLVELIL 31 HMADMVTWLKETEVVQGKDR 
4 SSSPTSSASSFSSSAPFLAS 18 APSPLVELILNHIVPPEDER 32 ETEVVQGKDRLTCAYPEKMR 
5 FSSSAPFLASAVSAQPPLPD 19 NHIVPPEDERQNRSFEGMVV 33 LTCAYPEKMRNRVLLELNSA   
6 AVSAQPPLPDQCPALCECSE 20 QNRSFEGMVVAALLAGRALQ 34 NRVLLELNSADLDCDPILPP   
7 QCPALCECSEAARTVKCVNR 21 AALLAGRALQGLRRLELASN 35 DLDCDPILPPSLQTSYVFLG   
8 AARTVKCVNRNLTEVPTDLP 22 GLRRLELASNHFLYLPRDVL 36 SLQTSYVFLGIVLALIGAIF   
9 NLTEVPTDLPAYVRNLFLTG 23 HFLYLPRDVLAQLPSLRHLD 37 IVLALIGAIFLLVLYLNRKG   
10 AYVRNLFLTGNQLAVLPAGA 24 AQLPSLRHLDLSNNSLVSLT 38 LLVLYLNRKGIKKWMHNIRD   
11 NQLAVLPAGAFARRPPLAEL 25 LSNNSLVSLTYVSFRNLTHL 39 IKKWMHNIRDACRDHMEGYH 
12 FARRPPLAELAALNLSGSRL 26 YVSFRNLTHLESLHLEDNAL 40 ACRDHMEGYHYRYEINADPR 
13 AALNLSGSRLDEVRAGAFEH 27 ESLHLEDNALKVLHNGTLAE 41 YRYEINADPRLTNLSSNSDV   
14 DEVRAGAFEHLPSLRQLDLS 28 KVLHNGTLAELQGLPHIRVF       
 
Table 13: Matrix system used for making up thirteen h5T4 peptide pools 
  1 2 3 4 5 6 
7 1 2 3 4 5 6 
8 7 8 9 10 11 12 
9 13 14 15 16 17 18 
10 19 20 21 22 23 24 
11 25 26 27 28 29 30 
12 31 32 33 34 35 36 
13 37 38 39 40 41   
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Table 14: Individual 5T4 peptides used in ex vivo ELISpot 
 
 
Mouse strain Sequence 
C57BL/6 
VSFRNLTHL 
NSLVSLTYV 
SAPSPLVEL 
TSYVFLGIV 
BALB/c 
LSHNPLADL 
RGPAAGDGR 
GGCSRGPAA  
RSFEGMVVAALLAGR 
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2.8. Tetramerization 
Fluorescent tetrameric pMHCI complexes were produced by mixing conjugated 
streptavidin and biotinylated pMHCI monomers at a 1:4 molar ratio. Briefly, 30 ug 
biotinylated M123/pp89 H2-LD-restricted 168YPHFMPTNL176 (Peptide synthetics). 
monomers were tetramerized over 100 mins by mixing with appropriate Streptavidin-
Allophycocyanin (SA-APC) (For every 10 μg of monomer 8 μl of SA-APC was used) 
(Life-Technologies). 
 
2.9. Tetramer staining 
Isolated murine lymphocytes were centrifuged at 2,000 rpm for 2 min (RT) and washed 
once with 200 µl of PBS. Following another spin at 2,000 rpm for 2 min, the supernatant 
was removed and the cells were stained with 25 µl of Zombie Aqua fixable viability dye 
(BioLegend) (1:500 in PBS) at RT for 5 min avoiding exposure to light. 100 µl of PBS 
was then added and the cells were centrifuged at 2,000 rpm for 2 min (RT). The 
supernatant was discarded and the cells were stained with 25 μg/ml of SA-APC 
conjugated pp89/M123 tetramer for 15 min at 37˚C. Cells were then washed with 100 
μl FACS buffer and stained with anti-CD16/32 Fc-block (Biolegend) (1:50 in FACS 
buffer) for 20 min at 4°C with limited exposure to light. Subsequently, the cells were 
washed with 100 μl FACS buffer, centrifuged at 2,000 rpm for 2 minutes, and the 
supernatant was removed. Cells were then stained with the following anti-mouse 
antibodies, anti-CD3, anti-CD4, anti-CD8, anti-CD27, anti-CD44, anti-CD69 and anti-
CD103, (Table 1), all 1/100 in FACS buffer and incubated for 20 min at 4˚C. Cells were 
then washed with 100 μl FACS buffer and centrifuged at 2,000 rpm for 2 minutes. 
Supernatant was removed and the cells were reconstituted in 200 µl of FACS buffer 
and analysed with an Attune NxT flow cytometer (Thermo-Fisher) using FlowJo 
software (TreeStar inc, USA). 
 
2.10. Intracellular cytokine staining (ICS) 
Resuscitated murine splenocytes were pipetted into a V-bottomed 96-well plate 
containing 200 µl of RPMI (10% FBS; L-glutamine; pen/strep) and stimulated with 3 
μg/ml of MHCI-restricted peptides (M123/pp89 H2-LD-restricted 168YPHFMPTNL176) or 
with 3 μg/ml MHCII-restricted peptides (IAHQRITLTARCLRL and 
SQQKMTSLPMSVFYS; Innovative Peptide Solutions). For MHCI-restricted peptide 
stimulated wells, 2 μg/ml of Brefeldin A (Sigma) was added after 1 hour of stimulation 
and incubated for a further 5 hours at 37˚C 5% CO2. For MHCII-restricted peptides 2 
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μg/ml of Brefeldin A was added after 2 hours of peptide stimulation and incubated for 
a further 4 hours at 37˚C 5% CO2. Post-stimulation, cells were centrifuged at 2,000 rpm 
for 2 min (RT). The supernatant was discarded, and the cells were washed with 100 
µl of FACS buffer and centrifuged at 2,000 rpm for 2 min (RT). Cell pellets were stained 
using 25 µl of Zombie Aqua fixable viability dye (BioLegend) (1:500 in PBS) for 5 
minutes avoiding any exposure to light. Cells were then washed with 100 μl FACS 
buffer and centrifuged at 2,000 for 2 min (RT). Cells were then washed with 100 μl 
FACS buffer and stained with anti-mouse anti-CD16/32 Fc-block (Biolegend) (1:50 in 
FACS buffer) for 20 min at 4°C with limited exposure to light. Cells were further washed 
using 100 μl FACS buffer and centrifuged at 2,000 rpm for 2 minutes. The supernatant 
was discarded and the cells were stained for the following cell surface markers, anti-
mouse anti-CD3, anti-CD4, anti-CD8, anti- Killer cell lectin-like receptor subfamily G 
member 1 (KLRG1) and anti-CD44 (Table 1) (all 1/100) (Biolegend) and incubated for 
20 min at 4˚C. Cells were then washed in 100 μl FACS buffer. Cells were then fixed 
with 4% PFA solution for 20 mins at 4°C. Cells were then washed with 100 μl FACS 
buffer and 25µl of Saponin buffer was added to the cells for 20 mins 4°C. Cells were 
then washed with an excess of Saponin buffer and FACS buffer. Cells were then 
stained with the following intracellular anti-mouse antibodies, anti-IFN-γ and anti-TNF-
α for 20 mins 4°C. Cells were then washed using 100 μl of FACS buffer and spun at 
2,000rpm for 2 mins. Cells were then reconstituted in 200 µl of FACS buffer and 
analysed using an Attune NxT flow cytometer FlowJo software. 
 
2.11. Flow cytometry 
To look at enhanced Green Fluorescent Protein (eGFP) and phycoerythrin (PE) 
expression in infected cells, cells were harvested as detailed in section 2.2.1 and 
washed twice with PBS (Life Technologies), followed by a spin at 1,500 rpm for 3 min. 
The cell pellet was then resuspended in 200 μl of PBS (Life Technologies) to get a 
single cell suspension and fixed in 2% (v/v) PFA (section 2.1) for 15 min at 4˚C. eGFP 
expression and (PE) fluorescence was monitored on Accuri C6 flow cytometer via the 
FL1 and FL2 detector, respectively, and analysed on Accuri C6 264 software. The cell 
gating strategy involved differentiating the cells based on forward scatter (FSC) which 
is proportional to the size of the cell and side scatter (SSC) which indicates cell 
granularity.  In instances where extracellular staining was required, washed cells were 
stained with primary antibody at 4˚C for 30 min. After that, unbound antibody was 
removed by washing the cells with PBS (Life Technologies) and secondary antibody 
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was added at 4 ˚C for an additional 30 minutes. The cells were washed and fixed with 
2% PFA (section 2.1) then analysed on the flow cytometer. 
 
2.12. Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad 
Software, Inc., CA, USA). To compare 2 sets of data, unpaired student’s t test was 
performed with two tailed distribution whereas for multiple datasets either unpaired 
one-way ANOVA or two-way ANOVA tests were performed with an additional Tukey’s 
post-test. Survival rates were graphed using Kaplan and Meier method and analysed 
using the log-rank (Mantel-Cox) or Gehan-Breslow-Wilcoxon test. Data was plotted as 
mean ± standard deviation (SD) and statistical significance in figures and tables is 
indicated as follows; *p < 0.05; **p < 0.01; ***p< 0.001 and ****p<0.0001. 
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Chapter 3 Results 
 
 
3.1. Generation and analysis of conditionally replicating CMV in 
vitro 
 
Multiple viruses were generated during the course of this study. More information 
regarding the generation and analysis of these vectors is provided in subsequent 
sections. The vectors are listed in Table 15 (human CMV) and Table 16 (mouse CMV), 
along with some key characteristics, and are shown for reference purposes. The 
names of all the viruses are displayed in column 1. Names use the following 
nomenclature (refer to tables 15 and 16): (M1SV40213M444) where 1 represents the 
species specificity of the vector (H for human and M for mouse), 2 – promoter driving 
expression of tetR (SV40, RSV or MCMV IE for human CMV vectors and SV40, RSV 
or HCMV IE promoters for mouse CMV), 3 represents the number of tetO inserted 
upstream of essential CMV genes and 4 is the gene being regulated. Three tetR-based 
MCMV vectors (MRSV2M100-tetR-P2A-M36; MHCMVie2M100RSVIE2; 
MRSV2M100HCMVieIE2) have two copies of tetR – one replacing m157 and the second 
in either IE2 (M122) or at the end of M36. pAL numbers represent an internal laboratory 
reference to be used by members of the group. Wild type (WT) viruses as well as 
viruses sent by collaborators (M50-1 and SCP-GFP) have distinct names. 
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Table 15: Human CMV vectors used and generated in this study 
(1)- species specificity of the vector; (2) – promoter driving tetR expression; (3) – 
number of tetO; (4) – the gene being regulated. pAL – plasmid number used for 
laboratory reference. MCMV IE - mouse cytomegalovirus immediate early; RSV – 
Rous Sarcoma virus; tetR – tetracycline repressor; WT – wild type. 
 
 
Name 
pAL 
number 
(1) 
Species 
(2) tetR 
promoter 
Location 
of TetR 
(3) 
Number 
of tetO 
(4) 
Location 
of tetO 
WT Merlin 1111 Human - - - - 
H2UL131A 1938 Human - - 2 UL131A 
HSV40 1916 Human SV40 RL13 - - 
HRSV 1917 Human RSV RL13 - - 
HMCMVie 1924 Human MCMV IE RL13 - - 
HSV401UL44 2048 Human SV40 RL13 1 UL44 
HSV402UL44 2049 Human SV40 RL13 2 UL44 
HRSV1UL44 2145 Human RSV RL13 1 UL44 
HRSV2UL44 2051 Human RSV RL13 2 UL44 
HMCMVie1UL44 2135 Human MCMV IE RL13 1 UL44 
HMCMVie2UL44 2136 Human MCMV IE RL13 2 UL44 
HRSV1UL54 2141 Human RSV RL13 1 UL54 
HRSV2UL54 2142 Human RSV RL13 2 UL54 
HMCMVie1UL54 2147 Human MCMV IE RL13 1 UL54 
HMCMVie2UL54 2148 Human MCMV IE RL13 2 UL54 
HSV401UL75 2017 Human SV40 RL13 1 UL75 
HSV402UL75 2018 Human SV40 RL13 2 UL75 
HRSV1UL75 2025 Human RSV RL13 1 UL75 
HRSV2UL75 2026 Human RSV RL13 2 UL75 
HMCMVie1UL75 2027 Human MCMV IE RL13 1 UL75 
HMCMVie2UL75 2028 Human MCMV IE RL13 2 UL75 
HRSV1UL85 2115 Human RSV RL13 1 UL85 
HRSV2UL85 2123 Human RSV RL13 2 UL85 
HMCMVie1UL85 2116 Human MCMV IE RL13 1 UL85 
HMCMVie2UL85 2130 Human MCMV IE RL13 2 UL85 
HRSV1UL100 2122 Human RSV RL13 1 UL100 
HRSV2UL100 2125 Human RSV RL13 2 UL100 
HMCMVie1UL10
0 
2131 
Human 
MCMV IE RL13 1 UL100 
HMCMVie2UL10
0 
2129 
Human 
MCMV IE RL13 2 UL100 
HRSV1UL123 2127 Human RSV RL13 1 UL123 
HRSV2UL123 2126 Human RSV RL13 2 UL123 
HMCMVie1UL12
3 
2117 
Human 
MCMV IE RL13 1 UL123 
HMCMVie2UL12
3 
2121 
Human 
MCMV IE RL13 2 UL123 
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Table 16: Mouse CMV vectors used and generated in this study 
Name 
pAL 
number 
Strain 
(1) 
Species 
(2) tetR 
promoter 
Locatio
n of 
TetR 
(3) 
Number 
of tetO 
(4) 
Location 
of tetO 
WT K181 1918 K181 Mouse - - - - 
MSV40 1931 K181 Mouse SV40 m157 - - 
MRSV 1937 K181 Mouse RSV m157 - - 
MHCMVie 1978 K181 Mouse HCMV IE m157 - - 
WT FRT 2208 Smith Mouse - - - - 
M50-1 2168 Smith Mouse CMV M50 2 M50 
SCP-GFP 2169 Smith Mouse CMV 
m48.2 
(SCP) 
2 - 
MSV401M44 2053 K181 Mouse SV40 m157 1 M44 
MSV402M44 2054 K181 Mouse SV40 m157 2 M44 
MRSV1M44 2056 K181 Mouse RSV m157 1 M44 
MRSV2M44 2057 K181 Mouse RSV m157 2 M44 
MHCMVie1M4
4 
2058 K181 
Mouse 
HCMV IE m157 1 M44 
MHCMVie2M4
4 
2133 K181 
Mouse 
HCMV IE m157 2 M44 
MSV401M75 2060 K181 Mouse SV40 m157 1 M75 
MSV402M75 2061 K181 Mouse SV40 m157 2 M75 
MRSV1M75 2063 K181 Mouse RSV m157 1 M75 
MRSV2M75 2064 K181 Mouse RSV m157 2 M75 
MHCMVie1M7
5 
2065 K181 
Mouse 
HCMV IE m157 1 M75 
MHCMVie2M7
5 
2066 K181 
Mouse 
HCMV IE m157 2 M75 
MRSV1M85 2124 K181 Mouse RSV m157 1 M85 
MRSV2M85 2120 K181 Mouse RSV m157 2 M85 
MHCMVie1M8
5 
2068 K181 
Mouse 
HCMV IE m157 1 M85 
MHCMVie2M8
5 
2069 K181 
Mouse 
HCMV IE m157 2 M85 
MRSV1M100 2119 K181 Mouse RSV m157 1 M100 
MRSV2M100 2118 K181 Mouse RSV m157 2 M100 
MHCMVie1M1
00 
2071 K181 
Mouse 
HCMV IE m157 1 M100 
MHCMVie2M1
00 
2072 K181 
Mouse 
HCMV IE m157 2 M100 
MRSV1M123 2074 K181 Mouse RSV m157 1 M123 
MRSV2M123 2075 K181 Mouse RSV m157 2 M123 
MHCMVie1M1
23 
2077 K181 
Mouse 
HCMV IE m157 1 M123 
MHCMVie2M1
23 
2099 K181 
Mouse 
HCMV IE m157 2 M123 
MRSV2M100
HCMVieIE2 
2304 K181 
Mouse RSV and 
HCMV IE 
m157 and 
IE2 
2 M100 
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MHCMVie2M1
00RSVIE2 
2307 K181 
Mouse HCMV IE 
and RSV 
m157 and 
IE2 
2 M100 
MRSV2M100
-tetR-P2A-
M36 
2311 
K181 
 
Mouse RSV and 
endogeno
us M36 
End of M36 2 M100 
(1) - species specificity of the vector; (2) – promoter driving tetR expression; (3) – 
number of tetO; (4) – the gene being regulated. pAL – plasmid number used for 
laboratory reference. HCMV IE - human cytomegalovirus immediate early; IE – 
immediate early; RSV – Rous Sarcoma virus; tetR – tetracycline repressor; WT – wild 
type. 
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Table 17: Growth properties of tet-regulated HCMV vectors 
Virus growth refers to productive transfection producing infectious virus virions. Difference in  
HFFF-HTERTs -/+ DOX was measured by transfecting viral BAC DNA into HFFF-HTERTs 
supplemented with DOX. After appearance of plaques the cells were split in half and grown in 
-/+ DOX. Differences in plaque sizes are represented as a ‘✓’. ‘HFFF-HTERTs – hTERTs vs 
HFFF-TET’ comparison was performed by infecting HFFF-HTERTs – hTERTs (regular 
fibroblasts) and HFFF-TET (constitutively expressing tetR) monolayers under a semi-solid 
overlay. Plaque sizes were compared between these two cell types.  
DOX – doxycycline; n/a – not applicable; HFFF-HTERTs - hTERT immortalized human foetal 
foreskin fibroblasts; HFFF-TET - human foetal foreskin fibroblasts transduced with tetR; WT – 
wild type; ✓ - productive infection/observed differences in virus growth; X – non-productive 
infection/no differences observed in virus growth.       
Name 
Virus 
growth 
Difference in HFFF-
HTERTs -/+ DOX 
HFFF-HTERTs vs 
HFFF-TET 
WT Merlin ✓ X X 
H2UL131A ✓ ✓ ✓ 
HSV40 ✓ X X 
HRSV ✓ X X 
HMCMVie ✓ X X 
HSV401UL44 n/a X X 
HSV402UL44 n/a X X 
HRSV1UL44 ✓ X X 
HRSV2UL44 X X X 
HMCMVie1UL44 ✓ X X 
HMCMVie2UL44 ✓ X X 
HRSV1UL54 ✓ X ✓ 
HRSV2UL54 ✓ ✓ X 
HMCMVie1UL54 ✓ X X 
HMCMVie2UL54 ✓ X X 
HSV401UL75 ✓ X X 
HSV402UL75 ✓ X X 
HRSV1UL75 ✓ X X 
HRSV2UL75 ✓ X X 
HMCMVie1UL75 ✓ X X 
HMCMVie2UL75 ✓ ✓ X 
HRSV1UL85 ✓ X X 
HRSV2UL85 ✓ X X 
HMCMVie1UL85 ✓ X X 
HMCMVie2UL85 ✓ X X 
HRSV1UL100 ✓ X X 
HRSV2UL100 ✓ X X 
HMCMVie1UL100 ✓ X X 
HMCMVie2UL100 ✓ X X 
HRSV1UL123 ✓ ✓ ✓ 
HRSV2UL123 ✓ X X 
HMCMVie1UL123 ✓ X X 
HMCMVie2UL123 ✓ X X 
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Table 18: Growth properties of tet-regulated MCMV vectors 
BAC DNA transfections leading to production of infectious virions is shown in column 1.  
Difference in NIH 3T3s -/+ DOX was measured by transfecting viral BAC DNA into NIH 3T3s 
supplemented with DOX. After appearance of plaques, the cells were divided up and grown in 
-/+ DOX. Differences in plaque sizes are represented as a ‘✓’. ‘NIH 3T3s vs NIH 3T3-Tets’ 
comparison was performed by infecting NIH 3T3s (regular fibroblasts) and NIH 3T3-Tets 
(constitutively expressing tetR) monolayers under a semi-solid overlay. Plaque sizes were 
compared between these two cell types.  
DOX – doxycycline; NIH 3T3s – mouse embryo fibroblasts; NIH 3T3-Tets – mouse embryo 
fibroblasts transduced with tetR; WT – wild type; ✓ - productive infection/observed differences 
in virus growth; X – non-productive infection/no differences observed in virus growth.     
Name 
Productive 
virus infection 
Difference in 
NIH 3T3s -/+ 
DOX 
NIH 3T3s vs NIH 
3T3-Tets 
WT K181 ✓ X X 
MSV40 ✓ X X 
MRSV ✓ X X 
MHCMVie ✓ X X 
WT FRT ✓ X X 
M50-1 ✓ ✓ ✓ 
SCP-GFP ✓ ✓ ✓ 
MSV401M44 X X X 
MSV402M44 X X X 
MRSV1M44 ✓ X X 
MRSV2M44 ✓ X X 
MHCMVie1M44 ✓ X X 
MHCMVie2M44 ✓ X X 
MSV401M75 X X X 
MSV402M75 X X X 
MRSV1M75 ✓ X X 
MRSV2M75 ✓ X X 
MHCMVie1M75 ✓ X X 
MHCMVie2M75 ✓ X X 
MRSV1M85 ✓ X X 
MRSV2M85 ✓ X X 
MHCMVie1M85 ✓ X X 
MHCMVie2M85 ✓ X X 
MRSV1M100 ✓ X X 
MRSV2M100 ✓ X X 
MHCMVie1M100 ✓ X X 
MHCMVie2M100 ✓ X X 
MRSV1M123 ✓ X X 
MRSV2M123 ✓ X X 
MHCMVie1M123 ✓ X X 
MHCMVie2M123 ✓ X X 
MRSV2M100HCMVieIE2 ✓ ✓ ✓ 
MHCMVie2M100RSVIE2 ✓ ✓ ✓ 
MRSV2M100-tetR-P2A-M36 ✓ ✓ ✓ 
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3.1.1. Construction of HCMV vectors using TREx system 
 
3.1.1.1. Insertion of tetR in place of RL13 
In order to generate safe and effective HCMV vectors, I elected to control virus 
replication using the TREx system. While the Tet-Off system allows repression of 
constitutively expressed genes upon addition of DOX, both the TREx and Tet-On 
systems only allow expression in the presence of DOX; thus, a vector would be 
rendered dependent on DOX for replication. A key difference between the two 
systems, however, is the fact that Tet-On is an activation system whereas TREx relies 
on de-repression. In addition to this, in TREx vectors, the gene of interest is expressed 
from an endogenous native promoter, and is therefore expressed at the natural time 
and amount whilst in Tet-On vectors, expression of the gene is under the control of an 
exogenous promoter.  Since I wanted to minimise disruption to the natural CMV 
infection cycle, I adopted the TREx system. To engineer the vectors, two elements 
need to be inserted into the virus backbone – the tetR and tetO. In the absence of 
tetracycline or its analogue DOX, tetR homodimers bind to tetO inserted upstream of 
the target gene and inhibit transcription initiation, thereby preventing virus replication. 
Addition of DOX blocks the binding of tetR to the tetO, thus allowing for gene to be 
expressed and, as a result, the virus is able to replicate. It is crucial that tetR replaces 
a non-essential virus gene and does not interfere with expression of other virus 
proteins. In HCMV, mutations in RL13 are rapidly selected when clinical strains are 
grown in vitro and thus far, no beneficial function has been ascribed to the gene, 
making it an ideal location for inserting transgenes (Stanton et al. 2010).   
 
The tetR was inserted via two rounds of recombineering (see Figure 7). First by 
replacing the RL13 gene with a Ampr/LacZ/sacB selection cassette and selecting for 
ampicillin resistance and blue colouring, and then performing a second round of 
recombineering and replacing the cassette with the tetR gene. Colonies were screened 
for loss of the recombineering cassette (by selecting on sucrose; sacB makes colonies 
sensitive to sucrose). At this point, DNA was prepared from individual colonies, BACs 
were screened by restriction digest analysis, and sequenced to confirm that no major 
genome re-arrangements or mutations had occurred in the region of interest. Next, it 
was important to determine the level and timing of expression of tetR, to ensure it 
would suppress transcription of essential virus genes described in section 3.1.1.2. 
Since transcription of RL13 occurs late in the CMV replication cycle, it was necessary 
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to test alternative promoters that would drive earlier tetR gene expression. For this, a 
recombineering selection cassette was inserted upstream of tetR and then replaced 
with well characterized promoters (either SV40, RSV or MCMV IE) to generate three 
parental viruses: HSV40, HRSV or HMCMVie, respectively. To confirm that no genome re-
arrangement had occurred during recombineering, the viruses were digested with 
HindIII and their restriction digest pattern (Figure 8) was compared to that of WT Merlin. 
The viruses were also sequenced to ensure that no mutations had occurred during 
PCR amplification. 
 
Sufficient levels of tetR are required to efficiently repress genes. To select vectors with 
the highest tetR expression, human fibroblasts were infected with all the vectors and 
cell lysates were analysed for tetR levels (Figure 9). IE1 and actin controls were used 
to indicate productive infection with no evidence of toxicity. Interestingly, RSV promoter 
driven expression could be detected as early as 8 h pi and increased over the course 
of infection until 72 hours. Unexpectedly, tetR expression could not be detected when 
driven by either the SV40 or MCMV IE promoter even at late stages of virus infection. 
Although SV40 and RSV are strong viral promoters, they failed to induce detectable 
levels of tetR expression in HF-hTERTs. These BACs have been transfected, and all 
produced infectious virions (Table 17) that grew to good titres, thus, insertion of the tet 
repressor did not affect their viability. 
 
  
 
9
3
 
 
  
Figure 7: Cloning of tetracycline repressor expression cassette into human CMV vectors. Vectors HSV40, HRSV and HMCMV IE were 
generated via four steps of recombineering (numbers of the left). First, RL13 gene in WT Merlin strain (schematic depicted at the top) was 
replaced with the Ampr/LacZ/sacB selection cassette (step 1) which was then replaced with the tetR gene (green) (step 2). In the third step 
of recombineering, Ampr/LacZ/sacB selection was inserted upstream of tetR and then replaced (step 4) with either SV40, RSV or MCMV 
IE promoters. Arrows indicate the orientation of protein-coding regions. Ampr/LacZ/sacB selection cassette is displayed in blue. Black 
arrows represent the promoters. 
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Figure 8: Restriction endonuclease (HindIII) fragment profiles of WT Merlin, HSV40, HRSV and HMCMVie DNA. HSV40, HRSV and HMCMV 
IE BAC DNA was purified and digested with HindIII for 1 hour (37˚C). DNA fragments were compared to digested WT Merlin BAC DNA 
to confirm that no recombination or major mutations had arisen during BAC generation.  The marker (M) lane (kb) is depicted on the left. 
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Figure 9: RSV promoter-driven expression of tetR detected in human fibroblasts as early as 8 h pi. Expression levels of tetR 
(inserted at the RL13 locus) regulated by SV40, RSV and MCMV IE promoters were analysed at 8, 24, 48 and 72 hpi. HFFFS were 
infected at an MOI of 5 with the various HCMV constructs and cell lysates were collected at indicated times. Expression of tetR in HSV40, 
HRSV and HMCMVie viruses was compared to WT Merlin (negative control) and HF-Tet cell line (positive control) that constitutively express 
tetR and has previously been shown to efficiently repress gene expression (Stanton et al. 2010). IE1 expression represents HCMV 
infections whilst β-actin served as a housekeeping protein. 
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3.1.1.2. Insertion of tetO upstream of UL44, UL54, UL75, UL85, 
UL100 and UL123 
The fact that tetR binds to tetO can be utilised in the context of vector development 
since careful positioning of tetO sequences close to transcription start sites can ablate 
formation of the transcription initiation complex (Yao et al. 1998). Previous work by 
Stanton et al, has shown that the location of tetracycline operator sequences affects 
the degree of gene regulation and thus, virus replication (Stanton et al. 2010). In their 
work, one or two tetO were inserted 19 and 44 bp upstream of the RL13 gene. Of these 
four configurations, only the presence of a single tetO 19 bp upstream enabled tight 
control of RL13 expression. When regulating UL131A, one or two tetO were placed 4, 
16 or 33bp upstream of the gene translation start site. Strong control of transcription 
occurred in vectors containing 2 tetO 16 or 33 bp in front of the coding region (Stanton 
et al. 2010). From these experiments, it was apparent that tetO worked when placed 
16-33 bp upstream of the ATG, whereas the number of tetO required was gene-
dependent. I therefore inserted a selection cassette 20 bases upstream of six different 
HCMV genes (Figure 10). In the second round of recombineering, I replaced the 
cassette with a 100 bp oligonucleotide spanning the insertion site and containing one 
or two tetO sequences to generate a total of 28 vectors (Table 15). HCMV genes were 
chosen in which no other genes were directly upstream or in close proximity to the 
gene of interest, to facilitate insertion of tetO. 
 
HCMV genes are conventionally divided into three distinct kinetic classes (immediate 
early, early and late), where immediate early genes control the expression of early 
genes and early genes express proteins that replicate the viral genome, which in turn 
is required for the expression of late structural genes. I wanted to see whether 
suppressing gene expression at different stages of the replication cycle would have an 
effect in inducing differential control of virus replication. I therefore selected an 
immediate early (UL123/UL122, IE1/IE2), early (UL44 DNA polymerase processivity 
factor and UL54, DNA polymerase catalytic subunit that both make up the DNA 
polymerase complex) and late (UL75, gH (required for entry); UL85, minor capsid 
protein and UL100, gM (required for entry)) genes as my targets. All of the genes 
selected were highly conserved among the Betaherpesvirinae family, with homologues 
both in human and mouse CMV. Deletion of any of these genes would render the virus 
inactive as there are no other gene products with complementing functions.  
  
9
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Figure 10: Steps in cloning tetracycline operators (tetO) in HCMV vectors. TetO were inserted into HCMV vectors via two steps of 
homologous recombineering. In the first step, Ampr/LacZ/sacB selection cassette (displayed in dark blue) was inserted upstream of the 
‘gene of interest’ (light blue). The 'gene of interest' represents either UL44, UL54, UL75, UL85, UL100 or UL123, a gene that may be 
transcriptionally controlled by tetR binding. In the second step, the selection cassette was replaced with either one or two copies of tetO 
(light green). Arrows indicate the orientation of protein-coding regions. Green boxes illustrate the tetracycline operator gene. A promoter is 
represented by a black arrow (upstream of tetR gene). 
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Figure 11: Expression of inducible GFP by adenovirus vector (Ad-tetO-GFP) was inhibited to background levels in fibroblasts 
constitutively expressing tetR (HFFF-Tet). The cells were infected (MOI=50) with control adenovirus encoding GFP (Ad-GFP) or Ad-
tetO-GFP comprising of 2 tetO 10 bp upstream of eGFP. DOX was added at a concentration of 1 µg/ml to relieve repression of GFP 
expression. GFP expression levels were compared at 72 h pi BD Accuri C6 Cytometer. 
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3.1.2. Characterization of HCMV vector replication in vitro 
 
3.1.2.1. The impact of doxycycline on growth kinetics of HCMV 
in vitro 
The 28 tetR-regulated HCMV vectors (Table 15) generated in the study contained one 
or more tetO inserted upstream genes essential for efficient virus replication. In the 
absence of DOX, tetR should block expression of these genes thereby inhibiting virus 
propagation. To reconstitute all the viruses, I transfected the BACs into HFFF-hTERTs 
and supplemented the growth media every two days with 1 μg/ml of DOX. To facilitate 
dissemination of the virus, the transfected cells were trypsinized twice a week and re-
seeded back into the same flask. To see whether virus growth could be controlled in a 
reversible manner, the cells showing CPE were split into two flasks, where one 
continually received DOX and the other one did not. Comparison of plaque numbers 
(indicative of the replicative capacity of the virus) over the course of infection revealed 
that only three viruses (HRSV2UL54, HMCMVie2UL75 and HRSV1UL123) grew at a faster 
rate (Table 17) in the presence of DOX. For all of the remaining viruses, the plaques 
formed at a similar or sometimes somewhat faster rate in the cells where no DOX was 
present. This was contrary to what was predicted – if essential genes were tet-
repressed, then plaque sizes/numbers should have been reduced in the absence of 
DOX.  
 
3.1.2.2. Evaluation of HFFF-Tet cells 
The inability of DOX to provide conditional control over virus replication could be due 
to DOX not being stable in tissue culture or the tetR not being expressed at high 
enough levels to repress gene transcription. I therefore used a cell line (HFFF-Tet) that 
constitutively expresses tetR, at a level previously shown to inhibit gene transcription 
(Stanton et al. 2010), as a positive control. To ensure that these cells were functional, 
I infected the parental HFFF-hTERTs (which lack tetR expression) and HFFF-Tets with 
Ad-GFP and Ad-tetO-GFP viruses for 72 hours and compared GFP expression to 
mock-infected cells (Figure 11). Both vectors expressed GFP, however, the Ad-tetO-
GFP vector contains tetO upstream of GFP, making expression tetR-regulatable. 
Since HFFF-hTERTs do not express tetR, infecting with Ad-tetO-GFP conditional 
vector then adding or removing DOX did not affect expression of GFP. In HFFF-Tets, 
however, tetR binds to tetO and thus, inhibited GFP expression to background levels 
in the absence of DOX. Adding DOX blocked the binding between tetR and tetO 
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leading to 165-fold increase in GFP expression levels in HFFF-Tets infected with Ad-
tetO-GFP. Ad-GFP does not contain any tetO sequences, consequently infection of 
HFFF-hTERTs and HFFF-Tets resulted in comparable GFP levels in the absence and 
presence of DOX. 
 
To evaluate the stability of DOX in vitro (Figure 12), I infected HFFF-hTERTs and 
HFFF-Tets with Ad-tetO-GFP under four different DOX conditions and compared GFP 
levels to uninfected cells. I wanted to see whether DOX was stable in cell culture over 
4 days. Therefore, to some infected cells I added DOX once, only on the first day of 
infection, to other cells I changed DOX daily. GFP expression levels in infected HFFF-
hTERTs served as a positive control. Similar GFP expression levels were observed in 
infected HFFF-Tets receiving DOX, suggesting that DOX is stable in culture for at least 
4 days. 
  
 
1
0
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Doxycycline (DOX) is stable in vitro for at least 4 days. (A): DOX stability/functionality in HFFF-Tets and HFFF-hTERTs 
infected with Ad-tetO-GFP (MOI=50). The vector contains an eGFP gene downstream of tet-regulated HCMV MIE promoter. Infected cells 
were either supplemented with DOX once (day 0 of the experiment); daily or not supplemented at all. After 4 days, GFP expression in these 
cells was analysed using BD Accuri C6 Cytometer. (B) FACS plots showing the shift in eGFP expression levels in Ad-tetO-GFP infected 
fibroblasts over a course of 4 days. DOX was added to a 1 µg/ml concentration.  
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3.1.2.3. Comparative analysis of cell-cell HCMV spread 
Cytomegaloviruses disseminate via cell-free release as well as cell-to-cell spread that 
makes the virus less susceptible to neutralising antibodies. Both means of 
transmission may be important in vaccination. Clinically, cell-free spread is thought to 
be more relevant for inter-host spread whereas cell-to-cell spread is thought to be 
responsible for dissemination through the host (intra-host spread). 
 
To look in detail at the capacity of tet-regulated CMV vectors to spread via the cell-to-
cell route, I infected HFFF-hTERTs and HFFF-Tets in parallel and compared plaque 
sizes grown under a semi-solid overlay that inhibits cell-free virus spread. The HFFF-
Tets constitutively expressing tetR, served as a positive control for tetR expression. 
Since I had previously tested virus growth in HFFF-hTERTs in the presence and 
absence of DOX (Table 17) and did not observe major differences in the virus ability 
to replicate (all viruses grew in DOX), testing in HFFF-Tets showed whether the lack 
of differences was due to tetR expression. Each individual plaque was indicative of a 
single infection event/initially infected cell. Since WT Merlin does not contain tetR or 
tetO genes, it was used as a negative control in plaque size measurements (Figure 
13). In addition to this, I used a previously described H2UL131A virus that contains 
tetracycline operators upstream of UL131A, a gene that inhibits growth in fibroblasts. 
In the presence of tetR, UL131A expression is repressed and, as a result, the virus is 
able to spread more rapidly. As expected, WT Merlin virus spread was comparable in 
HFFF-Tets and HFFF-hTERTs. Although the majority of tetR-regulated viruses 
infected the two cell lines to a similar degree, for HRSV1UL54, HRSV2UL54, HRSV2UL75, 
HRSV1UL85, HMCMVie2UL85, HMCMVie1UL85 and HMCMVie2UL100 there was a slight, yet 
non-significant repression of virus replication in HFFF-Tet cells. The most striking 
difference, however, was observed for HRSV1UL123 and HMCMVie1UL123, where fewer 
and smaller plaques were detected in HFFF-Tets than in HFFF-hTERTs. In fact, 
HMCMVie1UL123 was not detectable in HFFF-Tets at all thus demonstrating the 
significance of UL123/IE1 expression on virus replication also identifying it as a key 
target in vaccine development.  
 
Next, I wanted to see whether repression of virus replication could be relieved by 
addition of DOX and whether tetR-regulated virus would grow to titres similar to WT 
virus. I selected HRSV1UL123 as the most promising vector and infected HFFF-hTERTs 
in the presence and absence of DOX and compared plaque sizes to those observed 
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in HFFF-Tets. As expected, plaque sizes (Figure 14) of WT Merlin were similar in the 
presence and absence of DOX. Surprisingly, however, I observed a 2.2-fold reduction 
in plaque size in HFFF-Tets. I also observed a 3-fold difference in H2UL131A growth 
in HFFF-hTERTs when compared to HFFF-Tets. H2UL131A virus served as a positive 
control since expression of UL131A results in inhibition of HCMV replication. In HFFF-
Tet cells expressing tetR, expression of UL131A gene is blocked thus, permitting virus 
replication. Larger H2UL131A plaques in HFFF-Tets were indicative that tetR was 
functional in the HFFF-Tet cells, although wide variation in plaque sizes meant that 
this was not statistically significant. As before, I could not detect infectious HRSV1UL123 
virus in HFFF-Tets, whereas cell-to-cell spread in the presence and absence of DOX 
was similar. This result suggests that stronger or earlier tetR expression as observed 
in HFFF-Tet cells that constitutively express tetR could suppress virus replication even 
more. 
 
Propagation of virus can lead to the accumulation of mutations that enable the virus to 
grow better in vitro (Dargan et al. 2010; Murrell et al. 2016). I wanted to see whether 
the reason for not observing a significant effect in different DOX conditions was due to 
acquisition of mutations that affected gene regulation by DOX. To limit mutagenesis of 
the virus genomes, I used purified BAC DNA and transfected both HFFF-hTERTs and 
HFFF-Tets with H2UL131A (positive control) and HRSV1UL123 and measured plaque 
sizes (Figure 15). I observed higher number of plaques in HFFF-TET cells as well as 
an 8.5-fold difference in infectivity for H2UL131A. HRSV1UL123, on the other hand, was 
more prominently repressed in HFFF-TETs with a 74-fold difference, thus, suggesting 
that the virus had not mutated in tetR or tetO regions and other factors were affecting 
regulation of virus replication.  
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Figure 13: Repression of UL123 in HCMV inhibits cell-to-cell spread. Cell-to-cell spread of 
control HCMV viruses (A) and tetR-based BAC-derived HCMV containing tetO upstream of 
UL44 (B), UL54 (C), UL75 (D), UL85 (E), UL100 (F), and UL123 (G). Plaque sizes of viruses 
were measured (using Fiji) after infecting HFFFs (○) or HFFF-TETs ( ) for 2 weeks under a 
semi-solid overlay medium to prevent cell-free virus spread. A single data point represents an 
individual plaque. Error bars show means ±SD. Panels B-F were analysed with one-way 
Analysis of Variance (ANOVA) with Tukey post-tests whilst panels A and G were assessed 
using unpaired 2-tailed t-test.  
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Figure 14: Addition of DOX relieves suppression of HRSV1UL123 growth.. WT 
Merlin (negative control), H2UL131A (positive control) and HRSV1UL123 were used to 
infect HFFF-TETs ( ) and HFFF-hTERTs in the absence (○), presence (●) of DOX for 
14 days. The cells were overlaid with semi-solid overlay media to impede cell-free virus 
spread. DOX in the media was replaced every three days. Data points denote 
individual plaque sizes. Error bars represent means ±SD. One-way ANOVA with Tukey 
post-test results are presented (***p< 0.001; ****p<0.0001).  
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Figure 15: Growth of BAC-derived viruses in HFFF-hTERT (○) and HFFF-TET ( ) 
cells. Sizes of plaques were measured at 2 weeks post-transfection (PT), with cells 
overlaid with semi-solid media to prevent cell-free spread of virus. 4 µg of DNA. Error 
bars represent means ±SD. One-way ANOVA with Tukey’s multiple comparisons post-
test are displayed (*p<0.05). 
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3.1.3. Construction of MCMV vectors using TREx system 
 
3.1.3.1. Replacing m157 with tetR gene 
Safety and efficacy evaluation of HCMV vectors needs to be carried out in animal 
models. Due to species specificity, it is not possible to grow HCMV in mice. I therefore 
modified the MCMV K181Perth strain in parallel to HCMV vectors (described in section 
3.1.1). To circumvent disruption of essential viral genes, I selected a region within 
m157 for inserting tetR. The m157 gene product binds to and stimulates the NK cell 
activation receptor Ly49H that is expressed by 50% of NK cells in the C57BL/6 mice 
strain (Smith et al. 2000). This in turn, leads to rapid clearance of the virus, making 
mice more resistant to MCMV. The majority of MCMV strains circulating in WT mice, 
however, encode m157 protein unable to activate NK cells via Ly49H (Voigt et al. 
2003). In addition to this, majority of wild mice lack the Ly49H receptor (Abolins et al. 
2017). Analogously to HCMV, tetR was inserted into MCMV via two recombineering 
steps (Figure 16). To establish early and high expression of tetR, a selection cassette 
was inserted upstream of the tetR gene and then replaced with either RSV, SV40 or 
HCMV IE promoter to give MRSV, MSV40 or MHCMVie, respectively. Next, I compared the 
levels of tetR expression driven by each of the promoters by performing a western blot 
analysis (Figure 17).  Expression regulated by the SV40 promoter was not detected 
even at 72 hpi. RSV and HCMV IE promoter-driven tetR expression, on the other hand, 
was detected as early as 24 hpi and continued increasing until 72 hpi.  
  
1
0
8 
  
Figure 16: Cloning of conditionally replicating MCMV vectors using the TREx system. MCMV genome comprises of a single unique 
sequence containing short terminal direct and internal repeats. To indicate location of m157, HindIII restriction digest fragments of the 
genome are shown. Each schematic diagram shows the four steps in recombineering performed and modifications made to the WT K181 
genome in order to generate MSV40, MRSV and MHCMVie. The m157 gene was replaced with Amp
r/LacZ/sacB selection cassette (dark blue) 
which in the second round of recombineering was replaced with the tetR gene (green). Next, the selection cassette was cloned upstream 
of tetR and then replaced with either SV40, RSV or HCMV IE promoter. Arrows indicate the gene and its orientation. Black arrows upstream 
of tetR in the bottom panel are indicative of the promoter that was inserted upstream to drive tetR expression. 
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Figure 17: RSV and HCMV IE promoters drive expression of tetR in MCMV 
vector as early as 24 h pi. NIH-3T3 cells were infected at an MOI of 3 and cells were 
harvested at either 8, 24, 48 or 72h. TetR (inserted in m157) expression in MSV40, 
MRSV and MHCMVie viruses was compared to WT K181 (negative control) and NIH-3T3-
TET cell line (positive control) transduced with a lentivirus to constitutively express 
tetR. IE1 expression reports on MCMV infection whereas β-actin expression serves 
as a loading control.  
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3.1.3.2. Insertion of tetO before M44, M75, M85, gM/M100 and 
IE1/M123 genes 
Either one or two tetO were inserted 20 bp upstream of MCMV genes, homologous to 
HCMV genes listed in section 3.1.1.2.  Overall, 24 MCMV vectors were generated via 
two rounds of recombineering (Figure 18). Cloning of vectors with regulated M54 gene 
expression was omitted due to insufficient spacing (8 bp) between the genes M54 and 
M55.  All purified BACs were transfected into NIH 3T3s and grown in media 
supplemented with DOX. Twenty of the transfected BACs except for MSV401M44, 
MSV402M44, MSV401M75 and MSV402M75 (Table 18) produced infectious virions.  
 
3.1.4. Growth phenotype of MCMV vectors in vitro 
 
3.1.4.1. The impact of doxycycline on growth kinetics of 
MCMV in vitro 
Growth efficiency of all 20 tetR-regulated MCMV vectors was tested in the presence 
and absence of DOX (Table 18). First, BAC DNA was transfected into NIH 3T3 cells 
and the media was supplemented with DOX until plaques started to form. Next, the 
effect of removal of DOX in half of infected cells was monitored until late stages of 
infection. All the transfected BACs produced infectious virions that spread through the 
cell monolayer at similar rates in the presence as well as absence of DOX. 
 
3.1.4.2. Functionality of NIH 3T3-Tet cells 
As with the HCMV vectors, I constructed a tetR expressing cell line as a control (NIH 
3T3-Tet). To ensure that NIH 3T3-Tets express functional tetR, NIH 3T3s and NIH 
3T3-Tets were infected with two Ads: Ad-GFP that constitutively expresses GFP and 
Ad-tetO-GFP in which GFP expression is controlled from a tet-regulated HCMV 
promoter (Figure 19). In the absence of tetR (NIH 3T3), GFP expression was not 
affected by DOX. I observed a 22-fold higher expression in NIH 3T3-Tets infected with 
Ad-tetO-GFP in the presence of DOX compared to the absence of DOX, thus showing 
that NIH 3T3-Tets were expressing tetR, and expression levels were sufficient to inhibit 
gene expression.
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Figure 18: Recombineering steps to insert tetO upstream of genes essential for MCMV replication. In the first round of 
recombineering, an Ampr/LacZ/SacB selection cassette (dark blue) was cloned upstream of the ‘gene of interest’ (either M44, M75, M85, 
M100 or M123). In the second round, either one or two copies of tetO were used to replace the selection cassette. Arrows show the 
orientation of genes. TetR is shown in dark green whilst tetO are represented by light green boxes.  
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Figure 19: TREx system works efficiently in the context of adenovirus. NIH 3T3 
and NIH 3T3-Tet cells were infected (MOI=500) with either a control adenovirus (Ad-
GFP) or an Ad expressing eGFP (Ad-tetO-GFP). The GFP gene expression in Ad-
tetO-GFP is under a tetR-regulated HCMV MIE promoter (2 tetO inserted 10 bp 
downstream of the TATA box). GFP expression was measured at 48 h pi . NIH 3T3-
TET constitutively express tetR. 
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3.1.4.3. Cell-to-cell MCMV spread in mouse fibroblasts 
Analysis of tet-regulated MCMV growth in the presence and absence of DOX 
(described in section 3.1.4.1) showed comparable virus growth kinetics in both 
conditions. To test whether the lack of transcriptional repression was due to insufficient 
tetR expression, plaque sizes of tet-regulated MCMVs were compared in NIH 3T3s 
and NIH 3T3-Tets in a 6-day plaque (Figure 20). All plaque measurements of 
recombinant viruses were compared to K181 MCMV (parental, non-tet regulated 
virus). Plaque sizes for the majority of the viruses, including the WT K181 MCMV 
strain, were slightly larger in NIH 3T3-Tets, suggesting that the production of the tetR 
cell line may have selected for cells that support slightly more efficient virus growth. 
Four of the viruses (MRSV1M100, MRSV2M100, MHCMVie1M100 and MHCMVie2M100), 
however, produced larger plaques in NIH 3T3s. It is noteworthy that all of these viruses 
contain tetO sequences upstream of M100. 
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Figure 20: Repression of M100/gM expression inhibits cell-to-cell virus spread. NIH 3T3 
(○) and NIH 3T3-Tets ( ) were infected with WT K181 (A) and MCMV containing tet-regulated 
M44 (B), M75 (C), M85 (D), M100 (E) and M123 (F). Cells were overlaid to prevent cell-free 
virus spread and plaque sizes of viruses were measured at 6 days pi. Each data point 
represents a single plaque. Error bars show means ±SD. The control viruses in panel A were 
analysed with unpaired 2-tailed t-test (*p<0.05). For panels B-F one-way ANOVA with Tukey 
post-test results are presented (*p<0.05; ***p< 0.001; ****p<0.0001). 
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3.1.4.4. Comparative analysis of tetR-regulated gM (M100) 
vectors to vectors described in the literature 
To compare my most encouraging tetR-regulated vectors to existing conditional 
MCMV vectors described in the literature, I obtained bacterial stabs of two MCMV 
vectors (M50-1 and SCP-GFP) from Zsolt Ruzsics, Ulrich Koszinowski’s laboratory 
(Rupp et al. 2005), both of which are based on the Smith strain of MCMV. M50-1 virus 
contains an M50 gene (encodes the structural major capsid protein), inserted at a 
different site in the genome, and expressed from a HCMV ie promoter, in which 
expression is de-repressed by the addition of DOX. SCP-GFP, on the other hand, has 
a tet-regulated m58.2 gene (codes for small capsid protein, SCP) fused with eGFP. 
SCP is essential for virus replication, fusion of eGFP to SCP gene has a dominant-
negative effect whereby expression of SCP-GFP fusion protein inhibits infectious virion 
production (Borst et al. 2001). Since tetO was inserted upstream of SCP-GFP fusion 
gene, addition of DOX would result in repression of growth even with the insertion of 
an additional SCP gene at an ectopic location which allows virus growth in the absence 
of DOX. Both of the vectors (Figure 21) were generated using a TREx-like system in 
the Smith strain of MCMV, and DOX administration regulated virus release by 3-fold 
and 1,000,000-fold in vitro for M50-1 and SCP-GFP, respectively (Rupp et al. 2005). 
In vitro, Smith produces larger plaques, replicates to higher titres than K181 and 
spreads faster in the cell monolayer. In vivo, on the other hand, K181 is considered to 
be more virulent than Smith and produces higher titres in salivary glands. This may in 
part be because Smith lacks intact MCK-2 gene, which limits virus tropism for 
peripheral blood leukocytes (PBLs) and reduces titres in salivary glands (Jordan et al. 
2011). 
 
BAC DNA was isolated and analysed by restriction digest analysis (Figure 22) to 
confirm that no major genome re-arrangement had occurred. BAC DNA was 
transfected into NIH 3T3s and grown in media with and without DOX for M50-1 and 
SCP-GFP, respectively. Following this, I compared the spread (Figure 23) of M50-1, 
SCP-GFP and my tet-regulated vectors in mouse fibroblasts under three conditions: 
with or without DOX and in cells constitutively expressing tetR to control for tetR 
expression levels. To prevent virus cell-free dissemination, infections were carried out 
under semi-solid overlay.  The overlay was replaced three times a week to maintain 
DOX concentrations in the media. Interestingly, I observed a 3.6-fold decrease in 
MRSV1M100 plaque sizes in NIH 3T3-Tet cells as compared to growth in NIH 3T3s. 
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Two tetO upstream of gM/M100 with the same virus backbone (MRSV2M100) resulted 
in tighter repression of virus growth where only six plaques where found in the absence 
of DOX. This repression was relieved with addition of DOX, with plaque sizes 
increasing by about 3-fold. In addition to this, virus replication was completely inhibited 
in NIH 3T3-Tets. Less efficient control of virus replication was observed for M50-1 and 
SCP-GFP viruses. M50-1 displayed smaller plaques in the absence of DOX and 
produced larger plaques (by a 2-fold) where DOX was added. Seven smaller plaques, 
indicative of productive virus infection were detected in NIH 3T3-Tet cells thus 
demonstrating that even high levels of tetR failed to control this virus. Plaque sizes for 
SCP-GFP, on the other hand, were comparable in all three different conditions.
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Figure 21: Structure of SCP-GFP and M50-1 viruses sent by Zsolt Ruzsics. Two tet operators (light green) driven by either SV40 or 
HCMV IE promoters were inserted upstream of SCP (m48.2) (top figure) and M50 (bottom figure), respectively. TetR in both of these 
vectors was regulated by the HCMV immediate-early promoter-enhancer. OriR6K represents the origin of replication whereas Zeo depicts 
zeocin resistance gene. Two FRT sites are flanking the zeocin gene, oriR6K and the regulation cassette between genes m16 and m17.The 
endogenous M50 gene in M50-1 vector is deleted.  
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Figure 22:  Genomic stability of SCP-GFP and M50-1 BAC 
DNA. BAC DNA was purified from bacterial stabs (kindly 
provided by Zsolt Ruzsics) and digested at 37 ˚C for 1 hour with 
either EcoRI or HindIII. Digested fragments were compared in 
size to digest profiles published in the literature (not shown) to 
test for recombination events/genome stability. 
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Figure 23: More stringent control of virus cell-to-cell spread in M100/gM tetR-
regulated vectors than vectors described in the literature. Plaque sizes of tetR-
regulated viruses in NIH 3T3-Tets ( ), and NIH 3T3s in the absence (○) and presence 
(●) of DOX were compared to inducible M50-1 and SCP-GFP vectors described in the 
literature as well as a WT control (WT K181). Infected cells were incubated for 6 days 
under a semi-solid overlay to prevent cell-free virus spread. DOX in the overlay media 
was replaced every two days. Each symbol shows an individual plaque. Error bars 
represent means ±SD. One-way ANOVA results with Tukey post-tests are presented 
(***p<0.001; ****p<0.0001). 
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3.1.5. Fusing a second copy of tetR to M36 or IE2 (M122) 
Plaque assay data, using viruses in which gM/M100 was tet-regulated, showed some 
repression of MCMV in the absence of DOX, but complete ablation of virus replication 
in tetR expressing cells. This suggested that higher and/or more rapid tetR expression 
from the virus backbone could inhibit virus replication completely. To test this theory, 
two regions in the MCMV genome for inserting a second copy of tetR were selected: 
IE2 (M122) and M36. IE2 is a commonly used region in MCMV vector design since it 
is non-essential for virus replication in vivo and does not have a counterpart in HCMV 
(Messerle et al. 1991; Manning & Mocarski 1988). M36, a homolog of UL36, was 
selected on the basis of proteomic data from HCMV (Weekes et al. 2014), which 
demonstrated that UL36 was expressed early in the HCMV replication cycle, and was 
one of the most abundant genes at this time, which circumvents the need to insert 
exogenous promoters. Although IE2 is expressed early in the virus replication cycle, 
members in our laboratory have shown that its expression is not abundant, therefore 
for this vector, I inserted either the RSV or HCMV IE promoters upstream of tetR. 
 
To generate MRSV2M100-tetR-P2A-M36 (Figure 24), a selection cassette was inserted 
downstream of M36 in MRSV2M100 and then replaced with a codon optimised tetR 
gene fused to the M36 ORF by a P2A linker. This linker functions to separate the M36 
and tetR proteins during translation, thus ensuring the function of one is not affected 
by the other. MHCMVie2M100RSVIE2 vector and MRSV2M100HCMVIEIE2 were both 
generated (Figure 25) via 4 rounds of recombineering. First, I inserted a selection 
cassette in IE2 and replaced it with tetR gene. Then, by inserting a selection cassette 
upstream of tetR I replaced it with the appropriate promoter. All BACs were 
transfected, grown in media supplemented with DOX and produced infectious virions.
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  Figure 24: Steps undertaken to generate MRSV2M100-tetR-P2A-M36. MRSV2M100-tetR-P2A-M36 was generated via two rounds of 
homologous recombineering. First, an Ampr/LacZ/sacB selection cassette was inserted at the end of M36. In the second step, the cassette 
was replaced with gene synthesized tetR-p2A. Arrows represent genes and their orientations. The selection cassette is displayed in blue 
whilst tetR and tetO genes are shown in green. Letters P2A represent the P2A linker used to fuse tetR to M36. Black arrows show the 
promoter driving tetR expression. 
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Figure 25: Cloning of MHCMVie2M100RSVIE2 and MRSV2M100HCMVIEIE2. Four recombineering steps showing insertion of a second copy of 
tetR and either an RSV or HCMV IE promoter upstream of tetR. In the first step, Ampr/LacZ/SacB selection cassette was inserted in 
M122/IE2 gene in either MHCMVie2M100 or MRSV2M100. In the second round, the selection cassette was replaced with tetR gene. Then, 
to insert a promoter upstream of tetR, two more recombineering steps were carried out: the selection cassette was cloned upstream of 
tetR and then replaced with either RSV or HCMV IE promoter to generate MHCMVie2M100RSVIE2 or MRSV2M100HCMVIEIE2, respectively. 
Arrows represent coding regions in the virus and their orientations. Ampr/LacZ/SacB selection cassette is displayed in blue whereas tetR 
and tetO is shown in dark and light green, respectively. Black arrows depict the promoters upstream of tetR. 
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3.1.6. Comparative analysis of cell-free release of M50-1, SCP-GFP 
and tet-regulated glycoprotein M (gM/M100) MCMV viruses in 
NIH 3T3 
M50-1 and SCP-GFP viruses have been analysed in vitro and have shown significant 
growth defects in the absence and presence of DOX, respectively (Rupp et al. 2005). 
Since the effect I observed in cell-to-cell spread of these viruses was minor (Figure 
23), I wanted to see whether I could recapitulate the previously published effects on 
cell-free release of these viruses. For this, I performed multistep growth assays 
whereby NIH 3T3s and NIH 3T3-Tets were infected at an MOI of 0.1. Supernatants 
were collected daily and then titrated on NIH 3T3 in the presence of DOX to relieve 
tetR repression and enable virus replication. In the absence of DOX, release of M50-
1 was reduced by as much as 14 orders of magnitude (Figure 26A). SCP-GFP, on the 
other hand (Figure 26B), was released to similar levels as M50-1 in the absence of 
DOX whilst addition of DOX resulted in maximum 211-fold decrease in cell-free virus 
titres. As expected, addition of DOX did not alter release of control virus.   
 
For comparison, I also infected NIH 3T3s and NIH 3T3-Tets with tet-regulated 
gM/M100 viruses MRSV2M100, MRSV2M100-tetR-P2A-M36, MRSV2M100HCMVIEIE2 and 
MHCMVie2M100RSVIE2 in the absence and presence of DOX (Figure 27). Since 
MRSV2M100 contains only one copy of tetR it is unsurprising that this virus was inhibited 
by 11-fold at day 5 (Figure 27C), in the absence of DOX. Although 
MRSV2M100HCMVIEIE2 and MHCMVie2M100RSVIE2 only differ in the placing of their 
promoters, the cell release profiles of these viruses were surprisingly distinct. 
MRSV2M100HCMVIEIE2 growth (Figure 27A) could be inhibited by 193-fold (day 5) in the 
absence of DOX whereas for MHCMVie2M100RSVIE2 (Figure 27B) there was only an 8.5-
fold difference. In addition to this, MHCMVie2M100RSVIE2 was the only virus that released 
infectious virions in 3T3 NIH-Tet cells. MRSV2M100-tetR-P2A-M36 (Figure 27D) 
displayed the strongest reduction in virus spread, with peak titres delayed from day 3 
until day 15 when grown in the absence of DOX. Furthermore, there was a 369-fold 
reduction (day 5) in virus release in NIH 3T3s where no DOX was added. 
 
M50-1 and SCP-GFP viruses have been well characterized in the literature and 
although the viruses can be controlled to high degree by removal of DOX, the 
replication phenotype resembled that of MRSV2M100 and MHCMVie2M100RSVIE2 viruses. 
Cell-free virus spread of MRSV2M100HCMVIEIE2 and MRSV2M100-tetR-P2A-M36 was 
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most effectively controlled by addition/removal of DOX. It is evident that expression of 
two copies of tetR may improve regulation of virus replication and the place for 
insertion of tetR plays a critical role.  
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Figure 26: Greater inhibition of cell-free virus release of double-negative tetR-
regulated SCP virus than M50. Supernatants of infected (MOI=0.1) NIH 3T3s and 
NIH 3T3-Tets in the presence (●) and absence (○) of DOX were collected daily and 
titrated on NIH 3T3s as a measure of cell-free released virus. For a more sensitive 
detection of infectious cell-released virus particles, DOX was added to the overlay 
media three times a week. Cell-free M50-1 (A) and SCP-GFP (B) were compared to 
WT K181 control (shown in black). TetR-regulated viruses are shown in light blue.  
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Figure 27: Insertion of second copy of tetR enhances control of virus replication. 
Virus titres released into the supernatant after infection of NIH 3T3 and NIH 3T3-Tets 
(■) (MOI of 0.1) in the absence (○) and presence (●) of DOX were titrated on NIH 3T3s 
for 6 days. A) MRSV2M100HCMVIEIE2; B) MHCMVie2M100RSVIE2; C) MRSV2M100 and D) 
MRSV2M100-tetR-P2A-M36 virus (shown in light blue) titres were compared to WT 
K181 (shown in black). Each dilution was performed in duplicates. Error bars represent 
mean ±SD. 
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3.1.7. Comparative sequence analysis of mutations acquired in 
MCMV during virus propagation 
Multi-step growth assays (discussed in section 3.1.6) indicated that even in the 
absence of DOX, viruses were able to replicate to some extent. This raised the 
possibility that they could have acquired mutations, or would be able to do so following 
further passage. To test whether this occurred, eleven virus samples were deep-
sequenced.  To determine whether initial stocks had acquired mutations during 
amplification in the presence of DOX, I selected stocks of the following viruses: 1) WT 
K181; 2) MRSV; 3) MRSV2M100; 4) MHCMIie2M100; 5) MRSV2M100HCMVieIE2; 6) 
MHCMVie2M100RSVIE2 7) MRSV2M100-tetR-P2A-M36; 8) M50-1 and 9) WT FRT. In 
addition to this, I extracted MHCMVie2M100RSVIE2 virus from NIH 3T3-tet passaged for 
17 days (further referred to as MHCMVie2M100RSVIE2 tet d17) as well as MRSV2M100-
tetR-P2A-M36 isolated from cells grown in the absence of DOX for 22 days (referred 
to as MRSV2M100-tetR-P2A-M36 -dox d22). First, I compared (Table 19) all of the 
viruses with a WT K181 backbone to a previously published K181 sequence 
(GenBank: AM886412.1). Altogether there were 45 sequence insertions/deletions or 
mutations in non-coding regions, 2 silent mutations, 3 missense mutations and 4 
nonsense mutations resulting in truncation of protein-coding sequence. Since the 
majority of the differences were shared by all the viruses, they either represent errors 
in the initial sequencing of the K181 BAC, or differences acquired by the BAC clone 
that we received, during propagation in E. coli. In addition to this, the reference 
sequence contained unknown nucleotides in two regions of the genome. My viruses 
were missing these nucleotides in the M58-M69 region, whereas in m142 gene, I 
identified the unknown sequence missing from the reference.   
 
To determine whether any mutations had spontaneously arisen due to in vitro passage, 
all of the tetR-regulated viruses were aligned with Multiple Alignment using Fast 
Fourier Transform (MAFFT) program. Sequence analysis (Table 20) revealed that all 
viruses except for MRSV2M100-tetR-P2A-M36 contained a silent base pair substitution 
in the tetR gene. This mutation appeared during the PCR amplification step whilst 
generating virus BACs. Although MRSV2M100HCMVieIE2 was lacking 197 bases in m58-
m69 intron, the deletion had occurred in the non-coding region, and thus is unlikely to 
affect translation of any genes. The main focus was to investigate how viruses were 
able to replicate in the absence of DOX or in tetR expressing cells and comparison of 
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MRSV2M100-tetR-P2A-M36 to MRSV2M100-tetR-P2A-M36 -dox d22 provided some 
insights. Interestingly, the virus passaged in the absence of DOX mutated in the 
second copy of tetR gene (fused to M36) and had a 5 bp deletion that resulted in a 
frameshift and deletion of a stop codon. In addition to this, genes M70 and m139 
mutated, however, the base substitutions did not affect m139 sequence whilst for M70 
there was one amino acid change.  
 
The viruses sent by Zsolt Ruzsics (WT FRT and M50-1) had not been sequenced 
before, therefore I wanted to see whether the sequence of WT FRT was identical to 
previously published WT Smith strain (GU305914.1) as well as compare M50-1 to WT 
FRT. A consensus sequence could not be generated for M50-1 as it clearly contained 
multiple virus variants. Some of the variants contained a 25 bp deletion in a non-coding 
region (data not shown) . In addition to this, there were deletions in M51 and m59 
genes and a large deletion spanning m151-m158 genes. Comparison of WT FRT to 
WT Smith reference sequence (Table 21), revealed that the identity of the two 
sequences was 99.5%. The WT FRT sequence contained 642 single-nucleotide 
polymorphisms (SNPs) (532 SNPs in ORFs), 9 deletions (7 in genes) and 9 insertions. 
The differences were found in 40 different genes; however, the majority of the 
mutations were silent or missense and did not affect protein translation. The genes 
that were severely affected with frameshift mutations resulting in premature stop codon 
insertion included m01, m03, m59, m150 and m161.  
 
3.1.8. Summary 
I applied TREx system to generate 55 virus vectors in which I identified a gene in 
HCMV (UL123/IE1) and MCMV (gM/M100) that can be targeted to control virus 
replication using DOX in vitro. Data revealed that my vectors could be further inhibited 
in cells constitutively expressing tetR thus suggesting that earlier/higher expression of 
tetR may improve vector safety. In MCMV, addition of a second copy of tetR improved 
the control of cell-free virus spread, particularly when expressed from the endogenous 
M36 promoter. In addition to this, comparison of gM/M100-targeting vectors to other 
vectors revealed that cell-free and cell-cell spread of my vectors could be controlled to 
a higher degree than those previously published (M50-1 and SCP-GFP). Deep-
sequencing of viruses suggested that escape mutants can occur by mutation of tetR, 
in the absence of DOX. 
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Table 19: Comparative analysis of tetR-regulated viruses and published WT 
K181 sequence (GenBank: AM886412.1) 
Virus 
Locatio
n 
Mutation 
ORFs/intron
s affected 
Effect of 
mutation 
All 0-41 41 bp deletion 
Non-coding 
region 
- 
All 735-736 C insertion m01 
Frameshift 
no stop 
codon 
All 28926 A deletion M25-m25.1 intron - 
All 
except 
MRSV2M1
00-tetR-
P2A-M36 
47566-
47567 
T insertion M35-M36 intron - 
All 
48938-
48939 
C insertion M36 intron - 
All 59492 T deletion M44-M45 intron - 
All 79556 T deletion M53-M54 intron - 
All 
85439-
85440 
Insertion of CG M55-M56 intron - 
All 85440 G>A M55-M56 intron - 
All 
92645-
92701 
Deletion (ref sequence has 
n’s) 
M58-M69 intron - 
All 
93275-
93276 
Insertion of G M58-M69 intron - 
All 93340 C deletion M58-M69 intron - 
All 
103004-
103005 
AT deletion M71-M72 intron - 
All 103006 A>T M71-M72 intron - 
All 
110069-
110070 
Insertion of 
ggggggtcccggctcg 
M76-M78 intron - 
All 112651 T>G M78-M79 intron - 
All 
112654-
112655 
Insertion of TT M78-M79 intron - 
All 115679 A deletion M80-M82 intron - 
All 121943 A deletion M84-m84.2 intron - 
All 140164 A deletion M96-M97 intron - 
All 
155092-
155093 
G insertion m106-m108 intron - 
All 155757 A deletion m106-m108 intron - 
All 155781 A deletion m106-m108 intron - 
All 
155927-
155928 
TC deletion m106-m108 intron - 
All 155929 T>C m106-m108 intron - 
All 157821 G>C m106-m108 intron - 
All 157822 T>G m106-m108 intron - 
All 160178 T deletion m106-m108 intron - 
All 160329 T deletion m106-m108 intron - 
All 160718 T deletion m106-m108 intron - 
All 161497 A deletion m106-m108 intron - 
All 161533 A deletion m106-m108 intron - 
All 166840 C>T m115 Missense 
All 166842 T>G m115 Silent 
All 171404 T deletion m118-m119 intron - 
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All 171929 C deletion m119 
Missense; 
frameshift 
and 
premature 
stop codon 
All 177098 G>T m121 Missense 
All 177100 T>G m121 Silent 
All 
179680-
179681 
G insertion m121-m124 intron - 
All 179786 A deletion m121-m124 intron - 
All 
183129-
183130 
C insertion 
m124.1-m125 
intron 
- 
All 183230 A deletion 
m124.1-m125 
intron 
- 
All 
183250-
183251 
CA deletion 
m124.1-m125 
intron 
- 
All 183917 T deletion m125-m126 intron - 
All 
188729-
188730 
Insertion of AG m132.1 
Premature 
stop codon 
All 190386 Deletion of T m134 
Frameshift, 
premature 
stop codon 
All 
197762-
197763 
G insertion m140-m141 intron - 
All 
199778-
199779 
39 bp insertion m142 
In-frame 
insertion 
All  
199779-
199785 
CGCAGCC (in reference 
sequence five n’s) 
m142 n/a 
All 
208756-
208757 
C insertion m150-m151 intron - 
All 
214337-
214338 
C insertion 
m154.4-m155 
intron 
- 
All 211539 T deletion m152-m153 intron - 
All 211561 T deletion m152-m153 intron - 
All 211576 A deletion m152-m153 intron - 
All 228037 A deletion m168 
Frameshift; 
premature 
stop codon 
All 230301 
Insertion of 
cccccccggccgtctgagtgcgcgc
gggcccc (sequence 41-72 in 
ref sequence) 
Non-coding 
region 
- 
TetR-regulated viruses sequenced and listed in the table: MRSV; MRSV2M100; 
MHCMIie2M100; MRSV2M100HCMVieIE2; MHCMVie2M100RSVIE2; MRSV2M100-tetR-P2A-
M36; MHCMVie2M100RSVIE2 virus from NIH 3T3-tet passaged for 17 days (referred to as 
MHCMVie2M100RSVIE2 tet d17) and MRSV2M100-tetR-P2A-M36 -dox d22 isolated from 
cells grown in the absence of DOX for 22 days. The viruses were sequenced by 
Andrew Davison and sequences were compared to WT K181 sequence (GenBank: 
AM886412.1) by MAFFT. 
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Table 20: Mutations associated with PCR/in vitro passage of my tetR-regulated 
MCMV viruses 
bp – base pairs; ORF – open reading frame; tetR-regulated MCMV vectors: MRSV; 
MRSV2M100; MHCMIie2M100; MRSV2M100HCMVieIE2; MHCMVie2M100RSVIE2; MRSV2M100-
tetR-P2A-M36; MHCMVie2M100RSVIE2 tet d17 (passaged in NIH 3T3-tets for 17 days) 
and MRSV2M100-tetR-P2A-M36 -dox d22 (grown in NIH 3T3 in the absence of DOX for 
22 days) were sequenced by Andrew Davison and sequences were aligned using 
MAFFT.  
Virus Location Mutation 
ORFs/introns 
affected 
Effect of mutation 
MRSV, 
MRSV2M100HCMVieIE2, 
MHCMVie2M100RSVIE2 
and 
MHCMVie2M100RSVIE2 
tet d17 
378 C>T 
tetR in IE2 and 
m157 
Silent 
MRSV2M100-tetR-
P2A-M36 -dox d22 
636-640 5 bp deletion tetR in M36 
Missense; no stop 
codon 
Frameshift/nonsense 
mutation? 
MRSV2M100HCMVieIE2 93677-
93873 
197 bp 
deletion 
M58-M69 intron - 
MRSV2M100-tetR-
P2A-M36 -dox d22 
100946 G>T M70 Missense 
MRSV2M100-tetR-
P2A-M36 -dox d22 
195227 C>T m139 Silent 
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Table 21: Comparison of WT FRT virus to published MCMV Smith reference 
sequence (GenBank: GU305914.1) 
Genes affected Mutations/differences Effect 
m01 1 deletion Premature stop codon 
m03 16 SNPs 1 insertion Missense; premature stop codon 
m04 69 SNPs 1 insertion Missense 
m05 32 SNPs 1 insertion Missense 
m06 2 SNPs 1 deletion In-frame deletion; silent substitutions 
m12 1 SNP Missense 
m16-m17 insertion of FRT (at 15679) - 
M50 5 SNPs Silent 
M51 1 SNP Silent 
M52 2 SNPs Silent 
M53 2 SNPs 1 insertion Insertion of alanine; silent 
M55 59 SNPs 1 insertion 1 deletion Missense; 
M56 1 SNP Silent 
m59 1 SNP 2 deletions Frameshift; premature stop codon 
M69 1 SNP Silent 
M70 2 SNPs Silent 
M72 5 SNPs Missense 
M72/M73 1 SNP Missense 
M73 7 SNPs Missense 
m74 19 SNPs Missense 
M75 29 SNPs Missense 
M76 2 SNPs Silent 
M78 4 SNPs Missense 
M79 2 SNPs Missense 
M80 10 SNPs 1 deletion In-frame; missense 
M82 6 SNPs 1 deletion In-frame; silent 
M83 12 SNPs Missense 
M84 10 SNPs Missense 
M85 1 SNP Silent 
M88 2 SNP Silent 
M94 11 SNPs Missense 
M97 1 SNP Missense 
m150 62 SNPs 1 insertion 
No start codon; frameshift; premature 
stop codon 
m151 136 SNPs 1 insertion 
Insertion of glutamic acid; In-frame; 
missense 
m152 2 SNPs Silent 
m154 4 SNPs Missense 
m155 8 SNPs Missense 
m156 2 SNPs 1 insertion Insertion of proline; missense 
m158 1 SNP Silent 
m161 1 insertion Frameshift; premature stop codon 
m164 1 SNP Silent 
Introns 110 SNPs - 
Non-coding 
region 
34 and 28bp deletions at ends 
of genome 
- 
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bp- base pairs; FRT –flippase (Flp) recognition site; SNP- single nucleotide polymorphism. WT 
FRT virus was sequenced by Andrew Davison and compared to MCMV Smith reference 
sequence (GenBank: GU305914.1) using MAFFT.  
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3.2.  In vivo characterization of tetracycline-controlled MCMV 
vectors 
Having generated CMV vectors that can be controlled by DOX in vitro, I next wanted 
to test vector safety as well as see how the viruses replicated in an animal system. In 
addition to this, I wanted to investigate the immunogenicity of my vectors since it  has 
been suggested that limited virus replication may induce stronger immune responses 
in comparison to responses induced by replication-deficient viruses (O’Hara et al. 
2012).  
 
3.2.1. Detection of M50-1, MRSV2M100, MHCMVie2M100 and 
MRSV2M100-tetR-P2A-M36 in vivo 
First, to test the safety of my vectors, BALB/c mice were infected with two of my most 
promising tet-regulated MCMV vectors (from in vitro analysis described in sections 
3.1.4 and 3.1.6) and virus growth was compared to WT MCMV in the absence of DOX 
in an acute MCMV infection setting (4 days). M50-1 has been well characterized by 
our collaborators in vitro, however, replication and safety profile of this virus has not 
been analysed in an animal system. I wanted to compare growth properties of my most 
promising MCMV vectors (MRSV2M100, MHCMVie2M100 and MRSV2M100-tetR-P2A-
M36) to those of M50-1 in BALB/c mice in the absence of DOX to determine whether 
they would exhibit similar levels of control in vivo, as I had seen in vitro (3.1.4.4 and 
3.1.6). Weight loss data (Figure 28 and Figure 29), indicative of virulence of the 
vectors, showed that infection with WT K181 resulted in loss of weight over the 4 days. 
In contrast, no weight loss was seen with the majority of tetR-regulated viruses. One 
tetR-regulated virus (MRSV2M100-tetR-P2A-M36) resulted in some initial weight loss, 
however the weight recovered by day 4.    
 
Following the 4-day infection, I measured virus titres in spleen, lung, liver and salivary 
glands.  I homogenized the organs to release virus, and infected NIH 3T3s under a 
semi-solid overlay in the presence of DOX for 6 days. I detected high WT K181 titres 
(Figure 30) in spleen and liver of infected mice. Infectious virus was also found in lungs 
of three infected mice whereas in salivary glands, WT K181 was detected only in one 
mouse. Although I didn’t detect any infectious MRSV2M100 virions in the spleen or lung, 
I found low titres in the liver and salivary glands of one mouse. MHCMVie2M100 was 
present in all tissues except for salivary glands at titres similar to the WT virus. 
Interestingly, I could not detect any replicating MRSV2M100-tetR-P2A-M36 virions in 
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any of the organs. Although significantly lower than WT virus, M50-1 virus was 
detected in all of the tissues analysed (Figure 31).  
 
For a more thorough evaluation of growth characteristics of tetR-regulated viruses I 
extracted DNA from aforementioned tissues and performed qPCR (Figure 32). Lower 
genome copies of all tetR-regulated viruses were found in all tissues analysed. In 
spleen and liver, the levels of M50-1, MRSV and MRSV2M100-tetR-P2A-M36 were 
significantly lower than WT virus control. In addition to this, M50-1 genome copies were 
significantly lower in the lung. Although the difference in genome copies of the WT 
virus and M50-1 were statistically more significant in three of the organs tested, the 
overall genome copy levels were comparable to those observed for other tetR-
regulated viruses. In fact, MRSV2M100-tetR-P2A-M36 DNA levels were the lowest 
observed in the spleen, liver and salivary glands. Since virus DNA levels in salivary 
glands were close to the limit of detection, it was difficult to draw conclusions on the 
levels of repression of virus replication in this organ.  
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Figure 28: Conditional M50-1 virus does not induce weight loss in BALB/c mice. 
Weight loss (mean ±SD of 4 mice per group) in BALB/c mice infected with 2x105 PFU 
of MCMV was monitored daily for 4 days post-injection and compared to weight loss 
in mice infected with WT Smith MCMV (positive control). Weight loss is expressed as 
percentage of original weight. 2-way ANOVA with Sidak’s multiple comparisons test 
results are presented in this graph (****p<0.0001). 
 
 
Figure 29: M100/gM-regulated MCMV vectors do not induce illness-associated 
weight loss in BALB/c mice. Weight loss in MCMV-infected BALB/c mice (2x105 
PFU) was measured daily post-infection and compared to WT K181 (positive control). 
Weight loss is expressed as mean ±SD (4 mice/group) of percent of starting weight. 
Data was analysed using 2-way ANOVA with Dunnett’s multiple comparisons test 
(*p<0.05; **p<0.01; ***p< 0.001; ****p<0.0001). 
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Figure 30: MRSV2M100-tetR-P2A-M36 is undetectable in mouse tissues in acute 
MCMV infection model. MCMV replication in the (A) spleen, (B) lung, (C) liver and 
(D) salivary glands at 4 days post infection was quantified by plaque assay. Organ 
homogenates were used to infect NIH 3T3 cells and incubated for 6 days under 
carboxymethyl cellulose overlay media to inhibit cell-free virus release. Results are 
expressed as mean ±SD (4 mice/group) PFU/g of tissue. Each symbol represents a 
single mouse. Data was analysed using 1-way ANOVA with Dunnett’s multiple 
comparisons post-tests (p<0.05. **p<0.01; ***p< 0.001). 
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Figure 31: M50-1 is detected at low levels in spleen, lung and liver of infected 
BALB/c mice. MCMV titres in the spleen (A), lung (B), liver (C) and salivary glands 
(D) of acutely infected BALB/c mice was measured by plaque assay. The 
aforementioned organs of mice infected with 2x105 PFU of MCMV at 4 days pi, were 
homogenised and used to infect NIH 3T3s under a semi-solid overlay media to prevent 
cell-to-cell spread. Virus titres are expressed as PFU/g (mean ±SD of 4 mice/group). 
Each symbol represents a single mouse. Data was compared using unpaired 2-tailed 
t-test (*p<0.05; **p<0.01; ***p<0.001). 
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Figure 32: MRSV2M100-tetR-P2A-M36 is the most stringently in vivo controlled 
virus tested.  Genome copy numbers in the spleen (A), lung (B), liver (C) and salivary 
glands (D) of BALB/c infected with 2x105 PFU MCMVs (at 4 d pi) were quantified by 
qPCR. Genome copies are displayed as mean (4 mice per group) ±SD. Virus genome 
copy numbers were compared by 1-way ANOVA followed by Dunnett’s multiple 
comparisons post-test whereas M50-1 data was analysed using unpaired 2-tailed t-
test (*p<0.05; **p<0.01; ***p<0.001). 
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3.2.2. Replicative capacity and immunogenicity of MRSV2M100-
tetR-P2A-M36 virus in BALB/c mice 
Comparative analysis of all of the TREx vectors identified MRSV2M100-tetR-P2A-M36 
as the conditionally replicating vector with the greatest potential as it was unable to 
replicate in the absence of DOX in vivo, more tightly controlled than vectors previously 
described in the literature. I therefore sought to look at effects of DOX administration 
on virus replication in vivo to see whether I could induce virus replication by feeding 
mice DOX. In this experiment, BALB/c mice were intra-peritoneally injected with either 
MRSV or MRSV2M100-tetR-P2A-M36 (absence of DOX, or presence of DOX in feed for 
one or two weeks). Instead of using WT K181 for comparison with a replication-
competent virus, I opted for MRSV, since this virus has the same backbone as 
MRSV2M100-tetR-P2A-M36 (i.e. it contains tetR in place of m157 gene and an RSV 
promoter upstream), however, it does not contain any tetO therefore its replication is 
not regulated.  
 
To investigate the virulence of my vectors, I monitored mice weight loss (Figure 33). 
Interestingly, mice infected with MRSV2M100-tetR-P2A-M36 did not lose any weight. 
On day 2, one of the groups receiving DOX displayed a statistically significant weight 
gain compared to MRSV virus infected mice. The following day (day 3), the weights of 
both groups infected with MRSV2M100-tetR-P2A-M36 and receiving DOX were 
significantly different to the MRSV control. This distinction, however, waned on day 3 as 
the mice infected with MRSV recovered and gradually gained weight. 
 
Following systemic administration (intraperitoneal route of injection), MCMV 
establishes acute infection in the spleen and liver as early as 48 hours (Hsu et al. 
2009). The virus then replicates in the lungs and eventually, at 6-8 days pi initiates 
productive replication in the salivary glands. Although the virus is cleared from the 
majority of susceptible tissues, it remains persistent in salivary glands and reaches 
peak titres at days 14-20. Salivary glands are also the site of virus transmission as it 
is secreted into saliva and spreads to other hosts. I wanted to see whether mice 
infected with either of my vectors were shedding infectious virions at 14 days post 
injection. To test this, I used 1 µl of saliva to perform qPCR (Figure 34). Surprisingly, 
none of the mice infected with the control virus (MRSV) shed any infectious virus. 
MRSV2M100-tetR-P2A-M36, on the other hand, was detected in some mice under all 
three different conditions (absence of DOX, addition of DOX for a week and two 
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weeks), however, this difference was not statistically significant when compared to 
control virus.    
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Figure 33: MRSV2M100-tetR-P2A-M36 does not induce weight loss in the 
presence/absence of DOX. Weight loss in MCMV-infected BALB/c mice were 
monitored daily on the day of injection and 8 d pi.  MRSV2M100-tetR-P2A-M36 – DOX 
represent a group of mice injected with MRSV2M100-tetR-P2A-M36  that did not receive 
DOX. MRSV2M100-tetR-P2A-M36+DOX 1 wk and MRSV2M100-tetR-P2A-M36 + DOX 2 
wks a groups of mice fed DOX for 1 and 2 weeks, respectively. The weights were 
compared to weights in mice infected with non-inducible MRSV vector (tetR in m157 and 
no tetO sequences). Mouse weight is expressed as percentage of original weight. 
Weight loss is shown as mean ±SD of five mice per group. Weight differences were 
compared by 2-way ANOVA followed by Dunnett’s multiple comparisons post-test 
(*p<0.05).        
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Figure 34: MRSV2M100-tetR-P2A-M36 is shed into saliva in 20% of infected mice. 
Saliva shedding of MCMV at day 14 pi was measured by collecting saliva and 
performing qPCR using IE1/M123 primers. Each symbol represents MCMV genome 
copy numbers in a single mouse. Data is shown as individual mice means (5 
mice/group) ±SD. MRSV represents control virus (non-inducible)-infected mice. Mice 
infected with MRSV2M100-tetR-P2A-M36 were either fed regular diet (no DOX) or DOX 
supplemented diet for either 1 or 2 weeks. Symbols represent average (of three) 
genome copy number/µl/mouse. 
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Figure 35: Early control of MRSV2M100-tetR-P2A-M36 in the absence of DOX is overcome later in the infection. A: Gating strategy 
on lymphocytes in the peripheral blood at 32, 67 or 96 d pi. Lymphocytes were discriminated based on side scatter (SSC) and forward 
scatter height (FSC-H) profile (panel 1). Panel 2: Singlets were then selected based on forward scatter height (FSC-H) and FSC-A. Panel 
3: Live CD8 lymphocytes were sorted into M123/pp89 tetramer-specific CD8+ T cells (panel 4). B: Frequencies of MCMV-specific CD8+ T 
cells in blood of infected BALB/c mice were measured on days 32, 67 and 96. The frequencies of circulating leukocyte populations in blood 
were quantified by FACs using a M123/pp89 (IE1) tetramer. Data represent the mean ±SD of 5 mice per group. Data obtained from mice 
infected with conditional MRSV2M100-tetR-P2A-M36 in the absence of DOX or presence of DOX (1 or 2 weeks) was compared to data from 
mice infected with non-conditional MRSV vector. 
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Next, I sought to analyse peripheral blood responses (by using a tetramer) to the viral 
protein M123/pp89 (IE1) at three timepoints: 32, 67 and 96 days pi (d pi) (for gating 
strategy see Figure 35A). Interestingly, similar frequencies of M123/pp89-specific 
lymphocytes were detected at 32 d pi (Figure 35B) in mice infected with the control 
virus (MRSV) as well as DOX-regulatable MRSV2M100-tetR-P2A-M36 that received DOX 
in the feed. Mice infected with MRSV2M100-tetR-P2A-M36 that did not receive DOX 
had lower levels of pp89-specific CD8+ T cells in comparison to the other two groups 
(not statistically significantly). However, during the course of infection, the levels 
increased and by day 96 were comparable to frequencies in mice infected with the 
control virus as well as mice infected with MRSV2M100-tetR-P2A-M36 receiving DOX.  
 
To determine in more detail whether CMV-specific lymphocyte populations varied in 
the spleen, lung, salivary glands and lamina propria at late stages (102 d pi) of MCMV 
infection, the organs were isolated from the mice and extracted lymphocytes were 
analysed by FACs. A M123/pp89 (IE1) tetramer was again used to distinguish MCMV-
specific lymphocyte populations within different experimental groups. In the spleen, 
(for gating strategy see Figure 36) the frequencies of pp89-specific CD8+ T cells were 
comparable within different groups (Figure 37). To further characterize CMV-specific 
lymphocyte populations, into tissue-resident memory T cells, cells expressing CD69 
(T-cell activation and tissue resident memory cell marker) and CD103 αE integrin 
(known to bind to E-cadherin on epithelial cells) were selected (Cepek et al. 1994). In 
addition to this, effector memory T cells were quantified based on expression of CD44 
(memory marker) and Killer cell lectin-like receptor subfamily G member 1, KLRG1 
(differentiation marker). High expression of CD27 was used to distinguish effector 
memory and central memory T lymphocyte populations.  
 
Analysis of lymphocytes in the spleen (Figure 38) revealed a trend whereby mice 
vaccinated with MRSV2M100-tetR-P2A-M36 receiving regular feed had lower 
frequencies of TCM, TEM and TRM cells. Although the percentage of TCM lymphocytes 
from mice injected with MRSV2M100-tetR-P2A-M36 was significantly lower than mice 
injected with MRSV virus, the total cell counts were similar. 
 
Interestingly, analysis of CMV-specific lymphocytes in the lung (for gating strategy see 
Figure 39) revealed that the percentage of tetramer-specific CD8+ (Figure 40) T cells 
was significantly lower in mice infected with MRSV. In addition to this, the percentage of 
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TCM population in MRSV2M100-tetR-P2A-M36 infected mice receiving DOX for 2 weeks 
was significantly lower than the control mice group. Total cell counts, on the other 
hand, showed that there were lower levels of CD4+, TCM, TEM, and TRM (Figure 41) in 
mice infected with the control virus (MRSV) although this difference was not statistically 
significant.  
 
In the salivary glands (for gating strategy see Figure 42) of mice injected with 
MRSV2M100-tetR-P2A-M36 receiving regular feed and feed containing DOX, tetramer-
specific CD8+ and TEM cell counts (Figure 43 and Figure 44) were significantly lower 
than in mice infected with MRSV. TCM levels were significantly lower in mice infected 
with MRSV2M100-tetR-P2A-M36 receiving regular feed and mice receiving DOX feed 
for 1 week whereas TRM levels were only lower in mice infected with MRSV2M100-tetR-
P2A-M36 receiving regular feed.  
 
We discovered CMV-specific lymphocytes (for gating strategy see Figure 45) in lamina 
propria of infected mice (Figure 46). Frequencies of CMV-specific T lymphocyte 
populations of MCMV-infected mice were low and thus, highly variable (Figure 47) 
Interestingly, however, phenotypic analysis of MCMV-specific CD8+ populations 
revealed that there were no central memory T cells detected in the lamina propria of 
any of the mice. 
 
To characterize the functionality of T cell responses, I carried out intracellular cytokine 
staining whereby lymphocytes isolated from spleens of MCMV-infected mice were 
stimulated for 6 hours with either MHC class I (M123/pp89) or class II (M53 - 
IAHQRITLTARCLRL and M78 - SQQKMTSLPMSVFYS) peptides. Cytokines (TNF-α 
and IFN-γ) accumulating in the ER were quantified by FACS. I elected to look at TNF-
α since this cytokine plays an antiviral role by blocking viral gene expression. IFN-γ, 
on the other hand, activates macrophages and NK cells and upregulates antigen 
presentation by increasing expression of class I and class I MHC molecules. 
Stimulation of CD4+ lymphocytes (for gating strategy see Figure 48) with M53 peptide 
resulted in higher production of IFN-γ in mice infected with MRSV2M100-tetR-P2A-M36 
(Figure 49) compared to MRSV infected mice. TNF-α levels were higher in MRSV2M100-
tetR-P2A-M36 groups receiving DOX for 1 and 2 weeks whereas production in 
MRSV2M100-tetR-P2A-M36-infected mice receiving regular feed was comparable to 
control mice. Stimulation with M78 peptide induced higher production of IFN-γ in MRSV, 
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MRSV2M100-tetR-P2A-M36 receiving regular feed and MRSV2M100-tetR-P2A-M36 
receiving DOX for 1 week whilst the levels of TNF-α+ CD4+ T cells were comparable 
among the different groups. Interestingly, stimulation with pp89 peptide (gating 
strategy shown in Figure 50) promoted accumulation of higher IFN-γ levels by CD8+ T 
cells (Figure 51) isolated from mice immunized with MRSV2M100-tetR-P2A-M36. TNF-
α levels, on the other hand, were similar in MRSV and MRSV2M100-tetR-P2A-M36 
injected mice receiving DOX but were higher in MRSV2M100-tetR-P2A-M36 receiving 
regular feed. 
 
3.2.3. Summary 
From my in vitro analysis of tetR-regulated virus vectors (section 3.1) it was evident 
that early and abundant tetR expression could inhibit virus replication to a high degree. 
Interestingly, the level of virus repression in vivo was even more pronounced. When 
mice were injected with MRSV2M100-tetR-P2A-M36 virus in the absence of DOX, virus 
was not detectable in any of the four tissues (spleen, lung, liver and salivary glands) 
analysed. M50-1 (a virus vector previously published in the literature), on the other 
hand, was present at low titre at all sites. Immunization of mice with MRSV2M100-tetR-
P2A-M36 (absence and presence of DOX) showed that 25-50% of the animals were 
shedding virus at 14 d pi as opposed to mice infected with the control vector (MRSV). 
Although this observation is surprising, it was not statistically significant due to the 
sample size in the experiment. At early times, where animals were not fed DOX, the 
DOX-regulated virus (MRSV2M100-tetR-P2A-M36) did not induce the same magnitude 
of immune response in the periphery as when animals were fed DOX suggesting that 
it was unable to replicate to the same extent. However, at later times, the 
immunogenicity of the vector was comparable to the control vector in the spleen, lung 
and gut implying that the virus either mutated or was able to overcome immune control 
mechanisms. In the salivary glands, MRSV (control virus) induced higher levels of 
central memory, effector memory and tissue-resident memory T cells thus suggesting 
that in this organ tetR vectors were unable to induce an immune response of a similar 
magnitude. 
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Figure 36: Gating strategy of lymphocyte populations in the spleen (102 d pi). A: 
The gate for lymphocytes was based on side scatter (SSC) and forward scatter (FSC) 
profile; live CD3+ lymphocytes (B); CD3+CD4+ T cells (C); CD3+CD8+ T cells (D); 
M123/pp89 tetramer (MCMV) specific CD8+ T cells (E). MCMV-specific CD8+ T cells 
were further classed into resident memory T cells (CD69highCD103high) (F); effector 
memory (CD44highKLRG1high) (G) and central memory (CD44highKLRG1lowCD27high) (H) 
cells. 
 
Figure 37: Representative FACs plots of CMV-specific CD8+ T cells in the spleen 
at 102 d pi. Concatenated FACs plots of: fluorescence minus one (FMO) of all four 
groups (A), tetramer-specific lymphocytes from MRSV infected mice (B), mice infected 
with MRSV2M100-tetR-P2A-M36 (regular feed) (C), mice infected with MRSV2M100-
tetR-P2A-M36 that received DOX for 1 week (D) and 2 weeks pi (E). 
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Figure 38: Comparable frequencies of CMV-specific TRM, TCM and TEM populations in spleens of BALB/c mice infected  (102 d pi) 
with conditional M100/gM-regulated MCMV and control virus. Top panel: Percentage of CD4+, tetramer-specific CD8+ T lymphocytes, 
tissue resident memory, central memory and effector memory CD8+ T lymphocytes. Bottom panel: total count of CD4+ T cells; tetramer-
specific CD8+ T cells; TRM, tissue resident pp89+ T cells; TCM, central memory and TEM, effector memory lymphocytes. Data was compared 
using one-way ANOVA with Dunnett’s post-test (*p<0.05; **p<0.01; ***p<0.001). 
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Figure 39: Gating strategy on lymphocyte populations in the lungs of MCMV-
infected (102 d pi) BALB/c mice. Side scatter (SSC) and forward scatter (FSC) profile 
was used to distinguish lymphocyte population (A); live CD3+ lymphocytes (B); CD3+ 
CD4+ T cells (C); CD3+ CD8+ T cells (D); M123/pp89 tetramer (MCMV) specific 
CD3+CD8+ T cells (E) identified as resident memory T cells (CD69highCD103high) (F); 
effector memory (CD44highKLRG1high) G) and central memory 
(CD44highKLRG1lowCD27high) (H) T cells. 
 
 
 
 
 
 
Figure 40: Representative FACs plots of pp89+ tetramer specific CD8+ T cells in 
lungs of MCMV infected mice at 102 d pi. Concatenated FACs plots of FMO of all 
four groups (A), tetramer-specific lymphocytes from MRSV infected mice (B), mice 
infected with MRSV2M100-tetR-P2A-M36 (regular feed) (C), mice infected with 
MRSV2M100-tetR-P2A-M36 that received DOX for 1 week (D) and 2 weeks pi (E). 
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Figure 41: Higher frequencies of CMV-specific lymphocyte populations in lungs of mice infected (at 102 d pi) with conditional 
MRSV2M100-tetR-P2A-M36 virus than control virus. Top panel: frequencies of CD4+, tetramer-specific CD8+ T cells and tissue-resident 
memory, central memory and effector memory CD8 T cell populations. Bottom panel: total cell counts of (left to right) CD4+; tetramer-
specific CD8+ T cells; TRM, tissue resident memory, TCM, central memory and TEM, effector memory CD8+ T cells. Data was analysed by 
one-way ANOVA with Dunnett’s post-test (*p<0.05; **p<0.01). 
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Figure 42: Gating strategy on lymphocyte populations in salivary glands (102 d 
pi). Lymphocytes were selected based on side scatter (SSC) and forward scatter 
(FSC) profile (A); live CD4+ lymphocytes (B); live CD8+ lymphocytes (C); M123/pp89-
specific CD8+ T cells (D) were classified into tissue resident memory cells (E), effector 
memory (CD44highKLRG1high) (F) and central memory (CD44highKLRG1lowCD27high) (G) 
populations. 
 
 
 
Figure 43: Representative FACs plots of CMV tetramer (pp89) specific 
lymphocyte populations in salivary glands of MCMV infected (at 102 d pi) 
BALB/c mice. Concatenated FACs plot of FMO of all four groups (A), tetramer-specific 
lymphocytes from MRSV infected mice (B), mice infected with MRSV2M100-tetR-P2A-
M36 (regular feed) (C), mice infected with MRSV2M100-tetR-P2A-M36 that received 
DOX for 1 week (D) and 2 weeks pi (E) 
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Figure 44: Lower frequencies of CMV-specific lymphocyte populations in salivary glands of mice infected with conditional 
MRSV2M100-tetR-P2A-M36 virus at 102 d pi. Top panel: frequency of CD4+ T lymphocytes, tetramer (CMV, pp89) specific CD8+ T cells, 
tissue resident memory, central memory and effector memory CD8+ T cells. Bottom panel: total cell counts of CD4+ T cells; tetramer-specific 
CD8 T cells; TRM, tissue-resident memory cells; TCM, central memory and TEM, effector memory T cells. Data was compared using one-way 
ANOVA with Dunnett’s post-test (*p<0.05; **p<0.01). 
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Figure 45: Gating strategy of lymphocytes from intestinal lamina propria of 
MCMV infected (102 d pi) BALB/c mice. A: lymphocytes were discriminated based 
on side scatter (SSC) and forward scatter (FSC) profile. B: Live CD3+ lymphocytes; C: 
CD3+ CD4+ T cells; D: CD3+ CD8+ T cells; E: pp89 tetramer (MCMV) specific CD3+CD8+ 
T cells. MCMV-specific CD8+ T cells were further sorted into resident memory T cells 
(CD69highCD103high) (panel F); effector memory (CD44highKLRG1high) (panel G) and 
central memory (CD44highKLRG1lowCD27high) (panel H). 
 
Figure 46: Concatenated FACs plots of MCMV-specific (IE1/pp89) CD8+ T 
lymphocytes in intestinal lamina propria at 102 d pi. (A): FMO in all groups; (B): 
MRSV-infected mice, (C): MRSV2M100-tetR-P2A-M36 (regular feed); (D): mice infected 
with MRSV2M100-tetR-P2A-M36 that received DOX for 1 week and (E): 2 weeks pi. 
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Figure 47: Conditional MCMV (MRSV2M100-tetR-P2A-M36) induces comparable frequencies of lymphocyte populations in the 
intestinal lamina propria as control virus. Lymphocytes from intestinal lamina propria of MCMV infected BALB/c mice were isolated and 
analysed by FACs. Top panel: percentage of CD4+ T cells, MCMV tetramer (pp89) specific CD8+ T cells and tissue resident memory, central 
memory and effector memory CMV-specific CD8 T cells. Bottom panel (left to right): total cell counts of CD4+ T cells; tetramer (CMV, pp89) 
specific CD8+ T cells; TRM, tissue resident memory, TCM, central memory and TEM, effector memory CD8+ T cells. 
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Figure 49: MRSV2M100-tetR-P2A-M36-specific CD4+ lymphocytes are functional 
and secrete IFN-γ and TNF-α. A: Frequency of IFN-γ and TNF-α secreted upon 6 h 
stimulation with either IAHQRITLTARCLRL (peptide I, M53) or SQQKMTSLPMSVFYS 
(peptide II, M78). Total count of IFN-γ and TNF-α-specific cells upon 6 h stimulation 
with peptide I (IAHQRITLTARCLRL) or peptide II (SQQKMTSLPMSVFYS). Values 
represent mean ±SD. Data was analysed by one-way ANOVA with Dunnett’s post-
tests (*p<0.05). 
Figure 48: Gating strategy for IFN-γ and TNF-α producing CD4+ T cells. A: 
lymphocytes were discriminated based on side scatter (SSC) and forward scatter area 
(FSC-A) profile. B: Single lymphocytes were then selected based on forward scatter 
height (FSC-H) and FSC-A. C: Live CD4 lymphocytes were further sorted into IFN-γ+ 
(D), TNF-α+ (E) T lymphocytes. 
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Figure 51: MRSV2M100-tetR-P2A-M36-specific CD8+ lymphocytes are functional 
and secrete IFN-γ and TNF-α. A: Frequencies of IFN-γ (left) and TNF-α (right); B: 
total counts of IFN-γ+ (left) and TNF-α+ (right) cells. Intracellular IFN-γ and TNF-α were 
quantified following a 6 h stimulation with pp89 CMV peptide. Data is represented as 
mean ±SD. 
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Figure 50: Gating strategy for IFN-γ and TNF-α producing CD8+ T cells. A: 
lymphocytes were discriminated based on side scatter (SSC) and forward scatter area 
(FSC-A) profile. B: Singlets were then selected based on forward scatter height (FSC-
H) and FSC-A. C: Live CD8 lymphocytes were further sorted into IFN-γ+ (D) and TNF-
α+ (E) T cells. 
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3.3. Adenovirus and cancer models 
 
As described in section 1.10.6, adenoviruses (Ads) have been widely used in humans 
as gene delivery agents, and have an excellent safety profile. I therefore wished to 
compare the immunogenicity and effectiveness of my CMV vectors with Ads 
expressing cancer antigens. We also took this opportunity to establish murine cancer 
models in which my vectors could be tested. 
 
3.3.1. Generation of first- and second-generation Ad-h5T4 vectors 
The adenoviruses used in this study are listed in Table 22. Two vector backbones (AdZ 
and AdZ2) were used, both based on adenovirus serotype 5 (Ad5). In the AdZ vector 
system, the E1 and E3 regions are deleted whereas in AdZ2, the E4 region is also 
deleted, except for E4-ORF6. ORF6 facilitates virus propagation in the helper cell line 
and stimulates expression from the HCMV major IE promoter in target cells upon 
vector delivery. Vectors expressed either GFP, human 5T4, or lacked a transgene 
(control, CTRL). Of the constructs used in this study, four (Ad-GFP, Ad-tetO-GFP, 
AdZ-CTRL and AdZ2-CTRL) had been previously cloned by members in the 
laboratory. Initially, vectors AdZ-h5T4 and AdZ2-h5T4 were used that had been 
generated by other colleagues in the laboratory, however, due to reasons described in 
section 3.3.3, vectors AdZ-h5T4 and AdZ2-h5T4 had to be re-engineered and re-
made.  
 
To generate AdZ-h5T4 and AdZ2-h5T4, BACs AdZ-CTRL and AdZ2-CTRL were used, 
respectively. A codon-optimised h5T4 gene containing a HCMV IE promoter upstream 
(GeneArt) was inserted via 2 rounds of recombineering. First, a selection cassette 
(Ampr/LacZ/sacB) was inserted into a cloning site between the HCMV MIE promoter, 
and the MIE polyA, within the E1A region, then the cassette was taken out and 
replaced with the h5T4 gene (Appendix B). The clones were analysed by restriction 
digest analysis and then sequenced to ensure that no mutations had occurred as result 
of cloning. The BACs were transfected into T-REx-293cells and infectious virus was 
collected and purified. Next, expression of 5T4 by these two vectors was analysed by 
western blot (Figure 52) and compared to first and second-generation control vectors 
AdZ-CTRL and AdZ2-CTRL, respectively. Both AdZ-h5T4 and AdZ2-h5T4 expressed 
strong levels of 5T4, that were comparable between vectors. 
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Table 22: Adenovirus vectors used in this study 
Name 
pAL 
number 
Serotype 
Deleted 
genes 
Modifications 
Ad-GFP 1136 5 E1 and E3 
HCMV promoter+ GFP 
inserted in E1. 
Ad-
tetO-
GFP 
1423 5 E1 and E3 
HCMV promoter+2 tet 
operators-GFP-polyA inserted 
in E1. 
AdZ-
CTRL 
1253 5 E1 and E3 
HCMV promoter-GFP-polyA 
inserted in E1. No transgene 
inserted. 
AdZ2-
CTRL 
1926 5 
E1, E3 and E4 
(except ORF6) 
HCMV promoter -poly A region 
in E1. No transgene inserted. 
AdZ-
h5T4 
2143 5 E1 and E3 
HCMV promoter+2 tet 
operators-h5T4-polyA inserted 
in E1. 
AdZ2-
h5T4 
2144 5 
E1, E3 and E4 
(except ORF6) 
HCMV promoter+2 tet 
operators-h5T4-polyA inserted 
in E1. 
 
*pAL number represents plasmid number in our laboratory database for internal 
reference. Ad – adenovirus; CTRL – control; GFP – green fluorescent protein; h5T4- 
human 5T4 antigen; HCMV – human cytomegalovirus; ORF – open reading frame. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: Recombinant adenovirus vectors express strong levels of 5T4. HFFF-
CARs were infected at MOI=10 and expression of h5T4 was detected at 48 h pi using 
mouse 5T4 antibody (AF5049, R&D Systems) (1:2000). AdZ-CTRL and AdZ2-CTRL 
were first- and second-generation empty vectors that served as a negative control, 
respectively. AdZ-h5T4 and AdZ2-h5T4 both contained codon-optimised h5T4 gene 
with HCMV promoter inserted into E1 region. AdZ-h5T4 had deleted E1 and E3 genes 
whereas AdZ2-h5T4 was also lacking E4 gene (except for ORF6). β-actin was used 
as a housekeeping gene control. 
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3.3.2. Establishment of mouse models expressing 5T4 antigen 
5T4 expression is normally restricted to foetal trophoblasts, yet it is also recognized as 
a tumour antigen found in a range of solid cancers (see section 1.9.3.1). I aimed to 
develop murine tumour challenge models in order to test the efficacy of an Ad vector 
encoding 5T4 as an immunization agent. The well characterized murine cell lines – 
CT26 and 4T1 (obtained from Awen Gallimore) have been used extensively in vivo in 
the development of anti-cancer immunotherapies and, more specifically, evaluation of 
the TroVAx vaccine efficacy (Abern et al. 2011). CT26 is a colon carcinoma cell line 
whereas 4T1 is a highly metastatic murine mammary carcinoma cell line (Mulryan et 
al. 2002). Tumour growth and metastatic spread of 4T1 cells in BALB/c mice very 
closely mimics stage IV of human breast cancer. Both CT26 and 4T1 cells are tumour 
cell lines syngeneic with the BALB/c mouse strain. Since I was also interested in 
looking at C57BL/6-derived cancer models, a Lewis lung carcinoma 1 (LLC1) cell line 
was sourced from ATCC. LLC1 cells have been described as highly tumorigenic and 
metastatic, forming tumour nodules in the lung (Bertram & Janik 1980). Intestinal 
epithelial cells from a murine colorectal cancer model were also kindly provided by Lee 
Parry (Cardiff University).  Apcfl/fl mice express an intestinal stem cell marker (leucine-
rich repeat-containing G-protein coupled receptor 5; LGR5) linked to a tamoxifen-
inducible cre recombinase, and have an adenomatous polyposis coli (APC) gene 
flanked by loxP sites. Treatment of these mice with tamoxifen induces a deletion of the 
APC gene in intestinal stem cells. Since APC is a tumour suppressor and plays a role 
in WNT signalling pathway, deletion of the gene induces colorectal tumorigenesis. 
 
5T4 expression in the different cell lines and cancer models was compared in a 
western blot analysis (Figure 53). Interestingly, the 4T1 cell line exhibited higher levels 
of 5T4 than either CT26 or LLC1 cell lines. Epithelial cells extracted from the large 
intestine of Apcfl/fl mice (treated with tamoxifen) expressed 5T4 to similar levels as 
LLC1 cells.   
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Figure 53: Mouse cancer models/cells expressing 5T4 . Small and large intestine 
samples from Apcfl/fl mice were obtained from Lee Parry. Small intestine (SI) and large 
intestine (LI) control samples were isolated from control mice whilst SI and LI exp 
represent experimental samples from mice treated with tamoxifen resulting in deletion 
of APC in the intestine, thus leading to cancer progression. Prior to lysis, the cells were 
sonicated for 30s. 4T1 (mammary carcinoma) and CT26 (colon carcinoma) cells were 
kindly provided by Awen Gallimore whereas Lewis lung carcinoma (LLC1) cells were 
purchased from ATCC. 250,000 cells were incubated in relevant media for 24h hours 
at 37˚C 5% CO2. β-actin serves as a loading control. 
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3.3.3. Mapping 5T4 epitopes in C57BL/6 mice 
In order to track CD8+ T cell responses following immunisation, a strategy was devised 
to map 5T4 peptide antigens presented in the C57BL/6 mouse model. Mice were 
immunised with either the AdZ-h5T4 or the control vector, then boosted after 6 weeks 
to stimulate a memory response. A week later, splenocytes were isolated and 
stimulated with whole 5T4 protein (Figure 54 panel A) in an Enzyme-Linked 
ImmunoSpot (ELISpot) assay. Since responses to whole 5T4 protein were low, I also 
tried stimulating the cells with thirteen peptide pools spanning the entire 5T4 protein 
(Figure 54 panel B). As expected, shorter peptides that do not require processing were 
more immunogenic. Peptide pools 1, 2, 5, 6, 8, 9 and 11 were identified as positive 
hits. By using the matrix system (Table 13) and the peptide prediction program 
NetMHC 3.4, I was able to identify the following 9mer peptides as strong binding 
candidates: VSFRNLTHL; NSLVSLTYV; SAPSPLVEL and TSYVFLGIV. To verify 5T4 
candidate epitopes predicted by NetMHC 3.4, splenocytes were stimulated overnight 
and IFN-γ release was quantified and compared for each peptide (Figure 54 panel C). 
All of the peptides induced responses higher than the positive control (PHA), thus 
confirming the previous prediction.  
 
While mapping the 5T4 epitopes progressed, it was considered prudent to sequence 
the adenovirus constructs used in the studies. This analysis revealed an in-frame 81 
bp deletion in the 5T4 gene. This deletion surrounded a short region of homology within 
the gene, suggesting that it could have been deleted by homologous recombination, 
during recombineering. AdZ-5T4 and AdZ2-5T4 viruses were therefore re-generated, 
this time using a codon-optimized 5T4 gene to minimize internal homology. In addition 
to re-mapping the epitopes, I also wanted to compare 5T4-induced immune responses 
to our first and second-generation vectors. By deleting E4 sequences, the second-
generation replication-deficient Ad vectors were developed to reduce the level of 
breakthrough early and late gene expression from the vector in vivo and thus be less 
inflammatory. Previous data from our laboratory (unpublished) showed that AdZ2 does 
not induce stress ligands recognised by NK cells on the cell surface, to the same extent 
as AdZ. The lower induction of stress ligands by AdZ2 had the potential to alter 
immunogenicity, either by promoting vector persistence, or by reducing NK activation. 
I was interested in how the altered backbone of the AdZ2 impacted its utility as a 
vaccination agent.   
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Sixteen C57BL/6 mice were vaccinated with newly generated first- and second-
generation control and 5T4 Ad vectors. A week after the boost, splenocytes were 
stimulated overnight with one of VSFRNLTHL, NSLVSLTYV, SAPSPLVEL, 
TSYVFLGIV peptides or a random peptide pool and then IFN-γ production was used 
as a readout of positive responses. Although 5T4-specific responses were variable, 
3/4 peptides induced T cell activation and high IFN-γ production (Figure 55 B). The 
negative control AdZ-CTRL and AdZ2-CTRL injected mice did not induce 5T4-specific 
responses (Figure 55 A).  There was also  no obvious difference in the magnitude of 
the 5T4 responses induced by the two types (first- and second-generation) of vectors. 
On the basis of this finding, further investigations were restricted to the more 
extensively studied first-generation Ad vector (AdZ). 
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Figure 54: Ex vivo IFN-γ responses to 5T4 peptides. A: 500,000 mouse splenocytes 
were stimulated with whole 5T4 protein (10 µg/ml) overnight. B: 270,000 splenocytes 
from mice injected with either AdZ-CTRL or AdZ2-h5T4 were incubated overnight with 
5T4 peptide pools spanning the entire protein. C: 100,000 splenocytes from a mouse 
injected with AdZ2-h5T4 were stimulated with 5T4 peptides at 5 μg/ml for 24 h. Peptide 
pool 7 and RPMI (supplemented with 10% FBS) were used as a negative and 1 μg of 
phytohemagglutinin (PHA) served as a positive control. Data represent the mean of 
duplicate samples ± SD. Responses are shown as the number of spot forming units 
(SFU) per well. 
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Figure 55: Recombinant first- and second-generation Ad-h5T4 vectors are 
immunogenic in C57BL/6 mice. 110,000 splenocytes isolated from mice vaccinated 
with AdZ-CTRL (mouse 1-4), AdZ2-CTRL (mouse 5-8), AdZ-h5T4 (mouse 9-12) and 
AdZ2-h5T4 (mouse 13-16) were stimulated overnight with 5 µg/ml of 5T4 peptides. For 
the negative control RPMI (supplemented with 5% FBS) was used whereas for the 
positive control it was 1 µg of PHA. Each response/mouse is represented as a mean 
of duplicate samples ± SD. IFN-γ release was quantified and is presented as spot 
forming unit (SFU) per well.  
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3.3.4. MHC restriction of 5T4 epitopes in C57BL/6 
Using the ELISpot assay, I was able to identify 5T4 epitopes, however, the assay does 
not provide information as to which of the MHC alleles are involved in the T cell 
response induced. According to the NetMHC 3.4 epitope prediction program, two of 
the identified 5T4 epitopes (NSLVSLTYV and SAPSPLVEL) may be presented to T 
cells by H-2Db molecule, TSYVFLGIV may be presented by H-2 Kb, whereas 
VSFRNLTHL may be presented by either/both. To test these predictions, a stability 
assay was carried out using T2 lymphocytes that had been transfected with either Kb 
or Db molecules. T2 cells are a human lymphoblast line that is class II MHC antigen-
deficient and lacks TAP that is involved in delivering peptides from the cytosol into ER 
or Golgi. T2 cells therefore express low amounts of MHC on the cell surface, until a 
peptide is added and binds to the MHC class I complex, thereby stabilizing it. Peptide 
dissociation rates greater than 3 hours indicate that a peptide is a promising T cell 
epitope (Burshtyn & Barber 1993; van der Burg et al. 1996; Peter et al. 2001). 
 
T-2Kb and T-2Db cells were pulsed with the four peptides at 37°C for 0, 2 and 4 hours 
and the ability of the peptides to stabilize H-2Kb and H-2Db was compared to a 
characterized peptide (KAVYNFATC), known to bind both Kb and Db complexes, by 
FACS. My results (Figure 56 A) confirmed the prediction generated by NetMHC; 
TSYVFLGIV stabilizes cell surface expression of H-2Kb as it quickly binds and remains 
relatively stable over the 4-hour period with half-life greater than 4 hours. The 
remaining three peptides (VSFRNLTHL, NSLVSLTYV and SAPSPLVEL) do bind Kb, 
and P1 binding was relatively stable. P2 and P3 complexes were less stable and 
dissociated quickly.  Db data (Figure 56 B), on the other hand, was in disagreement 
with the prediction program. However, since I could not detect any binding of my 
positive control peptide, even after an experimental repeat, I concluded that the cells 
may have lost the plasmid encoding the Db complex.  I was unfortunately unable to 
obtain fresh aliquots of the T-2Db cells within the timeframe of this study. 
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Figure 56: Binding and stability of Kb/peptide and Db/peptide complexes. 400,000 
T2-Kb and T2-Db cells were incubated with 20 µM peptide for 0, 2 or 4 hours. At each 
time point, the cells were thoroughly washed with ice-cold PBS and stained for Db or 
Kb molecules. Fluorescence index (FI) was calculated using the following formula: FI= 
(mean fluorescence sample – mean fluorescence background)/(mean fluorescence 
with no peptide – mean fluorescence background). KAVYNFATC peptide was used as 
a positive control as it is known to bind both Kb and Db molecules. 
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3.3.5. Effect of vaccination with Ad-h5T4 on tumorigenesis in 
Lewis lung carcinoma (LLC) model 
To establish the LLC1 tumour model, it was necessary first to determine the dosage 
of cells required to induce a gradual growth of subcutaneous tumours. In a survey of 
the literature, the route of tumour cell injection was highly variable and included 
intravenous injections, intratracheal instillations and subcutaneous intrascapular 
regions (Bertram & Janik 1980; Reppert et al. 2011; Savai et al. 2009). In addition to 
this, the dosage also varied between 5×104-106 cells per mouse (Bertram & Janik 
1980; Reppert et al. 2011; Savai et al. 2009). In our model, we wanted to implant LLC1 
cells subcutaneously into the left flank as we have done for all of our other cancer 
models. Based on other people’s work, three different concentrations were selected: 
105, 2×105 and 4×105 cells. Tumour growth in mice was monitored 3 times a week and 
once tumours were palpable, the growth rates were compared between different 
groups. Mice receiving 105 cells did not all develop tumours even at 20 days post 
challenge (Figure 57). Although mice receiving the highest dose all developed 
tumours, the rate of growth was too rapid, depriving the surrounding cells of oxygen 
and reaching the size constraints set by the Home Office, resulting in sacrifice of mice.  
Since 2×105 dose was sufficient to induce tumour growth in all the tested animals at a 
steady rate, it was used in future experiments. 
 
Peptide mapping demonstrated that immunisation with Ad vectors encoding 5T4 
induces an efficient T cell response specific for the expressed oncofoetal antigen in 
C57BL/6 mice (see previous section). To test the efficacy of the Ad recombinants in 
the LLC1 cancer model, the mice were immunized 6 weeks apart with 5 × 108 PFU of 
either AdZ-CTRL or AdZ-h5T4. In addition to this, a naïve control group was also 
included that did not receive anything. After the first Ad injection, the weight of the mice 
was monitored (Figure 58 A) as weight loss would indicate vaccine-induced illness. 
Since the weight of Ad-injected mice was comparable to naïve mice and exceeded the 
starting weight, monitoring was halted at 3 days post-injection and I concluded that 
these vectors were safe. At 7 weeks (1 week after the boost) all of the mice received 
2×105 LLC1 cells. Tumour formation was monitored 3 times a week. The first tumour 
growth was observed at 7 days post challenge (Figure 58 B). Surprisingly, mice that 
received AdZ-h5T4 developed tumours more rapidly than ones immunized with AdZ-
CTRL. In addition to this, naïve mice had delayed tumour growth. These results were 
not reflected in the survival data (Figure 58 C) as the majority of the mice needed to 
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be sacrificed due to Home Office regulations. The mice developed tumours that had a 
crater-like appearance and red discharge. Comparison of the spleen sizes showed 
that mice injected with AdZ-h5T4 had smaller spleens than the other two groups 
(Figure 58 D).     
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Figure 57: LLC1 tumour growth rate dependency on tumour cell dose. C57BL/6 
mice were subcutaneously challenged with either 1×105, 2×105 or 4×105 of LLC1 cells 
and tumour development was monitored weekly. Values represent average of 4-5 mice 
± SD. Tumour sizes were measured with a caliper and tumour volume was calculated 
using the following formula: (mm2) = width × length × smaller value (width or length) × 
(3.14⁄6). 
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Figure 58: AdZ-h5T4 is safe but not protective in the LLC1 cancer model. A: 
Weight loss induced by immunization with Ad vectors.  Weight loss is expressed as 
mean ±SD (4-6 mice/group) of percent of starting weight. B: Tumour volume was 
calculated using the following formula: (mm2) = width × length × smaller value (width 
or length) × (3.14⁄6). C: Survival rates for naïve mice, mice immunized with AdZ-CTRL 
and AdZ-h5T4 challenged with LLC1 tumours. D: Myeloid cell numbers in the spleen 
quantified and are shown as mean ±SD of four-six mice per group.  
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3.3.6. Responses to first-generation Ad5 vs second-generation 
Ad5 in BALB/c mice 
Two of the cancer models (4T1 and CT26) that I wanted to study were in BALB/c mice 
strain therefore the 5T4 epitopes identified in C57BL/6 would not be relevant. To see 
whether Ad vectors encoding 5T4 were also immunogenic in BALB/c mice, the same 
procedure was performed whereby mice were primed then boosted mice with 5 ×108 
PFU six weeks apart. First- and second-generation Ad vectors were used for a 
comparison. A week later, splenocytes from these mice were isolated and I used them 
to perform an ELISpot assay. Interestingly, the results (Figure 59 and Figure 60) 
showed that first-generation Ad vectors induced relatively stronger responses as both 
peptide pool 2 and 3 had more spot forming units (SFU). As a result, we opted for first-
generation vectors in preclinical tumour protection models. The peptide pools 1, 2, 3, 
7, 9 and 10 were identified as positive hits and a prediction program NetMHC 3.4 
identified four candidate peptide epitopes (data not shown) from these panels 
(LSHNPLADL, RGPAAGDGR, GGCSRGPAA and RSFEGMVVAALLAGR). The 
synthesized peptides were then tested using the remaining splenocytes from the same 
experiment, however, responses were weak and variable as compared to the positive 
control suggesting that 5T4 is less immunogenic in BALB/c mice. 
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Figure 59: AdZ-h5T4 induces 5T4-specific responses in BALB/c mice . 85,000 
splenocytes extracted from mice vaccinated with AdZ-CTRL (mouse 2-4) and AdZ-5T4 
(mouse 9-12) were stimulated overnight with 5T4 peptide pools (at a concentration of 
5 µg/ml/peptide) overlapping the entire 5T4 protein. RPMI (supplemented with 5% 
FBS) was used as a negative control whereas for the positive control 1 µg of PHA was 
added to the cells. Each bar represents a response/mouse that is a mean of duplicate 
samples ±SD. Spot forming unit (SFU) is indicative of a single lymphocyte releasing 
IFN-γ upon stimulation with 5T4.    
 
 
 
 
 
 
 
 
 
 
 
 
Results  
174 
 
 
N
e
g
a
t i
v
e
p
p
1
p
p
2
p
p
3
p
p
4
p
p
5
p
p
6
p
p
7
p
p
8
p
p
9
p
p
1
0
p
p
1
1
p
p
1
2
p
p
1
3
P
o
s
it
iv
e
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
S
F
U
/8
5
,0
0
0
 c
e
ll
s
N
e
g
a
t i
v
e
p
p
1
p
p
2
p
p
3
p
p
4
p
p
5
p
p
6
p
p
7
p
p
8
p
p
9
p
p
1
0
p
p
1
1
p
p
1
2
p
p
1
3
P
o
s
it
iv
e
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
S
F
U
/8
5
,0
0
0
 c
e
ll
s
A
B
M o u s e  5
M o u s e  6
M o u s e  7
M o u s e  8
M o u s e  1 3
M o u s e  1 4
M o u s e  1 5
M o u s e  1 6
A d Z 2 -C T R L
A d Z 2 -h 5 T 4
 
 
Figure 60: AdZ2-h5T4 is immunogenic in BALB/c mice. 85,000 splenocytes 
isolated from mice vaccinated with AdZ2-CTRL (mouse 5-8) and AdZ2-h5T4 (mouse 
13-16) were stimulated overnight with 5T4 peptide pools (5 µg/ml/peptide) covering 
the entire 5T4 protein. For the negative control, the cells were incubated with RPMI 
(supplemented with 5% FBS) whilst for the positive control, 1 µg of PHA was added. 
Responses are represented as spot forming units (SFU)/well (mean of duplicate 
samples ±SD).  
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3.3.7. 4T1 cancer model: Tumour growth in BALB/c mice 
vaccinated with Ad-h5T4 vectors 
Although 5T4 responses induced in BALB/c mice were weak in comparison to 
responses in C57BL/6, I wanted to see whether they were sufficient to protect mice 
from tumour challenge with 4T1 cells. The mice in my study received two injections 
(prime and boost) of either AdZ-CTRL or AdZ-h5T4 six weeks apart. One week later, 
105 4T1 cancer cells were implanted subcutaneously into the left flank of the animal.  
Following immunisation with the Ad recombinants, the animals did not lose any weight 
(Figure 61 A). Palpable tumours started to develop at 7 days post challenge (Figure 
61 B) and comparative analysis of the three groups showed that all the mice were 
developing tumours at a similar rate. I observed a small (statistically insignificant) delay 
by 4 days in death of naïve mice (Figure 61 C) and no differences were observed when 
the number of splenocytes was counted between the three groups (Figure 61 D).  
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Figure 61:  Homologous prime-boost with AdZ-h5T4 does not protect from 4T1 
mammary carcinoma model. BALB/c mice were vaccinated twice (day 0 and week 
6) with 5×108 PFU AdZ-CTRL or AdZ-h5T4.Following the boost,105 4T1 cells were 
subcutaneously implanted into the left flank. Weight loss of naïve mice or mice that 
received 5×108 PFU AdZ-CTRL or AdZ-h5T4 injection represented as mean ±SD (4-6 
mice/group) of percent of starting weight (A).  Tumour burden in naïve mice and mice 
prophylactically immunized with AdZ-CTRL or AdZ-h5T4 and challenged with 105 4T1 
cells a week after the boost (B). Tumours were measured with a caliper and tumour 
volume was calculated by using the formula: (mm2) = width × length × smaller value 
(width or length) × (3.14⁄6). Survival in mice with 4T1 cancer pre-treated with Ad 
vaccine (C). Splenocyte numbers (D) expressed as mean ±SD of four-six mice per 
group.  
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Figure 62: Naïve mice challenged with CT26 colon carcinoma survive longer 
than mice vaccinated with AdZ-h5T4. .BALB/c mice were vaccinated with 5×108 
PFU of recombinant adenoviruses twice six weeks apart. A week after the boost, the 
mice were injected with 105 CT26 cells. A: weight loss associated with vector-induced 
illness expressed as mean ±SD (4-6 mice/group) of percent of starting weight. B: 
Tumour growth was measured at least 3 times a week using a caliper. Tumour sizes 
were calculated using the formula (mm2) = width × length × smaller value (width or 
length) × (3.14⁄6). C: overall survival of mice challenged with CT26 cells. D: cell 
numbers in the spleen calculated and shown as mean ±SD of 4-6 mice per group.  
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3.3.8. CT26 cancer model: Tumour growth in BALB/c mice 
vaccinated with Ad-h5T4 vectors 
In addition to the 4T1 model, I also wanted to test the prophylactic effect of my Ad-
h5T4 vector in a colon cancer model setting.  As with the other cancer models, BALB/c 
mice were immunized with the Ads six weeks apart. On week 7 they were challenged 
with 105 CT26 cells. Vaccination with Ad vectors resulted in slight weight loss (Figure 
62A) on day 4, however by day 6 all of the mice had recovered. Tumour development 
was first observed at 10 days post tumour challenge. Interestingly, the naïve mice 
remained disease-free longer (Figure 62B) than mice injected with AdZ-CTRL or AdZ-
h5T4. In addition to this, I observed prolonged survival (Figure 62C) in naïve mice 
which was statistically significant. In a repeat experiment, however, I did not see any 
differences in survival rates of mice injected with AdZ-CTRL or AdZ-h5T4. However, 
the repeat experiment did not include a naïve control, therefore the significance of the 
naïve group cannot be entirely dismissed. Comparison of the sizes of the spleens 
showed that they were highly variable, however spleens in naïve mice were larger than 
those in mice injected with AdZ-CTRL or AdZ-h5T4 (Figure 62D). 
 
3.3.9. Summary 
I identified 5T4 epitopes in C57BL/6 mice and compared 5T4 expression in four 
different cells and tissues (4T1, CT26, LLC1 and intestine from Apcfl/fl mice). 5T4 
immune responses in BALB/c mice were weaker than C57BL/6, therefore, I could not 
confirm individual epitopes in this mouse strain. Although the adenovirus vectors I 
generated encoding 5T4 expressed high levels of this antigen, prophylactic 
immunization of BALB/c and C57BL/6 strains did not induce tumour rejection or 
improve overall survival.  
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Chapter 4 Discussion 
 
4.1. Generation and analysis of conditionally replicating CMV in vitro 
 
4.1.1. Conditional expression systems in the literature 
In this work, I attempted to generate conditionally replicating viruses whereby gene 
expression induced by a chemical agent would enable replication to occur. Previous 
studies have shown that conditional replication can be induced in different ways. One 
of the most established systems called Cre-lox recombination system consists of Cre 
recombinase enzyme and loxP splice sites that Cre recombinase binds to (Nagy 2000). 
LoxP sites flanking a gene of interest are recognized by the enzyme and cleaved, thus 
resulting in deletion of the flanked gene. Analogous systems such as flippase- flippase 
recognition target (FLP-FRT) have been based on the Cre-lox recombination system 
and work in a similar way (Lacroix et al. 2011). To establish temporal control of the 
protein of interest, Cre recombinase may be placed under the control of tissue-specific 
promoters (e.g. endothelial cell-specific Flt-1 promoter) and inducible promoters 
(interferon-inducible Mx dynamin-like GTPase 1 promoter or steroid-regulated 
promoters fused to ecdysone and oestrogen receptors). Cre-recombinase system has 
been previously used in the context of CMV to study virus spread in vivo (Sacher et al. 
2012). In that study, they inserted LoxP sites together with eGFP under the control of 
HCMV MIE promoter into an MCMV reporter virus. Infection of Cre mice allowed the 
investigators to study virus dissemination in cre-expressing tissues.  
 
Another strategy to achieve temporal protein expression is by fusing a destabilising 
domain (dd) (e.g. FK506 binding protein (FKBP) derived) to an essential virus gene 
that results in stable gene expression only in the presence of a stabilising ligand such 
as shield-1 or guard-1 (Banaszynski et al. 2006). This degron-based technology is 
highly-specific, non-toxic and has been tested both in vitro and in vivo. Although the 
safety and biodistribution of  shield-1 has not yet been tested in humans, it has been 
shown to be safe in mice (Banaszynski et al. 2008). A structurally similar FKBP ligand 
(AP1903) to Shield-1, however, has shown safety in a human phase I dose study 
(Iuliucci et al. 2001). In addition to this, a well-established ligand (trimethoprim; TMP), 
has been used by Iwamoto et al together with dd from E.coli dihydrofolate reductase 
and showed regulation of yellow fluorescent protein levels (Iwamoto et al. 2010). TMP 
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is an antibiotic with a well characterized safety profile in humans. Fusion of ddFKBP 
to immediate early genes IE1/IE2 and IE1/IE3 in both HCMV and MCMV, respectively, 
has been shown to result in tight regulation of virus replication that was shield-1-
dependent (Glass et al. 2009). In addition to this, escape mutants were not selected 
during the course of the study.  
 
The most interesting results, when generating conditionally replicating viruses, 
however, have been obtained using a tetracycline-based approach (Tet-On) in 
Benjamin Berkhout’s lab. In an attempt to generate conditionally replicating HIV-1 virus 
vector, the accessory Nef gene of the virus was replaced with rtTA whereas eight tetO 
sequences were placed in the long terminal repeat (LTR) region (Das & Berkhout 
2016). Due to the high mutation rate of HIV-1, the viruses did accumulate mutations 
that resulted in loss of six tetO sequences as well as an adaptation of more active rtTA 
variants. Interestingly, the loss of tetO did not lead to less efficient virus replication and 
the authors suggest that eight copies of tetO may have impeded a virus replication 
process. The group identified loss-of-function mutations in the rtTA and developed a 
safety lock where they introduced amino acid changes that would prevent virus 
mutations, as the mutations would need to be more complex (i.e. purine to pyrimidine 
and vice versa). Further development of the vector led to mutagenesis (mutations 
identified in a resistant virus variant) of the Env gene making replication-dependent on 
an additional chemical (entry inhibitor enfuvirtide; T20) (Das & Berkhout 2016). The 
HIV-1 vectors generated could thus be more strictly controlled as their replication was 
dependent on two drugs.  
 
All of the aforementioned conditional systems have been used in virus vectors to 
provide inducible gene expression and ensure safety. Since the virus I am working on 
(CMV) is linked to disease, I wanted to develop it in a way that would make it safe in 
the population but also induce immune responses similar to WT virus. 
 
4.1.2. In vitro analysis of M50-1 and SCP-GFP conditional Tet-On 
viruses 
TetR-based technology has been previously used to generate conditional MCMV 
vectors (Rupp et al. 2005). Rupp et al, used the Smith MCMV strain and regulated 
expression of either the M50 gene (only replicates in the presence of DOX) or a small 
capsid protein (dominant-negative mutant, replication is inhibited in the presence of 
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DOX). In vitro, the M50-1 virus replication was regulated by 1000-fold whereas SCP-
GFP-regulated virus by 100-1,000,000-fold. Interestingly, when I tested these two 
viruses in vitro, M50-1 was inhibited by 14-fold whereas for SCP-GFP it was 211-fold.  
It is noteworthy, however, that the purification protocol in the paper entailed additional 
steps to remove any traces of DOX (e.g. pelleting the viruses at 23,450 × g for 3 h, 
ultracentrifugation step over a 15% sucrose cushion and purification using an OptiPrep 
gradient). Our standard purification protocol, on the other hand, consisted only of 
pelleting the viruses at 21,612 × g for 1h 40 min followed by centrifugation over 20% 
sorbitol cushion. In addition to this, the differences in the control of virus replication 
observed by Koszinowski’s group were highly variable between different cell types and 
in their work, they used mouse embryonic fibroblasts (MEFs) whereas all of my in vitro 
experiments were carried out in a different fibroblast cell line (NIH 3T3). Finally, 
numerous sources recommend using tetracycline-free FBS whilst culturing the cells to 
reduce the leakiness of the system. Members in the lab have tested our FBS batch 
with adenovirus vectors encoding tetR-regulated GFP and showed that in the absence 
of DOX, GFP expression was not relieved, thus suggesting that tetracycline in the FBS 
was not present/at low levels. Although it is not stated in Rupp et al whether 
tetracycline-free FBS was used, it could have enhanced the difference in DOX-free 
condition (Rupp et al. 2005). When I performed plaque assays using SCP-GFP and 
M50-1 viruses, I showed that the cell-cell spread of these viruses was barely affected 
by the addition/removal of DOX, whereas cell-free virus spread was better controlled. 
In comparison, my K181-based viruses showed good control of both cell-free and cell-
cell spread. One possibility is that M50-1 and SCP-GFP have genetic differences that 
result in a lower efficiency of cell-cell spread to start with. However, since there are 
numerous differences between the virus strain used in M50/SCP, and my K181-based 
constructs, it is difficult to know whether this is the case. Importantly, however, more 
M50-1 virus genome copies were detected in mouse tissues than my most promising 
virus (MRSV2M100-tetR-P2A-M36) thus suggesting that M50-1 vector is not as safe in 
vivo as my vaccine vectors. 
 
4.1.3. Generation of TREx vectors 
 
4.1.3.1. Promoter expression 
By using the TREx system I generated 31 HCMV and 30 MCMV BACs. The tetR gene 
was placed under control of one of three different promoters. To minimize the chance 
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of homologous recombination with native promoters, the HCMV IE promoter was used 
in the MCMV vectors and vice versa. The promoters in this study were selected on the 
basis that they were strong and have been widely used in vector development. Both 
of the CMV promoters contain powerful enhancers. Interestingly, the MCMV enhancer 
is bidirectional whereas HCMV enhancer is unidirectional (Keil et al. 1987). In addition 
to the CMV MIE promoter I also tested expression by the SV40 and RSV promoters. 
Although I tested three different promoters in HCMV as well as MCMV vectors, only 
the RSV promoter showed efficient expression of tetR protein in both vectors. 
Interestingly, expression driven by RSV appeared earlier in human fibroblasts than in 
mouse fibroblasts. This difference in expression is likely due to the fact that the RSV 
promoter is more adapted to human cells. The lack of expression observed for the 
SV40 promoter in both HCMV and MCMV vector was surprising. Although the length 
and sequence of my SV40 promoter was identical to that used in other vectors, some 
SV40 promoters in the literature were longer and may have contained regions 
necessary for better expression in my CMV vectors. It is also possible that CMV 
modulates transcription factors required for SV40 promoter expression. I was surprised 
to see that the HCMV vector encoding the MCMV IE promoter did not express any 
detectable tetR levels. The MCMV ie promoter is a well-established promoter and 
widely used in gene cloning. To design my vectors I used a sequence previously 
published in (Chatellard et al. 2007). One possible explanation is that during virus stock 
preparation, homologous recombination occurred within the virus backbone that did 
not affect virus replication but affected the promoter itself.  
 
The majority of promoters used in molecular biology show comparable levels of 
transgene expression in different cell types. The CMV promoter, however has been 
shown to be the most variable displaying varying strength in regulation in different cell 
types (Qin et al. 2010). The EF1-α promoter, on the other hand, induces strong 
expression without major fluctuations in different cell types (Qin et al. 2010). I tried 
inserting this promoter into my vectors, however, the second round of recombineering 
was problematic. Not only was the efficacy of the insertion of the promoter low, the 
promoter was not inserted in the colonies sequenced even after numerous attempts.   
 
The most important conclusion from the use of different promoters however, was that 
the tightest control of viral expression was achieved by the MRSV2M100-tetR-P2A-M36 
vector. This suggests that the use of an endogenous viral promoter, that expresses at 
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IE times, is the best candidate for rapid and high expression of regulatory proteins that 
can control virus growth. It is noteworthy that although the exogenous promoters rarely 
produced detectable protein by 24h, pUL36 is detectable by 6h, reaches a maximum 
after just 18h, and is one of the most abundant proteins during infection (Weekes et 
al. 2014). By inserting a second copy at the end of M36 (a UL36 homologue in MCMV) 
I showed that vectors containing two copies of tetR were inhibited more in the absence 
of DOX than vectors containing a single tetR, thus suggesting that the level of tetR is 
crucial to reducing background expression of gene of interest in the absence of DOX, 
and M36 endogenous promoter is able to provide early and strong tetR expression.  
 
4.1.4. TetR-based vector growth in vitro 
It is interesting to note that although all of the HCMV viruses produced infectious 
virions, four MCMV BACs did not. These four BACs (MSV401M44, MSV402M44, 
MSV401M75 and MSV402M75) all contained SV40 promoters which is surprising, 
considering the fact that I could not observe any tetR expression from this promoter in 
the parental vector (MSV40) which only contains tetR and no tetO. The four viruses 
contained tetO upstream of M44 and M75 (gH), however this placement of tetO still 
gave viable virus in combination with other promoters driving tetR expression. We have 
occasionally observed the insertion of transposons into BACs during recombineering 
(Murrell et al. 2016). It is possible that such an insertion occurred in an essential region 
of the genome of these viruses, or that other unintended recombination events had 
occurred that prevented virus replication. 
 
When virus dissemination was tested in the absence and presence of DOX, HCMV 
viruses were more likely to be inhibited than MCMV viruses. In HRSV2UL54, 
HMCMVie2UL75 and HRSV1UL123 (Table 17) plaques were all inhibited in the absence of 
DOX whereas nearly all MCMV virions grew similarly (Table 18) in both conditions. 
However, when the viruses were tested in plaque assay conditions whereby cells were 
overlaid with semi-solid media, MCMV viruses were inhibited more stringently than 
HCMV viruses. During replication in cells without an overlay, the viruses would thus 
use both cell-cell and cell-free spread methods. These results may indicate differential 
reliance of each virus on cell-cell as opposed to cell-free spread. Clinically, cell-cell 
spread of the virus plays a role in intra-host virus dissemination whilst cell-free release 
is more crucial for inter-host spread. Cell-free release may thus play a more significant 
role in ensuring safety of a vaccine in the population. Another possible explanation for 
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differences in HCMV and MCMV spread is the purification method used to purify 
HCMV, since it did not include a sorbitol cushion step, which could have left low traces 
of DOX.  
 
I also observed more efficient spread of virus in fibroblasts expressing tetR, as 
opposed to the parental fibroblasts, for the majority of HCMV and MCMV viruses, 
irrespective of the presence or absence of DOX. During the production stages of tetR 
expressing fibroblasts, cell clones enabling more efficient virus replication may have 
been selected. Nevertheless, my in vitro analysis of the vectors showed that MCMV 
vectors containing tetO upstream of M100 (gM) and HCMV vectors with inducible 
UL123 (IE1) expression could be controlled in a conditional manner.  The majority of 
MCMV and HCMV vectors, however, were not DOX-dependent and replicated 
irrespective of DOX in the media. It is possible that this variation in how controllable 
gene expression was, resulted from differences in promoter structures. In previous 
work by Stanton, not only was the positioning of tetO sequences essential to the level 
of control of gene expression, but it also depended on the copy number of tetO, and 
this can be gene-dependent (Stanton et al. 2010). Nevertheless, it appeared from 
Stanton et al that placing tetO approximately 20bp upstream of the ATG worked well. 
My work shows that this is not necessarily the case, and the positioning of tetO for 
each candidate gene needs to be tested individually, a single rule does not apply to 
every gene. It is possible that targeting of IE1 and gM in HCMV and MCMV, 
respectively, may be improved further by adjusting the location of tetO sequence 
inserted.  
 
4.1.5. Stability of tetR-based vectors in vitro 
To determine whether propagation of my tetR-regulated viruses in the absence of DOX 
selected for escape mutants, I sent samples to be sequenced. Previous work with the 
Smith MCMV strain showed that MCMV genome, unlike HCMV (Dargan et al. 2010; 
Murrell et al. 2016), is stable in vitro and only mutated in m09 gene and a non-coding 
region, thus the mutation rate of the virus is 1.4 ×10-7/bp/day (Cheng et al. 2010). In 
addition to this, comparison of K181Perth and K181Birmingham variants have shown that 
although the two viruses had been passaged for thirty years, they only differed in 13 
nucleotides (Timoshenko et al. 2009). However, by passaging MRSV2M100-tetR-P2A-
M36 in vitro, I was able to select out a mutant that grew well even in the absence of 
DOX. Sequencing revealed that one of the copies of tetR had a 5 bp deletion, 
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presumably making the protein non-functional. Whether this would also occur in vivo 
is currently unknown, however an activation system such as Tet-On could reduce this 
problem. Since Tet-On is an activation system, any mutations in the rtTA would mean 
that the virus would not be able to replicate in the presence of DOX thus making the 
virus vector safer. As shown by Berkhout et al, rtTA can mutate, however, they used 
HIV-1 as a vector which is an RNA virus with notably higher rate of mutation (4.1 ± 1.7) 
× 10−3/base/cell in vivo) across the whole genome than CMV (Cuevas et al. 2015). The 
Tet-On regulatory system is unlikely to mutate as rapidly in the CMV vector and 
insertion of multiple copies (as in this study) or the use of safety lock nucleotide 
changes would diminish the likelihood of spontaneous mutations and escape mutants 
(Das & Berkhout 2016).  
 
The MRSV2M100-tetR-P2A-M36 virus we sequenced had also mutated in M70 and 
m139 genes. M70 is the viral helicase/primase protein whereas m139 contains an 
inflationary epitope in C57BL/6 mice and plays a role in mediating viral replication in 
macrophages and spleen. It would not be surprising to see such mutations in viruses 
isolated from in vivo studies, as escape mutants may mutate in genes that would 
facilitate DNA synthesis or in immunogenic epitopes that may be presented to T cells. 
It is interesting to note that a group in Birmingham have identified mutations in a 
temperature sensitive K181 (Birmingham) variant generated by exposing the virus to 
N-methyl-N’-nitro-N-nitrosoguanidine (NTG) and two of the genes that had mutated 
were M70 and m139 (Timoshenko et al. 2009). The selective pressure under which 
these viruses mutated in these two genes was different, however, and more studies 
need to be carried out to understand the stability of different MCMV strains. 
 
4.1.6. Comparison of WT FRT Smith strain to previously published 
sequences 
We sequenced WT FRT MCMV to determine whether any mutations had arisen whilst 
generating virus stocks. Sequence alignment to the most recently published WT Smith 
strain (GU305914.1) showed that the two viruses shared 99.5% similarity, however, 
frameshift disruptions were found in m01, m03, m59, m150 and m161 genes (Cheng 
et al. 2010). In order to see whether the virus sequence matched better to that 
sequenced by a different group, I aligned the WT FRT sequence to a sequence 
(U68299) published by Rawlinson and others (Rawlinson et al. 1996). Surprisingly, the 
sequence was more similar (99.78%) but contained more frameshift-disrupting 
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mutations (m20, m29.1, m30, m31, m45.1, m58, m129, m143, m150 and m161), most 
of the disrupted genes being at the genomic termini. Interestingly, Smith et al., have 
hypothesized that the Smith strain sequenced by Cheng and others may be a 
recombinant variant of the Smith and K181 virus strains (Smith et al. 2013). In addition 
to this, the Smith virus sequenced by Cheng et al had been propagated in vitro for 
longer and therefore may have selected for adaptive mutations. Two plaque 
purification steps prior to sequencing may have resulted in selection of a clone that 
was not representative of the virus. I thus, think Rawlinson’s sequence is a more 
accurate representation of our WT FRT sequence.  
 
Work by Alec Redwood’s lab have shown that MCMV genomes isolated from wild mice 
in different parts of Australia had a conserved genome size without major genome 
rearrangements, insertions or deletions (Smith et al. 2008).  Interestingly, 151 ORFs 
out of 190 displayed >98% amino acid similarity to the Smith strain and most 
differences were observed in genomic termini.  These subtle differences, however, 
resulted in different replicative capacity in mouse tissues in vivo. It is possible that 
MCMV strains used in different labs around the world are Smith variants that contain 
mutations and cell culture adaptations, and thus it is important to identify and clone a 
WT-like (‘clinical’) MCMV strain into a BAC for use as a reference as has been done 
for HCMV (Stanton et al. 2010).  BAC cloning is crucial for maintaining a stable 
genomic clone of the virus with minimal chance of recombination.  
 
4.2. In vivo characterization of tetracycline-controlled MCMV vectors 
 
4.2.1. Replication-deficient or replication-competent CMV 
vaccine? 
CMV use in vector development has been hindered due to safety concerns, as 
replication-competent virus has disease associations in immuno-naïve and 
immunosuppressed individuals. Replication-defective virus, however, may not retain 
the immunogenicity of WT virus. Several studies have compared replication-
competent and incompetent vectors and analysed the immune responses induced. 
Live-attenuated HCMV containing destabilising domains flanking two target genes 
replicated selectively in the presence of Shield-1 and proved to be safe in different 
animal systems (Wang et al. 2016). Analysis of immunogenicity of this CMV vector in 
multiple animals (mice, rabbits and rhesus macaques) showed induction of CD4+, 
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CD8+ T cells as well as neutralising antibodies (Wang et al. 2016). It is difficult to 
compare the breadth of immunogenicity of this vector, however, since the animals 
tested are not a natural host to the virus, so there is no ‘replication competent’ vector 
for comparison. In a different study, a spread-defective MCMV lacking glycoprotein L 
was compared to WT virus in two mouse strains (BALB/c and C57BL/6). Although ΔgL 
virus elicited memory inflation in both strains of mice and they followed a similar trend 
(contraction and maintenance of peptide-specific T cells), the responses were lower 
than those induced by WT virus, especially in C57BL/6. In BALB/c mice, no IE1/M123 
(pp89)-specific responses were detected at 1 or 4 weeks post- injection but they 
accumulated later during the course of infection. Interestingly, the data showed that in 
BALB/c and C57BL/6 mice viral antigens were expressed for at least 20 weeks and 
36-74 weeks, respectively (Snyder et al. 2011). 
 
In an acute infection, a spread-defective MCMV vector (lacking M94 gene) also elicited 
strong CD4+, CD8+ responses that were similar to those induced by WT virus (Mohr et 
al. 2010). The levels of neutralising antibodies induced, on the other hand, were lower 
than in WT CMV immunized mice. In addition to this, UV-irradiated virus failed to 
induce any neutralising antibodies. When persistence of virus was analysed in different 
tissues, viral genomes were found in the lungs a year post infection, thus suggesting 
that persistent expression of virus antigens facilitated the immune response observed 
(Mohr et al. 2010). In unpublished data from our own laboratory it has been shown that 
a WT virus (replication-competent) induces stronger virus-specific immune responses 
to CMV antigens (m139; M38 and IE3) than a replication-deficient virus ΔgL MCMV in 
C57BL/6 mice at 7 and 60 days pi. It has been previously shown in the literature by 
Louis Picker’s lab that the use of live-attenuated RhCMV vector encoding SIV antigen 
in rhesus macaques induced strong effector-memory responses capable of inducing 
protection against a highly pathogenic SIV strain (Hansen et al. 2011), however the 
basis for the unique immune responses described in the SIV model have not yet been 
elucidated. In addition to this, the use of live-attenuated CMV vectors would be unlikely 
to be permitted in humans due to safety concerns. Together this data argues that some 
level of replication is required to induce the same magnitude of immune response as 
a wildtype infection. 
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4.2.2. Immunogenicity of my conditionally-replicating MCMV 
vectors in BALB/c mice 
I wanted to see whether conditionally replicating viruses would surpass the immune 
responses observed for spread-defective and live-attenuated CMV vectors previously 
described in the literature. Peripheral CD8+ T cell responses to pp89/IE1 peptide 
showed that MRSV2M100-tetR-P2A-M36 immunized mice receiving DOX had higher 
levels of CMV-specific lymphocytes (comparable to control virus immunized mice) than 
those receiving regular feed up until day 32. On day 64, however, the levels were 
comparable between all groups. This strongly suggests that permitting limited viral 
replication can significantly improve T-cell induction at early times post-infection. It is 
possible that at later times, the conditional virus may have overcome its sensitivity to 
DOX, and thus replicated, resulting in an equal induction of T-cells with or without DOX 
addition. Tissues were kept from this experiment, and will be tested for virus load, as 
well as the tetR sequenced, to test this hypothesis.   
 
To determine whether T cell responses and/or T cell phenotype in tissues were 
affected by viral replication, BALB/c mice were immunized with my most promising 
MRSV2M100-tetR-P2A-M36 in the presence and absence of DOX. Overall, I did not 
observe distinct trends in my data. In mice immunized with MRSV2M100-tetR-P2A-M36 
I observed induction of CMV-specific CD8+ T lymphocytes in the spleen and lung at 
levels comparable to the control virus. In the salivary glands, however, the frequencies 
of CMV-specific lymphocytes were significantly higher than conditionally replicating 
virus. TCM, TEM, TRM populations were also lower in salivary glands of mice immunized 
with conditional CMV. This suggests that the MRSV2M100-tetR-P2A-M36 may be less 
efficient at replicating in salivary glands even in the presence of DOX. When I tested 
functionality of CMV-specific CD4+ and CD8+ T lymphocytes, I observed higher 
production of IFN-γ by IE1-specific CD8+ T and M53-specific CD4+ T cells in mice 
immunized with conditional virus. Even though statistically not significant, I observed 
a trend for higher levels of TNF-α produced in IE1-specific CD8+ T cells in MRSV2M100-
tetR-P2A-M36 immunized mice receiving regular feed. Both IFN-γ and TNF-α play a 
role as proinflammatory cytokines that are released by activated CD4+ and cytotoxic 
effector T cells. These cytokines are important for their antiviral effect aiding in viral 
clearance, as previously shown for MCMV (Pavic et al. 1993; Lučin et al. 1992). It has 
been previously shown that HCMV acts to disrupt TNF-α expression by 
downregulating its cell surface receptor (Baillie et al. 2003). It is possible that 
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MRSV2M100-tetR-P2A-M36 virus in mice receiving regular feed is less efficient at 
downregulating TNF-α cellular receptor. In addition to this, the virus may have acquired 
mutations that have allowed it to escape transcriptional repression and would thus 
explain ongoing virus replication that would induce higher production of TNF-α (but not 
lower levels of IFN-γ by IE1-specific CD8+ T cells).  
 
A further complication is that in my studies, I used viruses propagated in vitro. Tissue 
culture-derived virus has been previously shown to be less pathogenic than salivary 
gland-derived virus, due to non-genetic differences. As a result, viral infection may not 
be detectable in vivo up to 2 weeks pi with tissue culture-derived virus, but is detectable 
with salivary gland passaged virus (Osborn & Walker 1971; Reddehase 2002). The 
spread-deficient ΔgL virus described by Snyder et al  has also been generated in vitro 
(Snyder et al. 2011). Interestingly, they observed more attenuated peripheral immune 
responses to CMV-specific peptides in C57BL/6 than BALB/c mice. Others in my lab, 
however, have conducted a similar experiment and showed (data not published) that 
although ΔgL virus induces comparable %pp89/IE1 responses in the BALB/c mouse 
strain as WT virus, ΔgL virus induces lower CD8+ T cell expansion, thus resulting in 
lower total pp89+ cells in the blood as well as tissues. This suggests that C57BL/6 
would thus be a better mouse strain to look for differences in immune responses 
induced by the different viruses.  
 
4.2.3. Safety profile of my conditional MCMV vectors in vivo 
Importantly, although my MCMV vectors were not completely inhibited in vitro in the 
absence of DOX, they were much more strictly controlled in the absence of DOX in 
vivo. A possible explanation for this observation is the interaction of the virus with 
immune cells in vivo which in turn aids in the control of virus replication such that even 
a modest inhibition of vector replication in vivo is sufficient to ‘tip the balance’ between 
the virus and the host, towards the host. The fact that virus control is more stringent in 
an animal model thus suggests that vectors safety evaluation in vitro should be 
interpreted with caution. 
 
In an acute MCMV infection model, these conditional viruses were detected at low 
levels in the four organs tested. Rescue (with DOX administration) of any possibly 
replicating virus by plaque assay showed that no MRSV2M100-tetR-P2A-M36 virus 
could be detected in any organ. In comparison to a previously described conditional 
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MCMV virus (M50-1), MRSV2M100-tetR-P2A-M36 therefore displayed an improved 
safety profile. In a longitudinal experiment looking at chronic MCMV infection, saliva of 
infected mice was tested for presence of virus genomes. Interestingly, some mice did 
shed MRSV2M100-tetR-P2A-M36 DNA, but not the control virus, however, due to high 
variability this difference was not statistically significant. In addition to this, the 
peripheral blood responses to CMV IE1 antigen increased in mice immunized with 
MRSV2M100-tetR-P2A-M36 (receiving regular feed). This together with the sequencing 
data showing that propagation of MRSV2M100-tetR-P2A-M36 can result in mutations 
leading to loss of functional tetR suggests that these vectors may need to be modified 
further prior to translation to HCMV vector design and use in humans. 
 
Different strategies (described in section 4.1.1) have been developed to improve 
conditional vector safety. One approach would be to use the Tet-On system since it is 
an activation system and not a de-repression system such as the one I have used in 
my vector design. As mutations in the rtTA gene have been identified by Benjamin 
Berkhout’s lab, the use of their safety-lock amino acid modifications would provide an 
additional safety mechanism. In addition to this, a destabilising domain or loxP sites 
could be inserted next to an essential virus gene thus making virus replication 
dependent on additional ligands and not just DOX. An additional way to make the virus 
safe would be by inserting a thymidine kinase gene that would render it sensitive to 
acyclovir treatment. Lastly, treatment with ganciclovir, Benzimidazole l-Riboside 
1263W94 or 2-Bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole (BDCRB) 
should reduce viral burden and improve safety of the vector as these are drugs that 
have been previously shown to inhibit CMV replication (Biron et al. 2002). 
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4.3. Adenovirus and cancer models 
 
4.3.1. Efficacy of adenovirus vectors in tumour models in the 
literature  
Extensive research has been carried out using replication-deficient adenovirus vectors 
encoding tumour-associated antigens in anti-cancer vaccine development. Colorectal 
cancer antigen GUCY2C encoding Ad5 vector has been tested in conjunction with 
radiotherapy and showed anti-tumour effect in CT26-GUCY2C cancer model (Witek et 
al. 2014). Both of these treatments individually, however, did not display efficacy. An 
adenovirus vector (containing deletions in E1 and E2b (DNA polymerase) gene 
regions) encoding CEA displayed significantly stronger immune responses than first-
generation (E1 deleted) Ad-CEA vector (Gabitzsch et al. 2010). In addition to this, the 
immunogenicity of the vector provided an anti-tumour response in mice injected with 
MC38-cea2 (murine colon adenocarcinoma) cells and delayed tumour development. 
A recombinant adenovirus vector encoding PSA and prostate stem cell antigen 
demonstrated efficacy in murine prostate cancer model (RM11-PSA/PSCA) (Karan et 
al. 2011). Therapeutic immunization with the vaccine led to eradication of tumours in 
80% of immunized mice. It is therefore evident that adenovirus vectors make effective 
anti-cancer vaccines in mouse models when used in conjunction with tumour 
expressing antigens and have the potential to delay or even eradicate tumour 
development. 
 
Several studies have utilized the fact that a variety of different tumours express 5T4 
antigen in an attempt to treat cancer. T cells expressing chimeric receptors targeting 
h5T4 have been tested in vivo alongside bone marrow-derived DC (BMDC) and Ad-
h5T4 and showed that the use of h5T4-specific CR T cells alone, delayed progression 
of CT26-h5T4 tumours in 60% of  mice for as long as 8 weeks post challenge (Jiang 
et al. 2006). In a therapeutic setting, the use of h5T4-specific CR T cells with Ad-h5T4 
and BMDC (locally but not systemically) significantly improved mouse survival rates 
and delayed tumour growth. In a different study, retrovirally transduced DC lines 
DCh5T4 and Ad-h5T4 induced tumour growth delay in a B16 melanoma model (Ali et 
al. 2006). Prophylactically, DCh5T4/Adh5T4 was shown to be the most effective 
regimen inducing tumour protection in 5/7 mice for the entire length of the study. 
Immunization of C57BL/6 5T4 knock out (5T4 KO) mice with Ad-m5T4 resulted in 
induction of CD4+ and CD8+  immune responses sufficient to protect against B16 
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tumour challenge (F. V. Castro et al. 2012). WT mice immunized with the same vector, 
however, activated CD4+ and CD8+ T cells that displayed poor cytokine release 
profiles.  As a result, WT mice were not protected from B16 melanoma. The anti-
tumour responses were attributed to CD4+ T cells since depletion of these cells 
resulted in significantly ablated anti-tumour activity. Altogether this data provided the 
basis for the use of adenovirus vectors in my studies to examine anti-cancer efficacy, 
and to compare them to the efficacy of my CMV vectors.  
 
4.3.2. 5T4 epitope mapping 
In order to generate tetramers that would allow us to look at immune responses in vivo, 
I mapped 5T4 epitopes in two mouse strains (BALB/c and C57BL/6). The responses 
in C57BL/6 were strong and the epitopes identified were in line with epitopes predicted 
by NetMHC online program. I was unable to determine restriction of the epitopes due 
to T2 Db cells having lost the expression of Db encoding plasmid. H-2Db-restricted 
peptides tend to be nonamers whilst H-2Kb peptides are octamers. Since Db is known 
to bind peptides that have asparagine at position 5 and methionine or isoleucine at 
positions 8-10 (Miller & Collins 2006), it is likely that VSFRNLTHL is a Db-binder. The 
prediction program, however, suggested that it may bind both molecules. Kb, on the 
other hand, binds peptides that contain tyrosine or leucine at position 3 (minor anchor), 
either phenylalanine or tyrosine at position 5 and leucine at position 8 (Falk et al. 1991; 
Mutnts et al. 1991). Taking this criterion, peptide prediction output as well as peptide 
stability assay results into consideration, TSYVFLGIV is most certainly a H2-Kb-
restricted peptide. Peptide stability assays showed that peptides VSFRNLTHL, 
NSLVSLTYV and SAPSPLVEL did bind to T2 Kb cells, but the complexes were not 
stable. This can be explained by lack of anchor residue at position 5. Although the 
peptide prediction program predicted that NSLVSLTYV and SAPSPLVEL to be H-2Db-
restricted, I cannot confirm this entirely since T2 Db cell data was not reliable due to 
possible loss of Db molecule expression. 
 
4.3.3. LLC1 cancer model  
To my knowledge, no one had previously shown that LLC1 cells express 5T4 tumour-
associated antigen. Although in comparison to the other two cell lines (4T1 and CT26) 
I tested, LLC1 exhibited the lowest 5T4 expression, LLC1 cancer model is syngeneic 
for the C57BL/6 mouse strain. Since my epitope mapping studies showed that 5T4 
was more immunogenic in this mouse strain than in BALB/c, I wanted to establish a 
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cancer model and test h5T4-expressing Ad vectors. We performed a pilot study to 
elucidate the dosage of cells required to implant subcutaneously to induce tumour 
growth. Interestingly, although the highest dose used was 4×105 whereas in the 
literature it was 106, the rate of tumour growth was more rapid than that previously 
observed (Bertram & Janik 1980). One possible explanation for this is that the cells we 
used were of very early passage whereas those used by other groups may have been 
more heavily passaged resulting in longer doubling time. The tumours in the majority 
of the animals formed ulcerations as a result of high growth rate whereby hypoxic and 
necrotic centres in the tumours could be observed due to incomplete vasculature. 
Another hypothesis is that the location of tumour implantation resulted in easier 
accessibility for the animal to irritate the tissues surrounding the tumour through 
scratching or grooming. This hypothesis was supported by the fact that the size of the 
tumour did not affect the degree of ulceration. There were mice that had small tumours 
with discharge whereas others with large tumours did not. We injected the cells into 
the left flank whereas previous studies had injected LLC1 cells intravenously, 
intratracheally and subcutaneously in the intrascapular region which would not be as 
easily accessible for the animals thereby prolonging the endpoint of the experiment. 
Our animals, on the other hand, had to be sacrificed with tumours smaller than those 
previously reported in the literature due to Home Office regulations. 
 
Having identified a dose that induced tumours in all the animals at a steady rate, we 
tested Ad-h5T4 efficacy prophylactically. Surprisingly, naïve mice that had not received 
Ad vaccine displayed delayed tumour progression.  Comparison of spleen sizes 
showed that AdZ-h5T4 vaccinated mice had smaller spleens than other mice. It is 
interesting to note that other investigators have suggested that splenomegaly may be 
related to the breadth of immune response induced in tumour-bearing mice (Cao et al. 
2011). Spleen enlargement in tumour-bearing mice has been previously linked to 
extramedullary haematopoiesis and thus, the requirement for red blood cells (Casbon 
et al. 2015; Bronte & Pittet 2013). It would be interesting to analyse the phenotype of 
lymphocytes in these animals as it may explain why naïve animals were protected for 
longer. One of the hypothesis as to why the Ad-injected animals did not delay disease 
progression is T cell exhaustion and/or the induction of regulatory T cells.  
 
The efficacy of TReg depletion has been previously demonstrated in a B16m5T4 
melanoma (F. V. Castro et al. 2012). Phenotypic analysis of the splenic lymphocytes 
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would thus reveal the cause for the lack of tumour-specific response. It has been 
observed in the literature that LLC cancer model is not as immunogenic as 4T1 or 
CT26 and these cells also express less co-stimulatory markers on the cell surface 
(Lechner et al. 2013). This, together with the fact that 5T4 expression was lower than 
in 4T1 and CT26 could thus explain why a protective response was not observed in 
this cancer model. 
  
4.3.4. Lack of Efficacy of Ad-h5T4 in CT26 and 4T1 cancer models 
My work showed that 5T4 was not as immunogenic in BALB/c as it was in C57BL/6. 
Members from Adrian Hill’s lab have also observed similar levels of immunogenicity in 
this mouse strain (correspondence). I showed that 5T4 expression in CT26 and 4T1 
cells was very strong hence why I wanted to establish cancer models and test AdZ-
h5T4 vectors. Similarly to the LLC1 cancer model, both CT26 and 4T1-injected mice 
were not protected by vaccination with 5T4 expressing Ads. In the 4T1 model, survival 
of naïve mice was prolonged by 4 days whereas in CT26 model it was 7 days. 
Comparison of splenocyte numbers showed that they were comparable between 
different groups, however, in the CT26 naïve mice the spleens were slightly larger (not 
statistically significantly).  
 
Other groups have also used the CT26 cancer model and looked at prophylactic as 
well as therapeutic effect of MVA-h5T4 vaccination (Harrop et al. 2006; Mulryan et al. 
2002). Interestingly, the cell line they used was transfected with h5T4, thus increasing 
the expression of this antigen and enhancing the possible effect observed. In a 
prophylactic setting, the mice were immunized with MVA-h5T4 twice (2 weeks apart) 
and mice were challenged with 5×105 CT26-h5T4 cells i.v. 2 weeks after the boost. 
The vaccine induced a long-term (at least 6 months) protection against CT26 and was 
antibody-dependent since depletion of both CD4+ and CD8+ T cells did not have an 
effect on tumour development. In a therapeutic setting, however, CD4+ T cells played 
a significant role in anti-tumour protection. Although the dose of cells used was higher 
and the mode of administration was intravenous as opposed to subcutaneous, MVA-
h5T4 did induce protection in the CT26 model. It may be possible that the effect 
observed was due to higher expression of h5T4. It has been previously shown that 
CT26 and 4T1 express high levels of immunosuppressive factors compared to other 
cancer models (Lechner et al. 2013). CT26 model also displays higher levels of TReg 
frequencies, thus enhancing the immunosuppressive effect that would explain the lack 
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of efficacy of my Ad vectors (Lechner et al. 2013). To determine whether this was the 
case, TReg depletion would need to be carried out. In previous studies, depletion of TReg 
cells resulted in more potent responses to 5T4 (F. V. Castro et al. 2012; Elkord et al. 
2008). 4T1 cells, on the other hand, have been described as a highly heterogeneous 
cell line whereby different cell clones would display variable proliferation and 
metastasis potential. It cannot be ruled out that the cells implanted differed in the rate 
of proliferation, although this would explain high variability between mice and not 
experimental groups. 
 
4.3.5. The route of administration 
The route of administration of adenovirus vectors in cancer models described in the 
literature is primarily intratumoral. Some cancer cells, however, have low HF-CAR 
expression (the receptor to which Ad serotype 5 binds), thus resulting in limited antigen 
expression at the site of injection. In such cases, systemic delivery may be more 
favourable. Systemic injection (such as intravenous immunization) enables targeting 
of multiple different organs, and targeting of tumours where direct injection is not 
feasible, however high expression of HF-CAR in hepatocytes leads to liver uptake of 
adenoviruses. It has been shown that the half-life of adenovirus type 5 in the blood is 
less than 2 minutes (Alemany et al. 2000). Moreover, neutralising antibodies in the 
blood may inactivate the virus following subsequent injections. Interestingly, a study 
comparing intravenous and intratumoral routes of injection showed that only higher 
doses (5×108 PFU) of recombinant adenovirus vector (Ad-mIFN) injected 
intravenously displayed an anti-tumour effect in mice receiving intratumoral injections 
(Narumi et al. 2010). In addition to this, IFN-α, CD4+ and CD8+ levels within the tumour 
were higher following intratumoral administration than intravenous. Interestingly, 
intratumoral injection was shown to be effective not only at the site of injection but 
displayed a suppressive effect against a tumour implanted at a different location. There 
have also been studies comparing i.v. route of administration and subcutaneous 
immunization. It was shown that both routes of injection induced IFN-γ secreting CD8+ 
T cells, however, T cells elicited by i.v. injection were localized in the liver (Holst et al. 
2010). In addition to this, cytokine production/effector functions of these T cells 
became impaired at 2-4 months post-administration and accumulated in the spleen. 
Interestingly, it has also been demonstrated that more virus was required to be injected 
intravenously to induce a response of the same magnitude as the vector injected 
subcutaneously (Holst & Thomsen 2011). Induction of the response was more gradual 
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for intravenous injection, however, over time became stronger than s.c. (Holst & 
Thomsen 2011). Although s.c. injection is a type of local delivery, the use of higher 
virus doses (more than 109 virus particles) has been shown to result in viral entry into 
the bloodstream (Holst et al. 2010). 
 
In my experiments, each mouse received 5×108 PFU of recombinant adenoviruses. 
The inoculum was injected subcutaneously into the abdominal cavity. The tumours, on 
the other hand, were implanted into the left flank. Since we tested my vaccine vectors 
prophylactically, intratumoral injection was not considered. The fact that the vectors 
used were replication-deficient and I did not observe any anti-tumour effects could 
suggest that the virus particles did not manage to disseminate systemically and it is 
likely that they were either neutralized or were sequestered by the liver. Moreover, the 
responses induced may have been local and did not reach the site of tumour 
challenge. In the future, it would be interesting to administer the vaccine closer to the 
site of tumour injection site to see whether there would be an improvement in the 
efficacy of the anti-cancer vaccine. In addition to this, alternative injection approaches 
such as the microneedle-mediated immunization should be experimented with to 
reduce anti-vector immunity and enhance responses to the antigen and increase the 
numbers of tumour-infiltrating lymphocytes (Carey et al. 2015).  
 
The majority of vaccines in humans are injected intramuscularly (hepatitis A, hepatitis 
B, tetanus and rabies); subcutaneously (measles, mumps, rubella, varicella, zoster 
and meningococcal polysaccharide) or intradermally (rabies and influenza).  In a 
cancer setting, however, anti-cancer agents are delivered subcutaneously 
(monoclonal antibodies; i.e. trastuzumab and chemotherapy drugs azacitidine), 
intravenously (Cytoxan – chemotherapy drug and DC Sipuleucel-T (Provenge)) or 
intramuscularly (human papillomavirus) (Leveque 2014).  Although intratumoral route 
of injection has shown a lot of potential in an animal model, it would not be applicable 
to all types of cancers as some of them may not be easily accessible. Therefore, it is 
crucial to select the most appropriate route of immunization for the type of cancer at 
hand, however a vaccine that could be administered systemically would have wider 
utility than one requiring intratumoral delivery. In addition to this, a number of factors 
need to be taken into consideration when selecting the route of injection: type of 
immune responses required; whether there would be any cytotoxicity at the site of 
delivery and the volume of the inoculum. 
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4.3.6. Homologous prime/boost 
In humans, the majority of the population have neutralising antibodies to adenoviruses, 
which limits the efficacy to Ad vectors, however this is not the case in laboratory mice. 
In addition to this, the selected dose (5×108 PFU) had been previously optimised by 
members in the lab to induce a strong response to the transgene, but not to the vector 
itself, even following a homologous prime/boost regimen. In addition to this, it has been 
shown by another group that the use of 2 × 108–2 × 109 PFU results in significant 
accumulation of antigen-specific CD8+ T cells thus supporting the idea that not only is 
this dose safe but also immunogenic (Krebs et al. 2005).  
 
It has been suggested in the literature that a heterologous prime/boost regimen may 
be more effective than homologous regimen. In the prime stage of the vaccination, a 
naïve T cell is presented with antigens derived from the recombinant antigen as well 
as the vector which results in T cell activation and development of memory T cells. 
Heterologous boost entails immunization with a different delivery vector encoding the 
same antigen. Consequently, the memory response only to the antigen is induced. 
When the same delivery vector is used (in the case of homologous regimen), memory 
T cells specific to the vector may also be expanded. Lemckert et al has showed that 
injection of naïve mice with 109 virus particles (4 weeks apart) with either Ad11-Gag or 
Ad35-Gag resulted in significantly weaker immune responses than in mice that 
received a heterologous Ad11-Gag/Ad35-Gag or Ad35-Gag/Ad11-Gag injection 
(Lemckert et al. 2005). In addition to this, studies in which homologous regime with 
MVA vector encoding h5T4 was used or canary pox virus vector ALVAC(2)-h5T4, no 
5T4-specific responses were induced when analysed by an ex vivo ELISpot assay 
(Hanwell et al. 2013). In a murine cancer model immunized with MVA-h5T4 
(homologous regime), depletion of CD4+ and CD8+ T cells did not affect protection 
against tumour formation thus supporting the hypothesis that homologous vaccination 
regimens may reduce T cell immune responses induced (Harrop et al. 2006). The use 
of simian adenovirus ChAdOx1.h5T4 and MVA-h5T4 in a heterologous vaccination 
regimen resulted in protective 5T4-specific immune response in a B16 melanoma 
model. Homologous vaccination (MVA-h5T4), on the other hand, failed to induce a 
5T4-specific cellular response, thus suggesting that a heterologous prime/boost 
regimen may be more effective (Cappuccini et al. 2017). Interestingly, the order in 
which delivery vectors are injected may also play a crucial role in development of the 
immune response. It has been shown that vaccination with Adh5T4 followed by 
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DCh5T4 induced protection in B16 melanoma model when used prophylactically 
whereas injection with DCh5T4 followed by Adh5T4 did not (Ali et al. 2006). In a 
therapeutic setting, however, DCh5T4/Adh5T4 was more beneficial.  
 
In addition to the vaccination regimen used, it is possible that the T cell activation 
mechanism was faulty and the cells may have been exhausted (Krebs et al. 2005). It 
has been previously shown that replication-deficient adenovirus vector encoding lacZ 
was able to induce as many as 5-15% β-gal-specific CTL, however, these T cells 
displayed reduced effector cytokine production and consequently, Ad-lacZ vectors did 
not have a therapeutic effect in mice with βgal-expressing tumours.    
 
In this study, proof-of-concept experiments were performed to look at the capacity of 
Ad-h5T4 vectors in inducing protection against 5T4-expressing tumour challenge. The 
end-goal was to use CMV and Ad vectors in a prime boost regimen, however, due to 
time constraints these experiments were not conducted. Members in our lab have 
previously shown (data not published) that immunization with Ad serotype 4 encoding 
IE3 MCMV epitope followed by an MCMV boost resulted in induction of as many as 
40% of IE3-specific CD8+ T cells. Ad4-IE3 alone, induced 10% tetramer-specific CD8+ 
T cells. Ad serotype 5, on the other hand was less immunogenic (30% tetramer-
specific CD8+ T cells) although the responses were less variable. It will be interesting 
to determine whether the use of this approach will protect mice against LLC1, 4T1 and 
CT26 challenge. In addition to this, the previously established intestinal cancer model 
by Lee Parry would be another opportunity to analyse the responses induced by these 
two vectors. 
 
4.4. Overall conclusions and future perspectives 
To summarize, I have shown that in the context of CMV, the TREx system can be 
safely used in vivo. In order to achieve stringent control of virus replication, it was 
necessary to achieve early and abundant expression of tetR. Endogenous virus 
promoters (M36) showed efficacy in driving gene expression and thus, controlling virus 
replication. In addition to this, I showed that the location of tetO was crucial and highly 
variable between different genes, thus it is necessary to experiment with positioning 
tetO at different locations upstream of each candidate gene. These positions may also 
differ between human and mouse CMV genomes as gM and IE1 gene regulation in 
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MCMV (M100 and M123) and HCMV (UL100 and UL123), respectively, played a role 
in controlling virus replication.  
 
Immune responses to the vectors in vivo in the absence and presence of DOX did not 
follow strict trends. At 32 days pi, the conditional MCMV vector did, however, induce 
weaker immune responses in the absence of DOX in comparison to presence of DOX 
or control virus. This result suggests that the conditional virus is suppressed by the 
immune system in absence of DOX and is unable to replicate, however, at later 
timepoints in the infection the virus may have overcome this modulation. Although 
currently I do not know whether the virus escapes strict control of virus replication in 
the absence of DOX in vivo, by mutating in the tetR or tetO regions, sequencing of 
viruses isolated from mouse tissues would reveal this information.  
 
The results obtained in the course of this study provide a better understanding of CMV 
conditional replication in vitro and in vivo. The fact that conditional MCMV vector 
mutated in vitro in the absence of DOX, thus enabling virus replication, suggests that 
in place of the TREx system described in this study, Tet-On system should be used 
instead, although this in turn could present issues with the controlled gene not being 
expressed with the correct kinetics (immediate early, early and late). The sequence of 
rtTA gene could be optimised to prevent the chances of any possible mutations. My 
work identified M36 gene as a good location for insertion of tetR, thus fusing of rtTA at 
the end of M36 should therefore also result in stringent control of virus replication. In 
addition to this, I determined the positions for inserting tetO sequences that 
successfully enabled conditional expression of gM and IE1 genes in MCMV and 
HCMV, respectively. Further development of the vector could also involve insertion of 
a destabilising domain to regulate an essential virus protein. Both of these 
mechanisms would ensure conditional control of virus at the transcriptional as well as 
post-translational level. Ligands such as TMP or AP1903 should be tested in a mouse 
model as they have previously been characterized in humans and in the future, could 
be used in conjunction with HCMV vectors.  My colleagues have observed stronger 
differences in immune responses elicited by replication-deficient viruses compared to 
WT viruses in C57BL/6 and since I only looked at responses in BALB/c mouse strain 
it would be interesting to test my conditional MCMV vectors in C57BL/6.       
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In addition to CMV work, I mapped 5T4 epitopes in C57BL/6 and BALB/c mouse strains 
by using Ad-h5T4 replication-deficient vectors. I compared immunogenicity of first- and 
second-generation Ad vectors and showed that it was comparable in the BALB/c 
mouse strain. I showed that h5T4 is less immunogenic in BALB/c mice than C57BL/6. 
In preliminary experiments, the use of Ad-h5T4 vectors did not show prophylactic 
efficacy in 5T4-expressing cancer models (4T1, CT26 and LLC1). Adenovirus serotype 
5 (used in this study), although highly immunogenic in mice, is rapidly neutralised in 
humans due to pre-existing antibodies. Other, less common serotypes (e.g. serotype 
4) should be used instead. Since previous work by colleagues in the lab has shown 
that adenovirus prime immunization followed by a boost using CMV vector induced 
strong immune responses in mice, it would be interesting to repeat this experiment in 
a cancer model with vectors expressing 5T4 antigen/epitopes. 
 
Paul Klenerman’s group have previously shown that Ad-minigenes induce inflationary 
immune responses characteristic of CMV vectors (Colston et al. 2016).  I therefore 
generated Ad minigenes that contain 5T4 individual epitopes identified in this study. In 
addition to this, I made Ad vectors expressing UL40 HCMV gene fused to individual 
5T4 peptides. UL40 gene has a leader sequence containing an HLA-E ligand. 
Replacing HLA-E peptide sequence with 5T4 epitopes should result in efficient loading 
of epitopes onto HLA-E which consequently would induce strong inflationary T-cell 
responses. It would therefore be of interest to use Ad-5T4-minigene or Ad-UL40-5T4 
peptide vectors together with CMV vectors encoding 5T4 epitopes in a mouse model 
to identify the most effective combination in a prophylactic immunization regimen.     
 
As 5T4-specific immune responses are low in BALB/c mouse strain and we only 
established LLC1 cancer model in C57bl/5 mice, future work should focus on looking 
at anti-cancer efficacy in Apcfl/f mice (C57BL/6 background) kindly provided by Dr Lee 
Perry. This model represents a more natural progression of cancer since tumour cells 
do not need to be implanted into the mouse. Instead, treatment with tamoxifen leads 
to loss of APC and tumour formation in the intestine. Since we detected CMV-specific 
lymphocytes in intestines of infected mice, I believe that Ad/CMV prophylaxis should 
be effective in this cancer model. 
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Appendix A - Primers used in this study 
 
No. Primer Sequence (5'>3') 
Inserting tetR (in HCMV): 
1 
TetR RL13 
hom F 
TTAAGTACATATCTACCATGAAATACAGCAAAGATATACTAATGTC
TATCCATCCAATAGCGGTACCATGTCTAGATTAGATAAAAGTAAA
GTGATTAA 
2 
TetR RL13 
hom R 
AAGTGATTAACTCAGAATAAACACACCCAAACATTAATGACTAAA
GATAAAAAATTTTATTGATGTGCATATTATACCTTTCTCTTCTTTTT
TGGATCAG 
Inserting tetR (in MCMV): 
3 
SacB/Amp/
lacZ into 
m157 
MCMV 
K181 F 
GGACTGTTGACCGCCATCTGTTCTTGATTTCCCGAACGTTGCTTT
TTATCATATAGGTACCAATTTCTTTTGCGTCGGACCTGTGACGGA
AGATCACTTC 
4 
SacB/Amp/
lacZ into 
m157 
MCMV 
K181 R 
ACTACCGATACGGTCAGGGTAGCGTATACAGGACAGACTGGTAA
GATTAATATTCAAGGATCAGGAAAATTTTCAACTCTGAGGTTCTTA
TGGCTCTTGT 
5 
tetR into 
m157 
MCMV 
K181 F 
GTGAACGGCACGTTCGACCTCGATGTGACCACACACGTGGTCAA
GCCGGTCGTGTTGTACCAGAACTCGATTATACCTTTCTCTTCTTTT
TTGGATCAGA 
6 
tetR into 
m157 
MCMV 
K181 R 
AAACGCAGGAGAATCTGAACCCCGATATTTGAGAAAGTGTACCC
CGATATTCAGTACCTCTTGACATGTCTAGATTAGATAAAAGTAAAG
TGATTAACAG 
7 IE2 tetR F 
CTTTATTTATTGATTAAAAACCATGACATACCTCGTGTCCTCTCAC
TGAATCTTCTTCCTGACGGTCACCAGGTCTCTGGTTATACCTTTC
TCTTCTTTT 
8 IE2 tetR R 
GGGTAGCAGCTGTAGTGAGAGTCTCTCGGGTCCGGGGGCGTGA
GGGACGCGACTGCTCACGGTTCTGTTTGTCTGTAGATATGTCTA
GATTAGATAAAAG 
9 
RpsL after 
M36 F 
TCGCTTTTTATTAACCTCCGTTTTGTTTATTTTTTTTCTCCCCTCAC
CCTCTCCGTCCCTTTCTTATCCGTTTTCCCTCCTGTGACGGAAGA
TCACTTCG 
10 
RpsL after 
M36 R 
CGGGATCAACGATCCACCGTGTCGGCGATGTATCGAGAGGAGG
AGGGTCAAGCTCTTTAAGATGACACGGGGATATCGACTGAGGTT
CTTATGGCTCTTG 
11 
P2A-tetR 
M36 F 
TTTTTATTAACCTCCGTTTTGTTTATTTTTTTTCTCCCCTCACCCTC
TCCGTCCCTTTCTTATCCGTTTTCCCTTTATACCTTTCTCTTCTTTT
TTGGAT 
12 
P2A-tetR 
M36 R 
ACCATCGGGATCAACGATCCACCGTGTCGGCGATGTATCGAGAG
GAGGAGGGTCAAGCTCTTTAAGATGACACGGGGATATCGAAGCG
GCTCCGGTGCCA 
13 
bef tetR 
IE2 F 
TGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCT
GTTAATCACTTTACTTTTATCTAATCTAGACATCCTGTGACGGAAG
ATCACTTCG 
14 
bef tetR 
IE2 R 
GGTAGCAGCTGTAGTGAGAGTCTCTCGGGTCCGGGGGCGTGAG
GGACGCGACTGCTCACGGTTCTGTTTGTCTGTAGATCTGAGGTT
CTTATGGCTCTTG 
Promoters upstream tetR (in HCMV): 
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15 
sacB 
before 
tetR 
HCMV F 
ACACATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATA
TACTAATGTCTATCCATCCAATAGCGGTACCCCTGTGACGGAAGAT
CACTTCG 
16 
sacB 
before 
tetR 
HCMV R 
TTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCT
GTTAATCACTTTACTTTTATCTAATCTAGACATCTGAGGTTCTTATG
GCTCTTG 
17 
MCMV 
ie1 prom 
HCMV F 
CACATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATAT
ACTAATGTCTATCCATCCAATAGCGGTACCCAAGTACACTGACTCA
ATAGGGA 
18 
MCMV 
ie1 prom 
HCMV R 
GGGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGC
GCTGTTAATCACTTTACTTTTATCTAATCTAGACATGAAGACTGCGA
CGGTACC 
19 
RSV 
prom 
HCMV F 
CACATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATAT
ACTAATGTCTATCCATCCAATAGCGGTACCACTCTCAGTACAATCT
GCTCTGA 
20 
RSV 
prom 
HCMV R 
GTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGC
TGTTAATCACTTTACTTTTATCTAATCTAGACATTTGGAGGTGCACA
CCAATGT 
21 
SV40 
prom 
HCMV F 
CACATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATAT
ACTAATGTCTATCCATCCAATAGCGGTACCTGCATCTCAATTAGTCA
GCAACC 
22 
SV40 
prom 
HCMV R 
TGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTG
TTAATCACTTTACTTTTATCTAATCTAGACATAAGCTTTTTGCAAAAG
CCTAGG 
Promoters upstream tetR (in MCMV): 
23 
sacB 
before 
tetR 
k181 F 
TTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCT
GTTAATCACTTTACTTTTATCTAATCTAGACATCTGAGGTTCTTATGG
CTCTTG 
24 
sacB 
before 
tetR 
k181 R 
GAGGTGGCGTGTGAAACGCAGGAGAATCTGAACCCCGATATTTGA
GAAAGTGTACCCCGATATTCAGTACCTCTTGACCCTGTGACGGAAG
ATCACTTCG 
25 
RSV 
before 
tetR 
k181 F 
GGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCG
CTGTTAATCACTTTACTTTTATCTAATCTAGACATTTGGAGGTGCAC
ACCAATG 
26 
RSV 
before 
tetR 
k181 R 
AGGTGGCGTGTGAAACGCAGGAGAATCTGAACCCCGATATTTGAG
AAAGTGTACCCCGATATTCAGTACCTCTTGACACTCTCAGTACAAT
CTGCTCTGA 
27 
SV40 
before 
tetR 
k181 F 
TGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTG
TTAATCACTTTACTTTTATCTAATCTAGACATAAGCTTTTTGCAAAAG
CCTAGG 
28 
SV40 
before 
tetR 
k181 R 
AGGTGGCGTGTGAAACGCAGGAGAATCTGAACCCCGATATTTGAG
AAAGTGTACCCCGATATTCAGTACCTCTTGACTGCATCTCAATTAGT
CAGCAACC 
29 
HCMV 
MIE 
before 
tetR 
k181 F 
ACGGGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAAT
GCGCTGTTAATCACTTTACTTTTATCTAATCTAGACATCAGGCTGGA
TCGGTCC 
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30 
HCMV 
MIE 
before 
tetR 
k181 R 
TTGGAGGTGGCGTGTGAAACGCAGGAGAATCTGAACCCCGATATT
TGAGAAAGTGTACCCCGATATTCAGTACCTCTTGACCTGGCATTAT
GCCCAGTAC 
31 
RSV tetR 
IE2 F 
GGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCG
CTGTTAATCACTTTACTTTTATCTAATCTAGACATTTGGAGGTGCAC
ACCAATG 
32 
RSV tetR 
IE2 R 
GGGTAGCAGCTGTAGTGAGAGTCTCTCGGGTCCGGGGGCGTGAG
GGACGCGACTGCTCACGGTTCTGTTTGTCTGTAGATACTCTCAGTA
CAATCTGCTC 
33 
HCMV 
tetR IE2 
F 
TTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCT
GTTAATCACTTTACTTTTATCTAATCTAGACATggtggCAGGCTGGAT
CGGTCC 
34 
HCMV 
tetR IE2 
R 
GGGTAGCAGCTGTAGTGAGAGTCTCTCGGGTCCGGGGGCGTGAG
GGACGCGACTGCTCACGGTTCTGTTTGTCTGTAGATCTGGCATTAT
GCCCAGTACA 
TetO-RpsL-TetO cassette before genes (in HCMV): 
35 
before 
UL44 F 
CCAGCGTCGGCGGCTCCGAGAGGCGCGTCTTGCGATCCATCCC
GGACAGCGTGCAAGTCTTCTCTATCACTGATAGGGACTGAGGTT
CTTATGGCTCTTG 
36 
before 
UL44 R 
CCGGTCGTCGTGTGTGCTCTCTATAAAACTTTCGCTCGCTCGCGC
CCGCTCCTTAGTCGTCCCTATCAGTGATAGAGACCTGTGACGGA
AGATCACTTCG 
37 
before 
UL54 F 
CGCCGGTCACGCCGCCGCTCAGATACGGGTTGAAAAACATAGCG
GACCGTGAGAGGCTGATCTCTATCACTGATAGGGACTGAGGTTC
TTATGGCTCTTG 
38 
before 
UL54 R 
TAAACTGGATATCTAGGTGCTGCATGTGTATTTTCTTTGTGATTTT
GCTTCGTAAGCTGTCCCTATCAGTGATAGAGACCTGTGACGGAA
GATCACTTCG 
39 
before 
UL75 F 
CGGCGAGGATGATGAGGTAGGAGGGGAGGCCTGGCCGCATAGC
GCGGCCGCGCCGCTGGGTCTCTATCACTGATAGGGACTGAGGTT
CTTATGGCTCTTG 
40 
before 
UL75 R 
ATCCTTTCTCTCCTTCTCTCGGGTGTAACGCCAACCACCACCTGG
ATCACGCCGCTGAATCCCTATCAGTGATAGAGACCTGTGACGGA
AGATCACTTCG 
41 
before 
UL85 F 
GGTCGAAAGTGCAGAAGATGTTGGCCTCCATGGCCGCCATAGCG
GCGGTGAAATCCTGGCTCTCTATCACTGATAGGGACTGAGGTTCT
TATGGCTCTTG 
42 
before 
UL85 R 
CTCGCTCTGACGCCGCGCCCGGTGCAGACGTTGTTCGTCTCCGC
TTCTCCTCCGTCGCGTCCCTATCAGTGATAGAGACCTGTGACGG
AAGATCACTTCG 
43 
before 
UL100 F 
ATGTCCGTGTATTCACCTTATCCACGTGCGAGGGGGCCATGGCG
ATAGCGGCGGCCCGCTTCTCTATCACTGATAGGGACTGAGGTTC
TTATGGCTCTTG 
44 
before 
UL100 R 
TAGTATTTAACGACCCGCGAGCCTGTCGTCATCGGCGCGCCCCC
ATCGCCTCCCGAGCGTCCCTATCAGTGATAGAGACCTGTGACGG
AAGATCACTTCG 
45 
before 
UL123 F 
TCTATGGAGGTCAAAACAGCGTGGATGGCGTCTCCAGGCGATCT
GACGGTTCACTAAACGTCTCTATCACTGATAGGGACTGAGGTTCT
TATGGCTCTTG 
46 
before 
UL123 R 
CCCCATTGACGCAAATGGGCGGTAGGCGTTTACTATGGGAGGTC
TATATAAGCAGAGCTTCCCTATCAGTGATAGAGACCTGTGACGGA
AGATCACTTCG 
TetO-RpsL-TetO cassette before genes (in MCMV): 
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47 
before 
M44 F 
TCGGCGGTTCGTGCTCGCGAACTTTCCTACCACCCTCCATTCCC
GCGGAGATGTATGTGATCTCTATCACTGATAGGGACTGAGGTTCT
TATGGCTCTTG 
48 
before 
M44 R 
CTCGCTCGGTCGGTCGGTCTGTCTCGTGTCCTTCTTTCGCCGGC
GCGCCGCGATCTCGCTCCCTATCAGTGATAGAGACCTGTGACGG
AAGATCACTTCG 
49 
before 
M75 F 
TCGAACATAGCGCGATGGAGAGTATTAATGACAACTTCATGTCGC
GGGTCGGGGTGCGGATCTCTATCACTGATAGGGACTGAGGTTCT
TATGGCTCTTG 
50 
before 
M75 R 
GCGCCGACGAGCGTAATTAAGATATTTAAACAGGATCGACGAGA
TAGGGCCCTGCGACGTCCCTATCAGTGATAGAGACCTGTGACGG
AAGATCACTTCG 
51 
before 
M85 F 
TGAGGCGCTGCTCGAACGTGACCAAAACCGTCGTTTCCATGGTC
GTGGGTGTCGGTCTCCTCTCTATCACTGATAGGGACTGAGGTTCT
TATGGCTCTTG 
52 
before 
M85 R 
CGTGATCGAGCGGGTCCTCCCGAGCGGAAGGCGCAGCGCCGTC
GGACGTCACGCTCGCCTCCCTATCAGTGATAGAGACCTGTGACG
GAAGATCACTTCG 
53 
before 
M100 F 
GGTCCACGTGGGAGAGCGTCATGACGCCCGCTTTCGCCATCGTG
CAGGTGTCTCGTGTCCTCTCTATCACTGATAGGGACTGAGGTTCT
TATGGCTCTTG 
54 
before 
M100 R 
CGAGGCTCGGACGGTCTCTCTAAGGATGCTCTCACTATTTGACC
CGCCCCGTCGACCGCTCCCTATCAGTGATAGAGACCTGTGACGG
AAGATCACTTCG 
55 
before 
M122/M12
3 F 
CGATCATGATCATGTTGCAACTGGGTGCGGCGGGCTCCATCTCT
CTAAAAAAATATAATTTCTCTATCACTGATAGGGACTGAGGTTCTT
ATGGCTCTTG 
56 
before 
M122/M12
3 R 
ATTAGCACTGTATACTTTAGATATCTTCTGGTCTCTGTGGACATCT
GTTGATGATAAAATCCCTATCAGTGATAGAGACCTGTGACGGAAG
ATCACTTCG 
TetO before genes (in HCMV): 
57 
UL44 TetO 
F 
AGGCGCGTCTTGCGATCCATCCCGGACAGCGTGCAAGTCTTCTC
TATCACTGATAGGGACGACTAAGGAGCGGGCGCGAGCGAGCGA
AAGTTTTATAGAG 
58 
UL54 TetO 
F 
CAGATACGGGTTGAAAAACATAGCGGACCGTGAGAGGCTGATCT
CTATCACTGATAGGGACAGCTTACGAAGCAAAATCACAAAGAAAA
TACACATGCAG 
59 
UL75 TetO 
F 
GAGGGGAGGCCTGGCCGCATAGCGCGGCCGCGCCGCTGGGTC
TCTATCACTGATAGGGATTCAGCGGCGTGATCCAGGTGGTGGTT
GGCGTTACACCCGA 
60 
UL85 TetO 
F 
TTGGCCTCCATGGCCGCCATAGCGGCGGTGAAATCCTGGCTCTC
TATCACTGATAGGGACGCGACGGAGGAGAAGCGGAGACGAACA
ACGTCTGCACCGG 
61 
UL100 
TetO F 
TCCACGTGCGAGGGGGCCATGGCGATAGCGGCGGCCCGCTTCT
CTATCACTGATAGGGACGCTCGGGAGGCGATGGGGGCGCGCCG
ATGACGACAGGCTC 
62 
UL123 
TetO F 
GTGGATGGCGTCTCCAGGCGATCTGACGGTTCACTAAACGTCTC
TATCACTGATAGGGAAGCTCTGCTTATATAGACCTCCCATAGTAA
ACGCCTACCGC 
TetO TetO before genes (in HCMV): 
63 
UL44 
TetO-TetO 
F 
TGCGATCCATCCCGGACAGCGTGCAAGTCTTCTCTATCACTGATA
GGGAGATCTCTATCACTGATAGGGACGACTAAGGAGCGGGCGC
GAGCGAGCGAAA 
64 
UL54 
TetO-TetO 
F 
TGAAAAACATAGCGGACCGTGAGAGGCTGATCTCTATCACTGATA
GGGAGATCTCTATCACTGATAGGGACAGCTTACGAAGCAAAATCA
CAAAGAAAAT 
Appendices 
254 
 
65 
UL75 
TetO-TetO 
F 
CTGGCCGCATAGCGCGGCCGCGCCGCTGGGTCTCTATCACTGAT
AGGGAGATCTCTATCACTGATAGGGATTCAGCGGCGTGATCCAG
GTGGTGGTTGGC 
66 
UL85 
TetO-TetO 
F 
TGGCCGCCATAGCGGCGGTGAAATCCTGGCTCTCTATCACTGAT
AGGGAGATCTCTATCACTGATAGGGACGCGACGGAGGAGAAGC
GGAGACGAACAAC 
67 
UL100 
TetO-TetO 
F 
AGGGGGCCATGGCGATAGCGGCGGCCCGCTTCTCTATCACTGAT
AGGGAGATCTCTATCACTGATAGGGACGCTCGGGAGGCGATGG
GGGCGCGCCGATG 
68 
UL123 
TetO-TetO 
F 
TCTCCAGGCGATCTGACGGTTCACTAAACGTCTCTATCACTGATA
GGGAGATCTCTATCACTGATAGGGAAGCTCTGCTTATATAGACCT
CCCATAGTAA 
TetO before genes (in MCMV): 
69 
M44 TetO 
F 
AACTTTCCTACCACCCTCCATTCCCGCGGAGATGTATGTGATCTC
TATCACTGATAGGGAGCGAGATCGCGGCGCGCCGGCGAAAGAA
GGACACGAGACA 
70 
M75 TetO 
F 
GAGTATTAATGACAACTTCATGTCGCGGGTCGGGGTGCGGATCT
CTATCACTGATAGGGACGTCGCAGGGCCCTATCTCGTCGATCCT
GTTTAAATATCT 
71 
M85 TetO 
F 
ACCAAAACCGTCGTTTCCATGGTCGTGGGTGTCGGTCTCCTCTCT
ATCACTGATAGGGAGGCGAGCGTGACGTCCGACGGCGCTGCGC
CTTCCGCTCGGG 
72 
M100 TetO 
F 
CATGACGCCCGCTTTCGCCATCGTGCAGGTGTCTCGTGTCCTCT
CTATCACTGATAGGGAGCGGTCGACGGGGCGGGTCAAATAGTGA
GAGCATCCTTAG 
73 
M123 TetO 
F 
GATATCTTCTGGTCTCTGTGGACATCTGTTGATGATAAAATCCCTA
TCAGTGATAGAGAAATTATATTTTTTTAGAGAGATGGAGCCCGCC
GCACCCAGT 
TetO TetO before genes (in MCMV): 
74 
M44 TetO-
TetO F 
CACCCTCCATTCCCGCGGAGATGTATGTGATCTCTATCACTGATA
GGGAGATCTCTATCACTGATAGGGAGCGAGATCGCGGCGCGCC
GGCGAAAGAAGG 
75 
M75 TetO-
TetO F 
ACAACTTCATGTCGCGGGTCGGGGTGCGGATCTCTATCACTGAT
AGGGAGATCTCTATCACTGATAGGGACGTCGCAGGGCCCTATCT
CGTCGATCCTGT 
76 
M85 TetO-
TetO F 
TCGTTTCCATGGTCGTGGGTGTCGGTCTCCTCTCTATCACTGATA
GGGAGATCTCTATCACTGATAGGGAGGCGAGCGTGACGTCCGAC
GGCGCTGCGCC 
77 
M100 
TetO-TetO 
F 
CTTTCGCCATCGTGCAGGTGTCTCGTGTCCTCTCTATCACTGATA
GGGAGATCTCTATCACTGATAGGGAGCGGTCGACGGGGCGGGT
CAAATAGTGAGA 
78 
M123 
TetO-TetO 
F 
GGTCTCTGTGGACATCTGTTGATGATAAAATCCCTATCAGTGATA
GAGATCTCCCTATCAGTGATAGAGAAATTATATTTTTTTAGAGAGA
TGGAGCCCG 
Sequencing primers (in HCMV): 
79 
In tetR 
for 
HCMV 
RL13 R 
GAGCAAAGCCCGCTTATTTTTTAC 
80 
TetO-
UL44 F 
AATGGTCTTGGGCTGAAACG 
81 
TetO-
UL44 R 
AGGATGCTCAAGTGGTACC 
82 
TetO-
UL54 F 
ATAGAACATGAGAGGCAGCC 
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83 
TetO-
UL54 R 
GATTCTTTGGACGGACGGAC 
84 
TetO-
UL75 F 
TGCTGTTGTAGGTACACTGG 
85 
TetO-
UL75 R 
GACGGTAGATGTCCAGGTG 
86 
TetO-UL 
85 F 
GAGGATCTGGTTGCCTTCTA 
87 
TetO-
UL85 R 
CTACGTCCGAAACGCACTTTG 
88 
TetO-
UL100 F 
CCTTTCAAAGTCCACGACGTG 
89 
TetO-
UL100 R 
ACATTGTACGATAGGCACCG 
90 
TetO-
UL123 F 
TGCATAAGAAGCCAAGGGG 
91 
TetO-
UL123 R 
CAGTACATGACCTTACGGGA 
Sequencing primers (in MCMV): 
92 tetR F GTCAGTAACGATCGCAGAGC 
93 tetR R CACTCTTGTTAGTGCCGGT 
94 
In tetR 
for m158 
F 
GTAAAAAATCTTGCCAGCTTTCCC 
95 In tetR R GGGAAAGCTGGCAAGATTTTTTAC 
96 
In HCMV 
prom F 
GAGTCAAACCGCTATCCACG 
97 IE2 F ATACTACTGCATGCCCCT 
98 IE2 R CGCTCGATCCATTCTTCT 
99 
TetO-
M44 F 
TTCTTGACGGTCTGGACGAT 
100 
TetO-
M44 R 
CGGCCAGACGATTGGTTTTC 
101 
TetO-
M75 F 
GTGCGTGTTGAAGAGACAGC 
102 
TetO-
M75 R 
GGATGCGCTTCTTGAAGTCG 
103 
TetO-
M85 F 
ATCATCTGGTTACCCTCGAC 
104 
TetO-
M85 R 
TGCAGTACATCTGCGTGGA 
105 
TetO-
M100 F 
TCGCGTTGTACATCGTCAGG 
106 
TetO-
M100 R 
GCAGGAAAGCATAGATGGAC 
107 
TetO-
M123 F 
AAGGGAGAGTTAGGAGAGG 
108 
TetO-
M123 R 
TGGCACCCTGAGAGAACAA 
109 M36 F CAACATGAGAGGTGCCAGAC 
110 M36 R ACCACCATCGGGATCAACG 
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Appendix B - Human 5T4 sequence  
 
MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSSAPFLASAVSAQ
PPLPDQCPALCECSEAARTVKCVNRNLTEVPTDLPAYVRNLFLTGNQLAVLPAGAF
ARRPPLAELAALNLSGSRLDEVRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNA
SVSAPSPLVELILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASNHFLY
LPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLHLEDNALKVLHNGTLAEL
QGLPHIRVFLDNNPWVCDCHMADMVTWLKETEVVQGKDRLTCAYPEKMRNRVLL
ELNSADLDCDPILPPSLQTSYVFLGIVLALIGAIFLLVLYLNRKGIKKWMHNIRDACRD
HMEGYHYRYEINADPRLTNLSSNSDV 
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